{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "e0a6ad5e",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd \n",
    "import numpy as np\n",
    "import os, sys\n",
    "from tqdm import tqdm\n",
    "import warnings\n",
    "warnings.filterwarnings('ignore')\n",
    "while os.getcwd().split('/')[-1] != 'rag-llm-cancer-paper':\n",
    "    os.chdir('..')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "1cec3a19",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(1569, 6)\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>statement_id</th>\n",
       "      <th>standardized_cancer</th>\n",
       "      <th>raw_cancer</th>\n",
       "      <th>biomarker</th>\n",
       "      <th>therapy</th>\n",
       "      <th>modified_standardized_cancer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>17</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>Lung Non-small Cell Carcinoma</td>\n",
       "      <td>[ARAF S214C]</td>\n",
       "      <td>[Sorafenib]</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>18</td>\n",
       "      <td>Acute Myeloid Leukemia</td>\n",
       "      <td>Acute Myeloid Leukemia</td>\n",
       "      <td>[DNMT3A R882]</td>\n",
       "      <td>[Idarubicin]</td>\n",
       "      <td>Acute Myeloid Leukemia</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>19</td>\n",
       "      <td>Polycythemia Vera</td>\n",
       "      <td>Polycythemia Vera</td>\n",
       "      <td>[JAK2 V617F]</td>\n",
       "      <td>[Peginterferon Alfa-2b]</td>\n",
       "      <td>Polycythemia Vera</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>20</td>\n",
       "      <td>Polycythemia Vera</td>\n",
       "      <td>Polycythemia Vera</td>\n",
       "      <td>[JAK2 V617F]</td>\n",
       "      <td>[Fedratinib]</td>\n",
       "      <td>Polycythemia Vera</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>21</td>\n",
       "      <td>Melanoma</td>\n",
       "      <td>Melanoma</td>\n",
       "      <td>[NRAS G13D]</td>\n",
       "      <td>[Tanespimycin]</td>\n",
       "      <td>Melanoma</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   statement_id         standardized_cancer                     raw_cancer  \\\n",
       "0            17  Non-Small Cell Lung Cancer  Lung Non-small Cell Carcinoma   \n",
       "1            18      Acute Myeloid Leukemia         Acute Myeloid Leukemia   \n",
       "2            19           Polycythemia Vera              Polycythemia Vera   \n",
       "3            20           Polycythemia Vera              Polycythemia Vera   \n",
       "4            21                    Melanoma                       Melanoma   \n",
       "\n",
       "       biomarker                  therapy modified_standardized_cancer  \n",
       "0   [ARAF S214C]              [Sorafenib]   Non-Small Cell Lung Cancer  \n",
       "1  [DNMT3A R882]             [Idarubicin]       Acute Myeloid Leukemia  \n",
       "2   [JAK2 V617F]  [Peginterferon Alfa-2b]            Polycythemia Vera  \n",
       "3   [JAK2 V617F]             [Fedratinib]            Polycythemia Vera  \n",
       "4    [NRAS G13D]           [Tanespimycin]                     Melanoma  "
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import ast\n",
    "standardized_to_raw_mapping = pd.read_csv('external-validation/non-moa-database/civic/civic-db/civic_core__2025-09.csv')\n",
    "standardized_to_raw_mapping = standardized_to_raw_mapping.rename(columns={'modified_standard_cancer':'modified_standardized_cancer'})\n",
    "standardized_to_raw_mapping['biomarker']=standardized_to_raw_mapping['biomarker'].apply(ast.literal_eval)\n",
    "standardized_to_raw_mapping['therapy']=standardized_to_raw_mapping['therapy'].apply(ast.literal_eval)\n",
    "print(standardized_to_raw_mapping.shape)\n",
    "standardized_to_raw_mapping.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "ac74c413",
   "metadata": {},
   "outputs": [],
   "source": [
    "def create_synthetic_query(db: dict) -> str:\n",
    "    \"\"\"\n",
    "    Create a synthetic query based on the database entry.\n",
    "    \"\"\"\n",
    "    if len(db['biomarker']) > 1:\n",
    "        biomarker_str = \", \".join(db['biomarker'])\n",
    "    else:\n",
    "        biomarker_str = db['biomarker'][0]\n",
    "    query_text=f\"if a patient with {db['modified_standardized_cancer']} cancer has {biomarker_str.lower()}, what therapy is recommended?\"\n",
    "    return query_text\n",
    "\n",
    "def create_synthetic_answer(db: dict) -> str:\n",
    "    \"\"\"\n",
    "    Create a synthetic answer based on the database entry.\n",
    "    \"\"\"\n",
    "    if len(db['biomarker']) > 1:\n",
    "        biomarker_str = \", \".join(db['biomarker'])\n",
    "    else:\n",
    "        biomarker_str = db['biomarker'][0]\n",
    "    if len(db['therapy']) > 1:\n",
    "        therapy_str = \" + \".join(db['therapy'])\n",
    "    else:\n",
    "        therapy_str = db['therapy'][0]\n",
    "    answer_text=f\"If a patient with {db['modified_standardized_cancer']} cancer has {biomarker_str.lower()}, one recommended therapy is {therapy_str.lower()}.\"\n",
    "    return answer_text\n",
    "\n",
    "synthetic_query_list = []\n",
    "synthetic_answer_list = []\n",
    "synthetic_query_therapy_pair_dict = {}\n",
    "for _, row in standardized_to_raw_mapping.iterrows():\n",
    "    #create synthetic query and answer and add to dataframe\n",
    "    query = create_synthetic_query(row)\n",
    "    answer = create_synthetic_answer(row)\n",
    "    standardized_to_raw_mapping.at[_, 'prompt'] = query\n",
    "    \n",
    "    #add more therapy context to answers (context db)\n",
    "    statements = pd.read_csv('external-validation/non-moa-database/civic/civic-db/civic-draft.dereferenced.unique.context_db.csv')\n",
    "    statement_dict = dict(zip(statements['statement_id'], statements['context']))\n",
    "\n",
    "    summary = statement_dict.get(row['statement_id'], \"No statement available.\")\n",
    "    #summary, stmt_row = flatten_statements(fda_statements[_])\n",
    "    # if len(stmt_row['therapy_type']) > 1:\n",
    "    #     therapy_type = ' + '.join(stmt_row['therapy_type'])\n",
    "    # else:\n",
    "    # #     therapy_type = stmt_row['therapy_type'][0]\n",
    "    # if len(stmt_row['therapy_strategy']) > 1:\n",
    "    #     therapy_strategy = ' + '.join(stmt_row['therapy_strategy'])\n",
    "    # else:\n",
    "    #     therapy_strategy = stmt_row['therapy_strategy'][0]\n",
    "        \n",
    "    standardized_to_raw_mapping.at[_, 'answer'] = (\n",
    "        #f\"{answer} therapy type: {therapy_type.lower()}. therapy strategy: {therapy_strategy.lower()}. indication: {stmt_row['indication'].lower()} approval url: {stmt_row['approval_url']}\"\n",
    "        f\"{answer} entry url: https://civicdb.org/links/evidence_items/{row['statement_id']}\"\n",
    "    )\n",
    "    \n",
    "    #create synthetic query and ground-truth mapping dict\n",
    "    row['therapy'] = [therapy.lower().strip() for therapy in row['therapy']]\n",
    "    if query in synthetic_query_therapy_pair_dict.keys():\n",
    "        synthetic_query_therapy_pair_dict[query].append(set(row['therapy']))\n",
    "    else:\n",
    "        synthetic_query_therapy_pair_dict[query] = [set(row['therapy'])]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "66bfbdaa",
   "metadata": {},
   "outputs": [],
   "source": [
    "#split ranges for testing on small batches\n",
    "import random, math\n",
    "def split_ranges(max_int, num_ranges, samples=None, seed=42):\n",
    "    random.seed(seed)\n",
    "    step = math.ceil(max_int / num_ranges)\n",
    "    ranges = [(i*step+1, min((i+1)*step, max_int)) for i in range(num_ranges)]\n",
    "    \n",
    "    if samples is None:\n",
    "        return ranges\n",
    "    \n",
    "    # split samples evenly across ranges\n",
    "    n_per_range = samples // num_ranges\n",
    "    remainder = samples % num_ranges\n",
    "    \n",
    "    result = []\n",
    "    for i, r in enumerate(ranges):\n",
    "        count = n_per_range + (1 if i < remainder else 0)\n",
    "        result.extend(random.randint(r[0], r[1]) for _ in range(count))\n",
    "    \n",
    "    return result\n",
    "test_idx_list = split_ranges(standardized_to_raw_mapping.shape[0], 10, 50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "790bd9b9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0 if a patient with Non-Small Cell Lung Cancer cancer has eml4::alk fusion, alk l1196m, what therapy is recommended?\n",
      "1 if a patient with Neuroblastoma cancer has alk f1174l, what therapy is recommended?\n",
      "2 if a patient with Breast Cancer cancer has erbb2 l755w, what therapy is recommended?\n",
      "3 if a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, what therapy is recommended?\n",
      "4 if a patient with Non-Small Cell Lung Cancer cancer has ddr2 l63v, what therapy is recommended?\n",
      "5 if a patient with Head And Neck Squamous Cell Carcinoma cancer has mapk1 e322k, what therapy is recommended?\n",
      "6 if a patient with Glioblastoma cancer has pten expression, what therapy is recommended?\n",
      "7 if a patient with Lung Adenocarcinoma cancer has egfr l858r, what therapy is recommended?\n",
      "8 if a patient with Melanoma cancer has erbb4 mutation, what therapy is recommended?\n",
      "9 if a patient with Melanoma cancer has braf v600e, what therapy is recommended?\n",
      "10 if a patient with nan cancer has bap1 mutation, what therapy is recommended?\n"
     ]
    }
   ],
   "source": [
    "for i, e in enumerate(standardized_to_raw_mapping.loc[test_idx_list].prompt):\n",
    "    print(i, e)\n",
    "    if i == 10:\n",
    "        break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "d59b0b0a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0 If a patient with Non-Small Cell Lung Cancer cancer has eml4::alk fusion, alk l1196m, one recommended therapy is alectinib. entry url: https://civicdb.org/links/evidence_items/141\n",
      "1 If a patient with Neuroblastoma cancer has alk f1174l, one recommended therapy is alectinib. entry url: https://civicdb.org/links/evidence_items/37\n",
      "2 If a patient with Breast Cancer cancer has erbb2 l755w, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/284\n",
      "3 If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/276\n",
      "4 If a patient with Non-Small Cell Lung Cancer cancer has ddr2 l63v, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/271\n",
      "5 If a patient with Head And Neck Squamous Cell Carcinoma cancer has mapk1 e322k, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/791\n",
      "6 If a patient with Glioblastoma cancer has pten expression, one recommended therapy is epidermal growth factor receptor tyrosine kinase inhibitor. entry url: https://civicdb.org/links/evidence_items/774\n",
      "7 If a patient with Lung Adenocarcinoma cancer has egfr l858r, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/982\n",
      "8 If a patient with Melanoma cancer has erbb4 mutation, one recommended therapy is lapatinib. entry url: https://civicdb.org/links/evidence_items/770\n",
      "9 If a patient with Melanoma cancer has braf v600e, one recommended therapy is dactolisib + selumetinib. entry url: https://civicdb.org/links/evidence_items/1005\n",
      "10 If a patient with nan cancer has bap1 mutation, one recommended therapy is mc1568 + mocetinostat + vorinostat. entry url: https://civicdb.org/links/evidence_items/1235\n"
     ]
    }
   ],
   "source": [
    "for i, e in enumerate(standardized_to_raw_mapping.loc[test_idx_list].answer):\n",
    "    print(i, e)\n",
    "    if i == 10:\n",
    "        break"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a126d140",
   "metadata": {},
   "source": [
    "### generate synthetic queries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "ed9d44a5",
   "metadata": {},
   "outputs": [],
   "source": [
    "from utils.io import load_object, save_object\n",
    "save_object(synthetic_query_therapy_pair_dict, \n",
    "            \"external-validation/non-moa-database/civic/civic-db/synthetic_query_therapy_pair_dict.pkl\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "111f91d2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "if a patient with Non-Small Cell Lung Cancer cancer has araf s214c, what therapy is recommended? [{'sorafenib'}, {'sorafenib'}, {'trametinib'}]\n"
     ]
    }
   ],
   "source": [
    "for k, v in synthetic_query_therapy_pair_dict.items():\n",
    "    print(k, v)\n",
    "    break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "5dd611e7",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "with open(f\"external-validation/non-moa-database/civic/civic-db/synthetic_prompts__2025-09.json\", \"w\") as f:\n",
    "    json.dump(standardized_to_raw_mapping.prompt.to_list(), f)\n",
    "\n",
    "with open(f\"external-validation/non-moa-database/civic/civic-db/synthetic_answers__2025-09.json\", \"w\") as f:\n",
    "    json.dump(standardized_to_raw_mapping.answer.to_list(), f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "0e51d0ec",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "If a patient with Non-Small Cell Lung Cancer cancer has araf s214c, one recommended therapy is sorafenib. entry url: https://civicdb.org/links/evidence_items/17\n",
      "1569\n"
     ]
    }
   ],
   "source": [
    "_CONTEXT = standardized_to_raw_mapping.answer.to_list()\n",
    "print(_CONTEXT[0])\n",
    "print(len(_CONTEXT))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "ac618c58",
   "metadata": {},
   "outputs": [],
   "source": [
    "def _cache_paths(output_dir: str, embed_name: str, name: str, version: str = \"v1\"):\n",
    "    os.makedirs(output_dir, exist_ok=True)\n",
    "    return (\n",
    "        f\"{output_dir}/{embed_name}_{name}__{version}.faiss\",\n",
    "        f\"{output_dir}/{embed_name}_{name}__{version}.json\",\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "4bc446bb",
   "metadata": {},
   "outputs": [],
   "source": [
    "from dotenv import load_dotenv\n",
    "from openai import OpenAI\n",
    "from utils.embedding import retrieve_context, get_text_embedding, store_embedding #get_context_db,\n",
    "def get_context_db(context_chunks, CLIENT, model_embed):\n",
    "    context_embeddings=np.array([get_text_embedding(chunk, CLIENT, model_embed) for chunk in context_chunks])\n",
    "    index=store_embedding(context_embeddings)\n",
    "    return(index)\n",
    "import faiss\n",
    "load_dotenv()\n",
    "api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "_CLIENT = OpenAI(api_key=api_key)\n",
    "_MODEL_EMBED = \"text-embedding-3-small\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "46762d58",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Always prefer cached index if present; only build once\n",
    "force_rebuild=True\n",
    "version = '2025-09'\n",
    "index_path, ctx_path =_cache_paths(\"external-validation/non-moa-database/civic/civic-db/indexes\", \n",
    "                                   _MODEL_EMBED, \n",
    "                                   \"structured_context\", version=version)\n",
    "context_json_path=f\"external-validation/non-moa-database/civic/civic-db/synthetic_answers__{version}.json\"\n",
    "\n",
    "def build_index(context_json_path, index_path, ctx_path):\n",
    "    global _READY, _CLIENT, _CONTEXT, _INDEX, _MODEL_TYPE, _MODEL_NAME, _MODEL_EMBED\n",
    " \n",
    "    load_dotenv()\n",
    "    api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "    _CLIENT = OpenAI(api_key=api_key)\n",
    "    _MODEL_EMBED = \"text-embedding-3-small\"\n",
    "    \n",
    "    with open(context_json_path, \"r\") as f:\n",
    "            _CONTEXT = json.load(f)\n",
    "    _INDEX = get_context_db(_CONTEXT, _CLIENT, _MODEL_EMBED)\n",
    "    faiss.write_index(_INDEX, index_path)\n",
    "    with open(ctx_path, \"w\") as f:\n",
    "        json.dump(_CONTEXT, f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "51bdacce",
   "metadata": {},
   "outputs": [],
   "source": [
    "index_path = 'external-validation/non-moa-database/civic/civic-db/index/civic_2025-09_structured_context.faiss'\n",
    "ctx_path = 'external-validation/non-moa-database/civic/civic-db/index/civic_2025-09_structured_context.json'\n",
    "context_json_path = f'external-validation/non-moa-database/civic/civic-db/synthetic_answers__{version}.json'\n",
    "build_index(context_json_path, index_path, ctx_path)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "cf932f78",
   "metadata": {},
   "source": [
    "### perform extraction"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "7d2e0a6a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "('context_retriever/biobert_ner/tokenizer_config.json',\n",
       " 'context_retriever/biobert_ner/special_tokens_map.json',\n",
       " 'context_retriever/biobert_ner/vocab.txt',\n",
       " 'context_retriever/biobert_ner/added_tokens.json',\n",
       " 'context_retriever/biobert_ner/tokenizer.json')"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "biobert_dir = \"context_retriever/biobert_ner\"\n",
    "#download model from huggingface\n",
    "from transformers import AutoTokenizer, AutoModelForTokenClassification\n",
    "model = AutoModelForTokenClassification.from_pretrained(\"judithrosell/BioBERT_BioNLP13CG_NER_new\")\n",
    "tokenizer = AutoTokenizer.from_pretrained(\"judithrosell/BioBERT_BioNLP13CG_NER_new\")\n",
    "id2label = model.config.id2label\n",
    "\n",
    "#save locally\n",
    "model.save_pretrained(biobert_dir)\n",
    "tokenizer.save_pretrained(biobert_dir)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "79c8a4d1",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 1569/1569 [00:58<00:00, 26.75it/s]\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "[{'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['araf s214c']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['dnmt3a']},\n",
       " {'cancer_type': ['polycythemia vera cancer'], 'biomarker': ['jak2']},\n",
       " {'cancer_type': ['polycythemia vera cancer'], 'biomarker': ['jak2']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['nras g13d']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['neuroblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['neuroblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['alk']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['araf s214c']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['araf s214c']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['l576p']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'],\n",
       "  'biomarker': ['pdgfra']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'],\n",
       "  'biomarker': ['pdgfra']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'],\n",
       "  'biomarker': ['pdgfra']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'],\n",
       "  'biomarker': ['pdgfra']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['medullary thyroid cancer'], 'biomarker': ['jak2']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['nutlin-3', 'plx4720']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', 'eml4']},\n",
       " {'cancer_type': ['neuroblastoma cancer'], 'biomarker': ['alk f1174l', 'alk']},\n",
       " {'cancer_type': ['neuroblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['baiap2l1', 'fgfr3']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['kras g13d']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['npm1']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['npm1']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['npm1']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['npm1']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'],\n",
       "  'biomarker': ['npm1', 'cd123', 'anti-', 'cd33']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'],\n",
       "  'biomarker': ['npm1', 'anti', 'cd33']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['npm1']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['npm1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['tsc1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['tsc1']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['alk', 'eml4']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['ccnd3']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['cdk4']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['ddr2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['ddr2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['ddr2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['ddr2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['ddr2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['ddr2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['ddr2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr g719s']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['erbb2 g309a']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['esr1']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['esr1']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['esr1']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['esr1']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['esr1']},\n",
       " {'cancer_type': ['cholangiocarcinoma cancer'], 'biomarker': ['oga', 'fgfr2']},\n",
       " {'cancer_type': ['cholangiocarcinoma cancer'],\n",
       "  'biomarker': ['fgfr2', 'tacc3']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['flt3']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['flt3']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'],\n",
       "  'biomarker': ['tyrphostin ag', 'flt3']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['gata2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['l576p']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'],\n",
       "  'biomarker': ['v654a']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['kras g12d']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['kras g13d']},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': ['mgmt']},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': ['mgmt']},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': ['mgmt']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['pik3ca h1047r']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['rara']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['mtor', 'pten r233']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['tsc1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['csf1r', 'mef2d']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['prostate cancer cancer'], 'biomarker': ['igf2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['apc']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['apc', 'lk']},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': ['atm']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['atm']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['hematologic cancer'], 'biomarker': ['atm']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['thymic carcinoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['prostate cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['cdk12']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['prostate cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['prostate cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['prostate cancer cancer'], 'biomarker': ['brca2']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'],\n",
       "  'biomarker': ['pdgfra v561a']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['xrcc1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['gstp1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['mthfr']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['gstp1']},\n",
       " {'cancer_type': ['cervical cancer cancer'], 'biomarker': ['xrcc1']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['abcb1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['abcb1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['ercc2']},\n",
       " {'cancer_type': ['lung squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['fgfr1']},\n",
       " {'cancer_type': ['lung cancer cancer'], 'biomarker': ['fgfr1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['fgfr1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['ros1', None]},\n",
       " {'cancer_type': ['gastric adeno cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr', 'epidermal growth factor receptor tyrosine kinase']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'],\n",
       "  'biomarker': ['kif5b', 'ret']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['mtor kinase', 'hras']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['cd274']},\n",
       " {'cancer_type': [], 'biomarker': ['mtor', 'nan']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['akt2']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['akt1']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['pten']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['akt1']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['pik3ca', 'akt']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['pi3kbeta', 'pten']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['bet', 'pi3k']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['pten']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['nf2']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['bet', 'pi3k']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['braf', 'agk']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['braf', 'papss1']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['trim24', 'braf']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['nt5e']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'],\n",
       "  'biomarker': ['gsk321', 'idh1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr', 'epidermal growth factor receptor tyrosine kinase']},\n",
       " {'cancer_type': ['merkel cell carcinoma cancer'],\n",
       "  'biomarker': ['pik3ca', 'p471l']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['ret']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['rit1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['cd274']},\n",
       " {'cancer_type': ['neuroblastoma cancer'],\n",
       "  'biomarker': ['mycn', 'curaxin cbl0137']},\n",
       " {'cancer_type': ['basal cell carcinoma cancer'], 'biomarker': ['smo']},\n",
       " {'cancer_type': ['medulloblastoma cancer'], 'biomarker': ['ptch1']},\n",
       " {'cancer_type': ['medulloblastoma cancer'], 'biomarker': ['ptch1']},\n",
       " {'cancer_type': ['prostate cancer cancer'], 'biomarker': ['stk11']},\n",
       " {'cancer_type': ['head and neck squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['cdkn2a p16']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['breast cancer cancer'],\n",
       "  'biomarker': ['akti-1', 'erbb2', None]},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['erbb4']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['glioblastoma cancer'],\n",
       "  'biomarker': ['epidermal growth factor receptor tyrosine kinase']},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['glioblastoma cancer'],\n",
       "  'biomarker': ['epidermal growth factor receptor tyrosine kinase', 'pten']},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': ['pten']},\n",
       " {'cancer_type': ['head and neck squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['nrg1']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['nrg1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['nrg1']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['egfr g724s']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['egfr g719s']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['ereg']},\n",
       " {'cancer_type': ['head and neck squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['mapk1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['kras a146v']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['kras g12v']},\n",
       " {'cancer_type': ['papillary renal cell carcinoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['head and neck squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['fgfr1']},\n",
       " {'cancer_type': ['gastric adeno cancer'], 'biomarker': ['fgfr1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['fgfr1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['fgfr3']},\n",
       " {'cancer_type': ['head and neck cancer'], 'biomarker': ['ptprd']},\n",
       " {'cancer_type': ['prostate cancer cancer'], 'biomarker': ['defa1']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['notch1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['nrg1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['head and neck squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['ptprt']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['vegfa']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['dnmt1']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['kras']},\n",
       " {'cancer_type': ['lung cancer cancer'], 'biomarker': ['pdcd4']},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['tff3']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['cd44 cd44s']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['casp8']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['smarca4']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk c1156y', 'alk', 'eml4']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', 'eml4']},\n",
       " {'cancer_type': ['prostate cancer cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['gastric adeno cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['nrg1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb3']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['slfn11']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['birc5']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['endometrial cancer cancer'], 'biomarker': ['mre11']},\n",
       " {'cancer_type': ['gastric adeno cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['top1']},\n",
       " {'cancer_type': ['head and neck squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['cdkn1b']},\n",
       " {'cancer_type': ['lung squamous cell carcinoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['fgfr1']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['naprt']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['mantle cell lymphoma cancer'], 'biomarker': ['zeb1']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['ptp4a3']},\n",
       " {'cancer_type': ['esophageal cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['tyms']},\n",
       " {'cancer_type': ['prostate cancer cancer'], 'biomarker': ['tyms']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['top2a']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['top1']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['top1']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['prkaa2']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['hspa5']},\n",
       " {'cancer_type': ['gastric adeno cancer'], 'biomarker': ['eif4ebp1']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'],\n",
       "  'biomarker': ['kit']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['tubb3']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['y1092', 'egfr']},\n",
       " {'cancer_type': ['sarcoma cancer'], 'biomarker': ['igf1r']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['foxp3']},\n",
       " {'cancer_type': ['gastric adeno cancer'], 'biomarker': ['rps6']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['jak1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['dusp6']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['kras']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['braf']},\n",
       " {'cancer_type': ['pancreatic cancer'], 'biomarker': ['kras g12d', 'akt']},\n",
       " {'cancer_type': ['pancreatic cancer'],\n",
       "  'biomarker': ['mk2206', 'akt', 'pten']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['hspb1']},\n",
       " {'cancer_type': ['lung cancer cancer'], 'biomarker': ['nqo1 p187s']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['colorectal cancer cancer'],\n",
       "  'biomarker': ['epidermal growth factor receptor tyrosine kinase inhibitor',\n",
       "   'kras']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['kras']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr', 'epidermal growth factor receptor tyrosine kinase']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['pten']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['pancreatic adenocarcinoma cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['ntrk1', 'lmna']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['tpm3', 'ntrk1']},\n",
       " {'cancer_type': ['oligodendroglioma cancer'], 'biomarker': ['idh1']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['hla-dra']},\n",
       " {'cancer_type': ['lymphoplasmacytic lymphoma cancer'],\n",
       "  'biomarker': ['myd88']},\n",
       " {'cancer_type': ['colorectal cancer cancer'],\n",
       "  'biomarker': ['kras', 'b-raf', 'vegfr-2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['kras', 'b-raf', 'vegfr-2']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['kras']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['kras']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['kras']},\n",
       " {'cancer_type': ['neuroblastoma cancer'], 'biomarker': ['nras']},\n",
       " {'cancer_type': ['pancreatic adenocarcinoma cancer'],\n",
       "  'biomarker': ['kras', 'pi3kbeta']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['kras']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['prostate cancer cancer'], 'biomarker': ['mre11']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['ntrk1']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['ereg']},\n",
       " {'cancer_type': ['gastric adeno cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['gastric adeno cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['endometrial cancer cancer'], 'biomarker': ['kit']},\n",
       " {'cancer_type': ['endometrial cancer cancer'], 'biomarker': ['kit']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['ros1', None]},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['vhl']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['flt3']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['lung cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['egfr g465r']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['ets2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['egfr s492r']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['egfr r451c']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['egfr p753s']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['medulloblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['cd74', 'ros1']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['cebpa']},\n",
       " {'cancer_type': ['nan cancer'],\n",
       "  'biomarker': ['zmym2', 'fgfr1', 'midostaurin']},\n",
       " {'cancer_type': ['angiosarcoma cancer'], 'biomarker': ['kdr']},\n",
       " {'cancer_type': ['angiosarcoma cancer'], 'biomarker': ['kdr']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['tsc2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['head and neck squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['aldh1a2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['cip2a']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': ['pten']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['tbk1']},\n",
       " {'cancer_type': ['cancer cancer'],\n",
       "  'biomarker': ['gdc-0623', 'g-573', 'kras', 'mek']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['kras g12c']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['kras g12v']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['pd1', 'havcr2', 'anti-tim-3']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['erbb3']},\n",
       " {'cancer_type': ['breast cancer'], 'biomarker': ['mmp2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['mmp2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['gastric adeno cancer'], 'biomarker': ['hsph1']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['hsph1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['cd274']},\n",
       " {'cancer_type': ['sarcoma cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['cd274']},\n",
       " {'cancer_type': ['cancer cancer'],\n",
       "  'biomarker': ['kras g12c',\n",
       "   'epidermal growth factor receptor tyrosine kinase']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['kras']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['p154', 'alk', 'eml4']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['eml4']},\n",
       " {'cancer_type': ['colorectal adenocarcinoma cancer'],\n",
       "  'biomarker': ['kdr r961w']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk e6', 'eml4', 'alk']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', 'eml4']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', 'eml4']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', 'eml4']},\n",
       " {'cancer_type': ['uveal melanoma cancer'], 'biomarker': ['gnaq']},\n",
       " {'cancer_type': ['uveal melanoma cancer'], 'biomarker': ['gna11']},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': ['pms2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['kras']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['kit']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['nras']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['uveal melanoma cancer'], 'biomarker': ['gna11']},\n",
       " {'cancer_type': ['uveal melanoma cancer'], 'biomarker': ['gnaq']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['nras']},\n",
       " {'cancer_type': ['prostate cancer cancer'], 'biomarker': ['pten']},\n",
       " {'cancer_type': ['uveal melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['uveal melanoma cancer'], 'biomarker': ['bap1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['bap1']},\n",
       " {'cancer_type': ['endometrial cancer cancer'], 'biomarker': ['fgfr2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['alk']},\n",
       " {'cancer_type': ['anaplastic large cell lymphoma cancer'],\n",
       "  'biomarker': ['npm1', 'alk']},\n",
       " {'cancer_type': ['anaplastic large cell lymphoma cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['anaplastic large cell lymphoma cancer'],\n",
       "  'biomarker': ['npm1', 'alk']},\n",
       " {'cancer_type': ['inflammatory myofibroblastic tumor cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['inflammatory myofibroblastic tumor cancer'],\n",
       "  'biomarker': ['alk', 'ranbp2']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['eml4']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['fgfr1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['fgfr1']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'],\n",
       "  'biomarker': ['ros1', 'cd72']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['cd74', 'ros1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['ros1', None]},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['cd74', 'ros1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['cd74', 'ros1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['cd74', 'ros1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['cd74', 'ros1', 'ros1 g2101a']},\n",
       " {'cancer_type': ['diffuse large b-cell lymphoma cancer'],\n",
       "  'biomarker': ['alk', 'cltc']},\n",
       " {'cancer_type': ['diffuse large b-cell lymphoma cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['diffuse large b-cell lymphoma cancer'],\n",
       "  'biomarker': ['alk', 'cltc']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['pan-raf']},\n",
       " {'cancer_type': ['neuroblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['neuroblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['i1171']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk i1171', 'alk']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', 'eml4']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', 'eml4', 'alk v1180l']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', 'eml4']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['flt3 tkd']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pten']},\n",
       " {'cancer_type': ['colorectal adenocarcinoma cancer'],\n",
       "  'biomarker': ['ros1', None]},\n",
       " {'cancer_type': ['pancreatic cancer cancer'], 'biomarker': ['palb2']},\n",
       " {'cancer_type': ['pancreatic cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['pancreatic cancer cancer'], 'biomarker': ['brca2']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'],\n",
       "  'biomarker': ['pdgfra']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pdgfrb', 'ebf1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['endometrial cancer cancer'], 'biomarker': ['fgfr2']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['ppp1r15a']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['kras']},\n",
       " {'cancer_type': ['neuroblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['neuroblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['neuroblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['neuroblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', 'eml4']},\n",
       " {'cancer_type': ['colorectal adenocarcinoma cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['neuroblastoma cancer'], 'biomarker': ['alk']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', 'eml4', 'alk f1245c']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', 'eml4']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk g1269a', 'alk', None]},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['alk', 'eml4']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['i1171']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', 'eml4']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk g1202r', 'alk', 'eml4']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['alk g1269a', 'alk', None]},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['alk g1269a', 'alk', None]},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['npm1', 'alk']},\n",
       " {'cancer_type': ['head and neck cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['head and neck cancer'], 'biomarker': ['pik3ca h1047r']},\n",
       " {'cancer_type': ['head and neck cancer'], 'biomarker': ['pik3ca h1047r']},\n",
       " {'cancer_type': ['head and neck cancer'], 'biomarker': ['pik3ca h1047r']},\n",
       " {'cancer_type': ['medullary thyroid cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['liposarcoma cancer'], 'biomarker': ['cdk4']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['i1171']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['brca2']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['cdkn2a']},\n",
       " {'cancer_type': ['renal cell carcinoma cancer'], 'biomarker': ['cdkn2a']},\n",
       " {'cancer_type': ['renal cell carcinoma cancer'], 'biomarker': ['cdkn2b']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['cdkn2a']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['cdk4 r24c']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['cdkn2a']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr s768i']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr s768i']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['head and neck cancer'], 'biomarker': ['pik3ca h1047r']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['braf']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['papillary thyroid cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['sf3b1']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['sf3b1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['m541l']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['gdc']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['nras']},\n",
       " {'cancer_type': ['gastrointestinal neuroendocrine tumor cancer'],\n",
       "  'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['fip1l1', 'pdgfra']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['ros1', None]},\n",
       " {'cancer_type': ['inflammatory myofibroblastic tumor cancer'],\n",
       "  'biomarker': ['ros1', 'tfg']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['fip1l1', 'pdgfra']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'],\n",
       "  'biomarker': ['pik3ca h1047r']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['melanoma cancer'],\n",
       "  'biomarker': ['mitogen-activated protein kinase kinase']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['bet', 'pi3k', 'pten']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'],\n",
       "  'biomarker': ['mitogen-activated protein kinase kinase']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['rec-4881', 'mek']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['head and neck squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['head and neck squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['pik3ca h1047r']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['nf1']},\n",
       " {'cancer_type': ['melanoma cancer'],\n",
       "  'biomarker': ['nf1', 'az628', 'vtx-11e']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['nras']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['nras']},\n",
       " {'cancer_type': ['chronic lymphocytic leukemia cancer'],\n",
       "  'biomarker': ['tp53']},\n",
       " {'cancer_type': [], 'biomarker': ['calr']},\n",
       " {'cancer_type': ['head and neck squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['pten']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['ezh2']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['ccnd1']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['raf1']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['kras']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pdgfrb', None]},\n",
       " {'cancer_type': ['gastric adeno cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pten']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['pten']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pik3ca h1047r']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pik3ca h1047r']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['nras']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['cd274']},\n",
       " {'cancer_type': ['papillary adeno cancer'], 'biomarker': ['ret']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['rara']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['cd28', 'ctla4']},\n",
       " {'cancer_type': ['prostate cancer cancer'],\n",
       "  'biomarker': ['pi3kbeta', 'pten']},\n",
       " {'cancer_type': ['head and neck squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['notch1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['cdk6']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['flt3']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['brca2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['brca2']},\n",
       " {'cancer_type': ['melanoma cancer'],\n",
       "  'biomarker': ['mk2206', 'ci-1040', 'pten', 'akt', 'mek']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['esr1']},\n",
       " {'cancer_type': ['head and neck squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['flt3']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['ccnd1']},\n",
       " {'cancer_type': ['mantle cell lymphoma cancer'], 'biomarker': ['ccnd1']},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['ppfibp2', 'braf']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['braf', 'kiaa1549']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['hairy cell leukemia cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['uveal melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['dnmt3a']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['papillary thyroid cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['sarcoma cancer'], 'biomarker': ['rad23b']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['ret', 'ccdc6']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['fgfr3']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['fgfr1']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['fgfr2']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['fgf3']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['breast cancer cancer'],\n",
       "  'biomarker': ['mtor kinase', 'pik3ca', 'pp242']},\n",
       " {'cancer_type': ['breast cancer cancer'],\n",
       "  'biomarker': ['mtor kinase', 'pp242', 'pik3r1']},\n",
       " {'cancer_type': ['breast cancer cancer'],\n",
       "  'biomarker': ['mtor kinase', 'pp242', 'erbb2']},\n",
       " {'cancer_type': ['endometrial cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['endometrial cancer cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['pancreatic cancer cancer'], 'biomarker': ['stk11']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['stk11']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['stk11']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['akt2']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'],\n",
       "  'biomarker': ['kif5b', 'ret']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pik3ca h1047r']},\n",
       " {'cancer_type': ['thyroid cancer cancer'], 'biomarker': ['pik3ca h1047r']},\n",
       " {'cancer_type': ['thyroid cancer cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['thyroid cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['renal cell carcinoma cancer'], 'biomarker': ['fbxw7']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['mtor', 'fbxw7']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['fbxw7']},\n",
       " {'cancer_type': ['colorectal adenocarcinoma cancer'], 'biomarker': ['jun']},\n",
       " {'cancer_type': ['colon adenocarcinoma cancer'], 'biomarker': ['fos']},\n",
       " {'cancer_type': ['lymphoplasmacytic lymphoma cancer'],\n",
       "  'biomarker': ['img-', 'irak-1 / 4', 'myd88']},\n",
       " {'cancer_type': ['hepatocellular carcinoma cancer'], 'biomarker': ['kras']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['atrx']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['aurka']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['map2k1']},\n",
       " {'cancer_type': ['nan cancer'],\n",
       "  'biomarker': ['cul1', 'mitogen-activated protein kinase kinase']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['braf', 'zkscan1']},\n",
       " {'cancer_type': ['spindle cell sarcoma cancer'],\n",
       "  'biomarker': ['braf', 'kiaa1549']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['brca2']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'],\n",
       "  'biomarker': ['ros1', 'sdc4']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['jq1', 'i-bet151', 'mycl']},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': ['sgx523', 'hgf']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['cholangiocarcinoma cancer'], 'biomarker': ['errfi1']},\n",
       " {'cancer_type': ['systemic mastocytosis cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['sgk1', 'inh']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['cd274']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['cdk', 'ccne1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['akt', 'ccne1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr g719s']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['braf g596c']},\n",
       " {'cancer_type': ['synovial sarcoma cancer'], 'biomarker': ['smarcb1']},\n",
       " {'cancer_type': ['rhabdoid cancer cancer'], 'biomarker': ['smarcb1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['nf2']},\n",
       " {'cancer_type': ['malignant peripheral nerve sheath tumor cancer'],\n",
       "  'biomarker': ['jq1', 'nf1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb3']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb3']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb3 g284r']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['braf']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['mthfr']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['cdkn2a']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['fgfr1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['pdgfra']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['fip1l1', 'pdgfra']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['fip1l1', 'pdgfra']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['fip1l1', 'pdgfra']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr g719']},\n",
       " {'cancer_type': ['nut midline cancer'], 'biomarker': ['nutm1', 'brd4']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['tnks2', 'pdgfra']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['erbb3 v855a']},\n",
       " {'cancer_type': ['cholangiocarcinoma cancer'],\n",
       "  'biomarker': ['bicc1', 'fgfr2']},\n",
       " {'cancer_type': ['cholangiocarcinoma cancer'],\n",
       "  'biomarker': ['fgfr2', 'ahcyl1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['ptprd']},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['endometrial cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['rb1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['sqstm1', 'ntrk1']},\n",
       " {'cancer_type': ['mammary analogue secretory cancer'],\n",
       "  'biomarker': ['ntrk3', 'etv6']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pd-1', 'anti-', 'msh2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['msh6']},\n",
       " {'cancer_type': ['ewing sarcoma cancer'], 'biomarker': ['cdkn2a']},\n",
       " {'cancer_type': ['ewing sarcoma cancer'], 'biomarker': ['cdkn2b']},\n",
       " {'cancer_type': ['dermatofibrosarcoma protuberans cancer'],\n",
       "  'biomarker': ['cdkn2a']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['angiosarcoma cancer'], 'biomarker': ['ptprb']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['kras g12d']},\n",
       " {'cancer_type': ['hepatocellular carcinoma cancer'], 'biomarker': ['jak1']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['mantle cell lymphoma cancer'], 'biomarker': ['atm']},\n",
       " {'cancer_type': ['lung squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['fgfr1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['fgfr3']},\n",
       " {'cancer_type': ['cholangiocarcinoma cancer'], 'biomarker': ['fgfr2']},\n",
       " {'cancer_type': ['cholangiocarcinoma cancer'], 'biomarker': ['fgfr2', None]},\n",
       " {'cancer_type': ['cholangiocarcinoma cancer'], 'biomarker': ['fgfr2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['bicc1', 'fgfr2']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['fgfr2', None]},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['tacc3', 'fgfr3']},\n",
       " {'cancer_type': ['endometrial cancer cancer'],\n",
       "  'biomarker': ['bicc1', 'fgfr2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['akt3', 'akt']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['brca2']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['ati']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['uveal melanoma cancer'], 'biomarker': ['gna11']},\n",
       " {'cancer_type': ['uveal melanoma cancer'], 'biomarker': ['gnaq']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['nf1']},\n",
       " {'cancer_type': ['prostate cancer cancer'], 'biomarker': ['atm']},\n",
       " {'cancer_type': ['prostate cancer cancer'], 'biomarker': ['palb2']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['pdgfra p577s']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['pdgfra']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['pdgfra']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['pdgfra']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['mtap']},\n",
       " {'cancer_type': ['chordoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['erbb2 v773a']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['fgfr2']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['fgfr1']},\n",
       " {'cancer_type': ['head and neck squamous cell carcinoma cancer'],\n",
       "  'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['kras g12v']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['idh1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['pik3ca', 'pi103']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pten']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['erbb2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pik3ca c420r']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pik3ca k111n']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['pik3ca h1047l']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['pik3ca h1047r']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['pik3ca h1047r']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['kras g13d']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['kras a146t']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['kras a146v']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['kras g12c']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['kras g12d']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['idh1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['idh1']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['idh1']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['idh1']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'],\n",
       "  'biomarker': ['pdgfra v561d']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'],\n",
       "  'biomarker': ['kit']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'],\n",
       "  'biomarker': ['pdgfra']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr g719a']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca2']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca2 m1r']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca2 m1i']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca2']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca2 v211l']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca2 v211i']},\n",
       " {'cancer_type': ['ovarian cancer cancer'], 'biomarker': ['brca2']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['mucosal melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': ['mgmt']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['mgmt']},\n",
       " {'cancer_type': ['oligodendroglioma cancer'], 'biomarker': ['mgmt']},\n",
       " {'cancer_type': ['glioblastoma cancer'], 'biomarker': ['mgmt']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['mgmt']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['rrm1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['sarcoma cancer'],\n",
       "  'biomarker': ['fgf', 'fgfr1', 'vegf receptor']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['nras']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['idh1']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['map2k1']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['nras']},\n",
       " {'cancer_type': ['lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['ctag1b']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['ctag2']},\n",
       " {'cancer_type': ['solid tumor cancer'], 'biomarker': ['ntrk1', None]},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['ntrk3', None]},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['sqstm1', 'ntrk1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['ros1', None]},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['ntrk1', None]},\n",
       " {'cancer_type': ['sarcoma cancer'], 'biomarker': ['ntrk1', 'lmna']},\n",
       " {'cancer_type': ['colorectal adenocarcinoma cancer'],\n",
       "  'biomarker': ['ntrk1', 'lmna']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['mdm2', 'tp53']},\n",
       " {'cancer_type': ['leukemia cancer'], 'biomarker': ['tp53']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['arid1a']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['arid1a']},\n",
       " {'cancer_type': ['cervix cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['neuroblastoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': ['mertk']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['myc']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['flt3']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['flt3']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['fgfr1']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'],\n",
       "  'biomarker': ['tyrphostin', 'flt3']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['akt1']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['pik3ca']},\n",
       " {'cancer_type': ['follicular thyroid cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['uveal melanoma cancer'], 'biomarker': ['gna11']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['kras']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr l861q']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['egfr', 'multikinase']},\n",
       " {'cancer_type': ['lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['flt3']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'],\n",
       "  'biomarker': ['p551']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['egfr r108k']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['egfr t263p']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr g719']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr g719s']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr v742a']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr g719d']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr v774a']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr v834i']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr l838p']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['l747', 'egfr', 'p753delinss']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['egfr l858r']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['egfr l858r']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr l861']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['egfr l861q']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr r776c']},\n",
       " {'cancer_type': ['colorectal cancer cancer'], 'biomarker': ['arid1a']},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['melanoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['gastrointestinal stromal tumor cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['t785a', 'egfr']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['egfr l861r']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['chronic myelogenous leukemia cancer'],\n",
       "  'biomarker': ['bcr', 'abl1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['egfr']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': ['pold1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['pold1']},\n",
       " {'cancer_type': ['lung adenocarcinoma cancer'], 'biomarker': []},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['abl1']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'], 'biomarker': ['abl1']},\n",
       " {'cancer_type': ['cancer cancer'], 'biomarker': ['s628n']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['arid1a']},\n",
       " {'cancer_type': ['acute myeloid leukemia cancer'], 'biomarker': ['idh2']},\n",
       " {'cancer_type': ['non-small cell lung cancer cancer'],\n",
       "  'biomarker': ['alk', None]},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['brca1']},\n",
       " {'cancer_type': ['breast cancer cancer'], 'biomarker': ['brca2']},\n",
       " {'cancer_type': ['nan cancer'], 'biomarker': ['erbb2']},\n",
       " ...]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "version = '2025-09'\n",
    "import json\n",
    "context_json_path = f'external-validation/non-moa-database/civic/civic-db/synthetic_answers__{version}.json'\n",
    "with open(context_json_path, \"r\") as f:\n",
    "    _CONTEXT = json.load(f)\n",
    "#run BioBert NER on all contexts\n",
    "from utils.entity_prediction import extract_entities, db_extract_entities\n",
    "context_extracted_entities = []\n",
    "for ctx in tqdm(_CONTEXT):\n",
    "    context_extracted_entities.append(extract_entities(ctx, model, tokenizer))\n",
    "context_extracted_entities"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "9c72d0e7",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "1569it [00:00, 3470919.29it/s]"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0.191%\n",
      "14.978%\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "no_cancer_idx = []\n",
    "no_biomarker_idx = []\n",
    "for i, e in tqdm(enumerate(context_extracted_entities)):\n",
    "    if not e['cancer_type']:\n",
    "        no_cancer_idx.append(i)\n",
    "    if not e['biomarker']:\n",
    "        no_biomarker_idx.append(i)\n",
    "\n",
    "print(f\"{len(no_cancer_idx)*100/len(_CONTEXT):.3f}%\") #no cancer entity extracted %\n",
    "print(f\"{len(no_biomarker_idx)*100/len(_CONTEXT):.3f}%\") #no biomarker entity extracted %"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "f924f043",
   "metadata": {},
   "outputs": [],
   "source": [
    "#save\n",
    "os.makedirs(\"external-validation/non-moa-database/civic/civic-db/context_retriever/entities\", exist_ok=True)\n",
    "with open(f\"external-validation/non-moa-database/civic/civic-db/context_retriever/entities/synthetic_query_ner_entities__{version}.json\", \"w\") as f:\n",
    "    json.dump(context_extracted_entities, f, indent=4)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "41897169",
   "metadata": {},
   "source": [
    "### create validation test dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "f841116c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>statement_id</th>\n",
       "      <th>standardized_cancer</th>\n",
       "      <th>raw_cancer</th>\n",
       "      <th>biomarker</th>\n",
       "      <th>therapy</th>\n",
       "      <th>modified_standardized_cancer</th>\n",
       "      <th>prompt</th>\n",
       "      <th>answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1412</th>\n",
       "      <td>11139</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>[BRCA2 Mutation]</td>\n",
       "      <td>[Rucaparib]</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>if a patient with Ovarian Cancer cancer has br...</td>\n",
       "      <td>If a patient with Ovarian Cancer cancer has br...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>985</th>\n",
       "      <td>4759</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>Lung Non-small Cell Carcinoma</td>\n",
       "      <td>[EGFR L858R]</td>\n",
       "      <td>[Gefitinib, Erlotinib]</td>\n",
       "      <td>Non-Small Cell Lung Cancer</td>\n",
       "      <td>if a patient with Non-Small Cell Lung Cancer c...</td>\n",
       "      <td>If a patient with Non-Small Cell Lung Cancer c...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>432</th>\n",
       "      <td>1246</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Ewing Sarcoma Of Bone</td>\n",
       "      <td>[FGFR1 N546K]</td>\n",
       "      <td>[Ponatinib]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>if a patient with nan cancer has fgfr1 n546k, ...</td>\n",
       "      <td>If a patient with nan cancer has fgfr1 n546k, ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>964</th>\n",
       "      <td>4537</td>\n",
       "      <td>Chronic Myelogenous Leukemia</td>\n",
       "      <td>Chronic Myeloid Leukemia</td>\n",
       "      <td>[BCR::ABL1 Fusion, ABL1 V299L]</td>\n",
       "      <td>[Axitinib]</td>\n",
       "      <td>Chronic Myelogenous Leukemia</td>\n",
       "      <td>if a patient with Chronic Myelogenous Leukemia...</td>\n",
       "      <td>If a patient with Chronic Myelogenous Leukemia...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1169</th>\n",
       "      <td>7278</td>\n",
       "      <td>Acute Myeloid Leukemia</td>\n",
       "      <td>Acute Myeloid Leukemia</td>\n",
       "      <td>[IDH1 Mutation]</td>\n",
       "      <td>[Ivosidenib]</td>\n",
       "      <td>Acute Myeloid Leukemia</td>\n",
       "      <td>if a patient with Acute Myeloid Leukemia cance...</td>\n",
       "      <td>If a patient with Acute Myeloid Leukemia cance...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>812</th>\n",
       "      <td>2480</td>\n",
       "      <td>Gastrointestinal Stromal Tumor</td>\n",
       "      <td>Gastrointestinal Stromal Tumor</td>\n",
       "      <td>[KIT EXPRESSION]</td>\n",
       "      <td>[Imatinib]</td>\n",
       "      <td>Gastrointestinal Stromal Tumor</td>\n",
       "      <td>if a patient with Gastrointestinal Stromal Tum...</td>\n",
       "      <td>If a patient with Gastrointestinal Stromal Tum...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>303</th>\n",
       "      <td>991</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>[KRAS Mutation]</td>\n",
       "      <td>[Trametinib, Afatinib]</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>if a patient with Colorectal Cancer cancer has...</td>\n",
       "      <td>If a patient with Colorectal Cancer cancer has...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>664</th>\n",
       "      <td>1694</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Bladder Carcinoma</td>\n",
       "      <td>[ERBB2 Mutation]</td>\n",
       "      <td>[Platinum Compound]</td>\n",
       "      <td>NaN</td>\n",
       "      <td>if a patient with nan cancer has erbb2 mutatio...</td>\n",
       "      <td>If a patient with nan cancer has erbb2 mutatio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>538</th>\n",
       "      <td>1440</td>\n",
       "      <td>Lung Adenocarcinoma</td>\n",
       "      <td>Lung Adenocarcinoma</td>\n",
       "      <td>[RICTOR Amplification]</td>\n",
       "      <td>[Sapanisertib, Onatasertib]</td>\n",
       "      <td>Lung Adenocarcinoma</td>\n",
       "      <td>if a patient with Lung Adenocarcinoma cancer h...</td>\n",
       "      <td>If a patient with Lung Adenocarcinoma cancer h...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>567</th>\n",
       "      <td>1494</td>\n",
       "      <td>Melanoma</td>\n",
       "      <td>Skin Melanoma</td>\n",
       "      <td>[EZH2 Y646]</td>\n",
       "      <td>[GSK126]</td>\n",
       "      <td>Melanoma</td>\n",
       "      <td>if a patient with Melanoma cancer has ezh2 y64...</td>\n",
       "      <td>If a patient with Melanoma cancer has ezh2 y64...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>157 rows × 8 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      statement_id             standardized_cancer  \\\n",
       "1412         11139                  Ovarian Cancer   \n",
       "985           4759      Non-Small Cell Lung Cancer   \n",
       "432           1246                             NaN   \n",
       "964           4537    Chronic Myelogenous Leukemia   \n",
       "1169          7278          Acute Myeloid Leukemia   \n",
       "...            ...                             ...   \n",
       "812           2480  Gastrointestinal Stromal Tumor   \n",
       "303            991               Colorectal Cancer   \n",
       "664           1694                             NaN   \n",
       "538           1440             Lung Adenocarcinoma   \n",
       "567           1494                        Melanoma   \n",
       "\n",
       "                          raw_cancer                       biomarker  \\\n",
       "1412                  Ovarian Cancer                [BRCA2 Mutation]   \n",
       "985    Lung Non-small Cell Carcinoma                    [EGFR L858R]   \n",
       "432            Ewing Sarcoma Of Bone                   [FGFR1 N546K]   \n",
       "964         Chronic Myeloid Leukemia  [BCR::ABL1 Fusion, ABL1 V299L]   \n",
       "1169          Acute Myeloid Leukemia                 [IDH1 Mutation]   \n",
       "...                              ...                             ...   \n",
       "812   Gastrointestinal Stromal Tumor                [KIT EXPRESSION]   \n",
       "303                Colorectal Cancer                 [KRAS Mutation]   \n",
       "664                Bladder Carcinoma                [ERBB2 Mutation]   \n",
       "538              Lung Adenocarcinoma          [RICTOR Amplification]   \n",
       "567                    Skin Melanoma                     [EZH2 Y646]   \n",
       "\n",
       "                          therapy    modified_standardized_cancer  \\\n",
       "1412                  [Rucaparib]                  Ovarian Cancer   \n",
       "985        [Gefitinib, Erlotinib]      Non-Small Cell Lung Cancer   \n",
       "432                   [Ponatinib]                             NaN   \n",
       "964                    [Axitinib]    Chronic Myelogenous Leukemia   \n",
       "1169                 [Ivosidenib]          Acute Myeloid Leukemia   \n",
       "...                           ...                             ...   \n",
       "812                    [Imatinib]  Gastrointestinal Stromal Tumor   \n",
       "303        [Trametinib, Afatinib]               Colorectal Cancer   \n",
       "664           [Platinum Compound]                             NaN   \n",
       "538   [Sapanisertib, Onatasertib]             Lung Adenocarcinoma   \n",
       "567                      [GSK126]                        Melanoma   \n",
       "\n",
       "                                                 prompt  \\\n",
       "1412  if a patient with Ovarian Cancer cancer has br...   \n",
       "985   if a patient with Non-Small Cell Lung Cancer c...   \n",
       "432   if a patient with nan cancer has fgfr1 n546k, ...   \n",
       "964   if a patient with Chronic Myelogenous Leukemia...   \n",
       "1169  if a patient with Acute Myeloid Leukemia cance...   \n",
       "...                                                 ...   \n",
       "812   if a patient with Gastrointestinal Stromal Tum...   \n",
       "303   if a patient with Colorectal Cancer cancer has...   \n",
       "664   if a patient with nan cancer has erbb2 mutatio...   \n",
       "538   if a patient with Lung Adenocarcinoma cancer h...   \n",
       "567   if a patient with Melanoma cancer has ezh2 y64...   \n",
       "\n",
       "                                                 answer  \n",
       "1412  If a patient with Ovarian Cancer cancer has br...  \n",
       "985   If a patient with Non-Small Cell Lung Cancer c...  \n",
       "432   If a patient with nan cancer has fgfr1 n546k, ...  \n",
       "964   If a patient with Chronic Myelogenous Leukemia...  \n",
       "1169  If a patient with Acute Myeloid Leukemia cance...  \n",
       "...                                                 ...  \n",
       "812   If a patient with Gastrointestinal Stromal Tum...  \n",
       "303   If a patient with Colorectal Cancer cancer has...  \n",
       "664   If a patient with nan cancer has erbb2 mutatio...  \n",
       "538   If a patient with Lung Adenocarcinoma cancer h...  \n",
       "567   If a patient with Melanoma cancer has ezh2 y64...  \n",
       "\n",
       "[157 rows x 8 columns]"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "standardized_to_raw_mapping_subset=standardized_to_raw_mapping.sample(frac=.1, random_state=42)\n",
    "standardized_to_raw_mapping_subset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "9b1095dd",
   "metadata": {},
   "outputs": [],
   "source": [
    "standardized_to_raw_mapping_subset.to_csv(\"external-validation/non-moa-database/civic/civic-db/civic_small_testing_dataset.csv\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "2febe239",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>statement_id</th>\n",
       "      <th>standardized_cancer</th>\n",
       "      <th>raw_cancer</th>\n",
       "      <th>biomarker</th>\n",
       "      <th>therapy</th>\n",
       "      <th>modified_standardized_cancer</th>\n",
       "      <th>prompt</th>\n",
       "      <th>answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>11139</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>['BRCA2 Mutation']</td>\n",
       "      <td>['Rucaparib']</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>if a patient with Ovarian Cancer cancer has br...</td>\n",
       "      <td>If a patient with Ovarian Cancer cancer has br...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   statement_id standardized_cancer      raw_cancer           biomarker  \\\n",
       "0         11139      Ovarian Cancer  Ovarian Cancer  ['BRCA2 Mutation']   \n",
       "\n",
       "         therapy modified_standardized_cancer  \\\n",
       "0  ['Rucaparib']               Ovarian Cancer   \n",
       "\n",
       "                                              prompt  \\\n",
       "0  if a patient with Ovarian Cancer cancer has br...   \n",
       "\n",
       "                                              answer  \n",
       "0  If a patient with Ovarian Cancer cancer has br...  "
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "standardized_to_raw_mapping_subset = pd.read_csv(\"external-validation/non-moa-database/civic/civic-db/civic_small_testing_dataset.csv\")\n",
    "standardized_to_raw_mapping_subset.head(1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "b7d0300f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "# chunks: 157\n",
      "Min: 16\n",
      "Max: 31\n",
      "Mean: 21.044585987261147\n",
      "Median: 21.0\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "np.int64(3304)"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import tiktoken\n",
    "encoding = tiktoken.encoding_for_model(\"gpt-4o\")\n",
    "query_size=[len(encoding.encode(prompt)) for prompt in standardized_to_raw_mapping_subset.prompt]\n",
    "print(\"# chunks: \"+str(len(query_size)))\n",
    "print(\"Min: \"+str(np.min(query_size)))\n",
    "print(\"Max: \"+str(np.max(query_size)))\n",
    "print(\"Mean: \"+str(np.mean(query_size)))\n",
    "print(\"Median: \"+str(np.median(query_size)))\n",
    "np.sum(query_size)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "e99f320b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "# chunks: 157\n",
      "Min: 34\n",
      "Max: 52\n",
      "Mean: 42.82165605095541\n",
      "Median: 43.0\n"
     ]
    }
   ],
   "source": [
    "query_size=[len(encoding.encode(prompt)) for prompt in standardized_to_raw_mapping_subset.answer]\n",
    "print(\"# chunks: \"+str(len(query_size)))\n",
    "print(\"Min: \"+str(np.min(query_size)))\n",
    "print(\"Max: \"+str(np.max(query_size)))\n",
    "print(\"Mean: \"+str(np.mean(query_size)))\n",
    "print(\"Median: \"+str(np.median(query_size)))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "91ea1fa9",
   "metadata": {},
   "source": [
    "### perform evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "d58d0b52",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>statement_id</th>\n",
       "      <th>standardized_cancer</th>\n",
       "      <th>raw_cancer</th>\n",
       "      <th>biomarker</th>\n",
       "      <th>therapy</th>\n",
       "      <th>modified_standardized_cancer</th>\n",
       "      <th>prompt</th>\n",
       "      <th>answer</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>11139</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>['BRCA2 Mutation']</td>\n",
       "      <td>['Rucaparib']</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>if a patient with Ovarian Cancer cancer has br...</td>\n",
       "      <td>If a patient with Ovarian Cancer cancer has br...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   statement_id standardized_cancer      raw_cancer           biomarker  \\\n",
       "0         11139      Ovarian Cancer  Ovarian Cancer  ['BRCA2 Mutation']   \n",
       "\n",
       "         therapy modified_standardized_cancer  \\\n",
       "0  ['Rucaparib']               Ovarian Cancer   \n",
       "\n",
       "                                              prompt  \\\n",
       "0  if a patient with Ovarian Cancer cancer has br...   \n",
       "\n",
       "                                              answer  \n",
       "0  If a patient with Ovarian Cancer cancer has br...  "
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "standardized_to_raw_mapping_subset = pd.read_csv(\"external-validation/non-moa-database/civic/civic-db/civic_small_testing_dataset.csv\")\n",
    "standardized_to_raw_mapping_subset.head(1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "86757eea",
   "metadata": {},
   "outputs": [],
   "source": [
    "# ================== GENERAL IMPORTS ==================\n",
    "import os\n",
    "import json\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "# ================== UTIL FUNCTIONS ==================\n",
    "from utils.embedding import retrieve_context, get_text_embedding, store_embedding #get_context_db,\n",
    "from utils.prompt import get_prompt\n",
    "from llm.run_RAGLLM import run_RAG\n",
    "\n",
    "# Generate context vector database\n",
    "def get_context_db(context_chunks, CLIENT, model_embed):\n",
    "    context_embeddings=np.array([get_text_embedding(chunk, CLIENT, model_embed) for chunk in context_chunks])\n",
    "    index=store_embedding(context_embeddings)\n",
    "    return(index)\n",
    "\n",
    "\n",
    "# ================== MODEL & API IMPORTS ==================\n",
    "from mistralai.client import MistralClient\n",
    "from openai import OpenAI\n",
    "from llm.inference import run_llm\n",
    "import faiss\n",
    "synthetic_query_therapy_pair_dict=load_object(\"external-validation/non-moa-database/civic/civic-db/synthetic_query_therapy_pair_dict.pkl\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "462ed81c",
   "metadata": {},
   "outputs": [],
   "source": [
    "#setup env\n",
    "import faiss\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "_MODEL = 'gpt-4.1-nano' #this could be gpt-4o-2024-05-13, gpt-4o-mini-2024-07-18, etc.\n",
    "_MODEL_EMBED = 'text-embedding-3-small'\n",
    "api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "if not api_key:\n",
    "    raise ValueError(\"Missing API key. Please set OPENAI_API_KEY in your .env file.\")\n",
    "CLIENT=OpenAI(api_key=api_key)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "518a11a3",
   "metadata": {},
   "outputs": [],
   "source": [
    "_VERSION = '2025-09-04'\n",
    "version = '2025-09'\n",
    "_QUERY_DF=pd.read_csv(\"external-validation/non-moa-database/civic/civic-db/civic_small_testing_dataset.csv\",)\n",
    "context_json_path=f\"external-validation/non-moa-database/civic/civic-db/synthetic_answers__{version}.json\"\n",
    "with open(context_json_path, \"r\") as f:\n",
    "     _CONTEXT = json.load(f)\n",
    "index_path = 'external-validation/non-moa-database/civic/civic-db/index/civic_2025-09_structured_context.faiss'\n",
    "_INDEX = faiss.read_index(index_path)\n",
    "with open(f\"context_retriever/entities/civic_db_context_ner_entities__civic-202509.json\", \"r\") as f:\n",
    "     _DB_ENTITY = json.load(f)\n",
    "with open(f\"external-validation/non-moa-database/civic/civic-db/context_retriever/entities/synthetic_query_ner_entities__{version}.json\", \"r\") as f:\n",
    "    _QUERY_ENTITY = json.load(f)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "89279301",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Time elapsed for iteration 0: 5.0569 min\n"
     ]
    }
   ],
   "source": [
    "# Run RAG-LLM iterations\n",
    "from llm.run_RAGLLM import run_iterations_rag\n",
    "output_ls, input_ls, runtime_ls = run_iterations_rag(\n",
    "    num_iterations=1,#args.num_iter, \n",
    "    data=_QUERY_DF, \n",
    "    context_chunks=_CONTEXT, \n",
    "    db_entity=_DB_ENTITY,\n",
    "    query_entity=_QUERY_ENTITY, \n",
    "    num_vec=10, \n",
    "    index=_INDEX,\n",
    "    client=CLIENT, \n",
    "    model=_MODEL, \n",
    "    model_embed=_MODEL_EMBED, \n",
    "    model_type='gpt',\n",
    "    strategy=5,\n",
    "    max_len=None, \n",
    "    temp=0.0, \n",
    "    random_seed=None\n",
    "    )\n",
    "\n",
    "# Save results\n",
    "res_dict = {\n",
    "    \"full output\": output_ls, \n",
    "    \"input prompt\": input_ls, \n",
    "    #\"retrieval\": retrieval_ls,\n",
    "    \"runtime\": runtime_ls\n",
    "    }\n",
    "\n",
    "os.makedirs('external-validation/non-moa-database/civic/rag-llm/small-test', exist_ok=True)\n",
    "output_dir = 'external-validation/non-moa-database/civic/rag-llm/small-test'\n",
    "\n",
    "result_file=os.path.join(\n",
    "    output_dir,\n",
    "    f'RAGstra{str(5)}n{str(1)}temp{str(0)}_res_dict.pkl'\n",
    ")\n",
    "from utils.io import save_object\n",
    "save_object(res_dict, filename=result_file)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "50cf8516",
   "metadata": {},
   "outputs": [],
   "source": [
    "output_res = os.path.join(\n",
    "    output_dir,\n",
    "    f'RAGstra{str(5)}n{str(1)}temp{str(0)}_res_dict.pkl'\n",
    ")\n",
    "output_res = load_object(output_res)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "9ef647d1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'avg_exact_match_acc': 0.39490445859872614,\n",
       " 'avg_partial_match_acc': 0.6687898089171974,\n",
       " 'avg_precision': 0.6687898089171974,\n",
       " 'avg_recall': 0.49282133201844913,\n",
       " 'avg_f1': 0.5325042968355069,\n",
       " 'avg_specificity': 1.0,\n",
       " 'exact_match_acc': [False,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False],\n",
       " 'partial_match_acc': [True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  True,\n",
       "  False,\n",
       "  False,\n",
       "  False],\n",
       " 'precision_ls': [1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  0],\n",
       " 'recall_ls': [0.3333333333333333,\n",
       "  0.0,\n",
       "  1.0,\n",
       "  0.5,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.1111111111111111,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  0.07692307692307693,\n",
       "  0.5,\n",
       "  0.05263157894736842,\n",
       "  0.125,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.16666666666666666,\n",
       "  0.2,\n",
       "  1.0,\n",
       "  0.3333333333333333,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  0.3333333333333333,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  0.5,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.25,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.5,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.25,\n",
       "  0.5,\n",
       "  0.0,\n",
       "  1.0,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.5,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.5,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.3333333333333333,\n",
       "  1.0,\n",
       "  0.5,\n",
       "  0.1111111111111111,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  0.3333333333333333,\n",
       "  0.5,\n",
       "  0.09090909090909091,\n",
       "  0.3333333333333333,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  0.5,\n",
       "  0.05263157894736842,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.3333333333333333,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.0,\n",
       "  0.05263157894736842,\n",
       "  1.0,\n",
       "  0.3333333333333333,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  0.16666666666666666,\n",
       "  0.0,\n",
       "  0.0,\n",
       "  0.0],\n",
       " 'f1_ls': [0.5,\n",
       "  0,\n",
       "  1.0,\n",
       "  0.6666666666666666,\n",
       "  0.6666666666666666,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.19999999999999998,\n",
       "  1.0,\n",
       "  0,\n",
       "  0.14285714285714288,\n",
       "  0.6666666666666666,\n",
       "  0.1,\n",
       "  0.2222222222222222,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.2857142857142857,\n",
       "  0.33333333333333337,\n",
       "  1.0,\n",
       "  0.5,\n",
       "  0.6666666666666666,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0.6666666666666666,\n",
       "  0,\n",
       "  0,\n",
       "  0.4,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.6666666666666666,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0.4,\n",
       "  0.6666666666666666,\n",
       "  0,\n",
       "  1.0,\n",
       "  0.6666666666666666,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.6666666666666666,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.6666666666666666,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  0.6666666666666666,\n",
       "  0.19999999999999998,\n",
       "  0.6666666666666666,\n",
       "  1.0,\n",
       "  0.6666666666666666,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.6666666666666666,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.6666666666666666,\n",
       "  1.0,\n",
       "  0,\n",
       "  0.6666666666666666,\n",
       "  1.0,\n",
       "  0.5,\n",
       "  0.6666666666666666,\n",
       "  0.16666666666666669,\n",
       "  0.5,\n",
       "  0.6666666666666666,\n",
       "  1.0,\n",
       "  0.6666666666666666,\n",
       "  0.1,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  0.6666666666666666,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0,\n",
       "  0.5,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0.6666666666666666,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  0,\n",
       "  0.1,\n",
       "  1.0,\n",
       "  0.5,\n",
       "  0.6666666666666666,\n",
       "  1.0,\n",
       "  0.2857142857142857,\n",
       "  0,\n",
       "  0,\n",
       "  0],\n",
       " 'specificity_ls': [1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0,\n",
       "  1.0],\n",
       " 'pred_drugs_generic_set_ls': [{frozenset({'olaparib'})},\n",
       "  set(),\n",
       "  {frozenset({'ponatinib'})},\n",
       "  {frozenset({'axitinib'})},\n",
       "  {frozenset({'ivosidenib'})},\n",
       "  {frozenset({'everolimus'})},\n",
       "  {frozenset({'larotrectinib'})},\n",
       "  set(),\n",
       "  {frozenset({'sapanisertib'})},\n",
       "  {frozenset({'ipatasertib'})},\n",
       "  {frozenset({'osimertinib'})},\n",
       "  {frozenset({'crizotinib'})},\n",
       "  set(),\n",
       "  {frozenset({'erlotinib'})},\n",
       "  {frozenset({'olaparib'})},\n",
       "  {frozenset({'trastuzumab'})},\n",
       "  {frozenset({'alectinib'})},\n",
       "  {frozenset({'akt inhibitor mk2206'})},\n",
       "  {frozenset({'trastuzumab deruxtecan'})},\n",
       "  {frozenset({'afatinib', 'trametinib'})},\n",
       "  {frozenset({'alectinib'})},\n",
       "  {frozenset({'capivasertib', 'fulvestrant'})},\n",
       "  {frozenset({'olaparib'})},\n",
       "  {frozenset({'alectinib'})},\n",
       "  {frozenset({'olaparib'})},\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  {frozenset({'palbociclib'})},\n",
       "  {frozenset({'ceritinib'})},\n",
       "  set(),\n",
       "  {frozenset({'olaparib'})},\n",
       "  {frozenset({'crenolanib', 'imatinib'})},\n",
       "  {frozenset({'axitinib'})},\n",
       "  set(),\n",
       "  {frozenset({'gefitinib'})},\n",
       "  set(),\n",
       "  set(),\n",
       "  {frozenset({'vemurafenib'})},\n",
       "  {frozenset({'infigratinib'})},\n",
       "  {frozenset({'pembrolizumab'})},\n",
       "  {frozenset({'palbociclib'})},\n",
       "  {frozenset({'azacitidine', 'eprenetapopt'}),\n",
       "   frozenset({'cisplatin', 'doxorubicin', 'etoposide'})},\n",
       "  {frozenset({'imatinib'})},\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  {frozenset({'vemurafenib'})},\n",
       "  {frozenset({'tretinoin'})},\n",
       "  set(),\n",
       "  {frozenset({'larotrectinib'})},\n",
       "  {frozenset({'talazoparib'})},\n",
       "  {frozenset({'rucaparib'})},\n",
       "  {frozenset({'larotrectinib'})},\n",
       "  {frozenset({'erlotinib'})},\n",
       "  {frozenset({'cisplatin', 'fluorouracil'})},\n",
       "  {frozenset({'midostaurin'})},\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  {frozenset({'erlotinib'})},\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  {frozenset({'gemcitabine'})},\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  {frozenset({'vemurafenib'})},\n",
       "  {frozenset({'rucaparib'})},\n",
       "  {frozenset({'cixutumumab', 'teprotumumab'})},\n",
       "  set(),\n",
       "  {frozenset({'doxorubicin', 'salinomycin'})},\n",
       "  {frozenset({'pemigatinib'})},\n",
       "  {frozenset({'pemigatinib'})},\n",
       "  {frozenset({'tretinoin'})},\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  {frozenset({'crizotinib'})},\n",
       "  {frozenset({'crizotinib'})},\n",
       "  {frozenset({'capivasertib'})},\n",
       "  {frozenset({'trametinib'})},\n",
       "  {frozenset({'afatinib'})},\n",
       "  {frozenset({'sb202190'})},\n",
       "  {frozenset({'erlotinib'})},\n",
       "  {frozenset({'erlotinib'})},\n",
       "  {frozenset({'palbociclib'})},\n",
       "  {frozenset({'neratinib'})},\n",
       "  {frozenset({'olaparib'})},\n",
       "  {frozenset({'nilotinib'})},\n",
       "  {frozenset({'neratinib'})},\n",
       "  {frozenset({'tovorafenib'})},\n",
       "  {frozenset({'crizotinib'})},\n",
       "  {frozenset({'adjuvant chemotherapy'})},\n",
       "  set(),\n",
       "  {frozenset({'imatinib'})},\n",
       "  {frozenset({'afatinib'})},\n",
       "  {frozenset({'dacomitinib'})},\n",
       "  {frozenset({'olaparib'})},\n",
       "  {frozenset({'erlotinib'})},\n",
       "  {frozenset({'erlotinib'})},\n",
       "  {frozenset({'entrectinib'})},\n",
       "  {frozenset({'infigratinib'})},\n",
       "  {frozenset({'imatinib'})},\n",
       "  {frozenset({'trastuzumab'})},\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  {frozenset({'ponatinib'})},\n",
       "  {frozenset({'palbociclib'})},\n",
       "  {frozenset({'palbociclib'})},\n",
       "  set(),\n",
       "  set(),\n",
       "  set(),\n",
       "  {frozenset({'sapanisertib'})},\n",
       "  {frozenset({'entrectinib'})},\n",
       "  set(),\n",
       "  set(),\n",
       "  {frozenset({'alpelisib'})},\n",
       "  {frozenset({'neratinib'})},\n",
       "  {frozenset({'afatinib'})},\n",
       "  {frozenset({'letetresgene autoleucel'})},\n",
       "  set(),\n",
       "  {frozenset({'crizotinib'})},\n",
       "  {frozenset({'met tyrosine kinase inhibitor sgx523'})},\n",
       "  {frozenset({'bosutinib'})},\n",
       "  {frozenset({'regorafenib'})},\n",
       "  {frozenset({'imatinib'})},\n",
       "  {frozenset({'docetaxel'})},\n",
       "  set(),\n",
       "  {frozenset({'platinum compound', 'taxane compound'})},\n",
       "  set(),\n",
       "  {frozenset({'erlotinib'})},\n",
       "  {frozenset({'crizotinib'})},\n",
       "  {frozenset({'afatinib'})},\n",
       "  set(),\n",
       "  {frozenset({'crizotinib'})},\n",
       "  {frozenset({'imatinib'})},\n",
       "  set(),\n",
       "  {frozenset({'trastuzumab'})},\n",
       "  {frozenset({'irbesartan'})},\n",
       "  {frozenset({'dacomitinib'})},\n",
       "  {frozenset({'binimetinib'})},\n",
       "  {frozenset({'imatinib'})},\n",
       "  {frozenset({'afatinib', 'trametinib'})},\n",
       "  set(),\n",
       "  set(),\n",
       "  set()],\n",
       " 'true_drugs_generic_set_ls': [{frozenset({'olaparib'}),\n",
       "   frozenset({'cediranib', 'olaparib'}),\n",
       "   frozenset({'rucaparib'})},\n",
       "  {frozenset({'chemotherapy', 'osimertinib'}),\n",
       "   frozenset({'amivantamab', 'carboplatin', 'pemetrexed'}),\n",
       "   frozenset({'erlotinib', 'ramucirumab'}),\n",
       "   frozenset({'erlotinib', 'gefitinib'}),\n",
       "   frozenset({'lapatinib'}),\n",
       "   frozenset({'dacomitinib'}),\n",
       "   frozenset({'amivantamab', 'lazertinib'}),\n",
       "   frozenset({'gefitinib'}),\n",
       "   frozenset({'osimertinib'}),\n",
       "   frozenset({'erlotinib'}),\n",
       "   frozenset({'canertinib'}),\n",
       "   frozenset({'neratinib'}),\n",
       "   frozenset({'afatinib'})},\n",
       "  {frozenset({'ponatinib'})},\n",
       "  {frozenset({'axitinib'}), frozenset({'nilotinib'})},\n",
       "  {frozenset({'venetoclax'}), frozenset({'ivosidenib'})},\n",
       "  {frozenset({'everolimus'})},\n",
       "  {frozenset({'larotrectinib'})},\n",
       "  {frozenset({'erlotinib'}),\n",
       "   frozenset({'erlotinib', 'gefitinib', 'multikinase inhibitor aee788'})},\n",
       "  {frozenset({'sapanisertib'})},\n",
       "  {frozenset({'ipatasertib'})},\n",
       "  {frozenset({'osimertinib', 'rociletinib'}),\n",
       "   frozenset({'dacomitinib'}),\n",
       "   frozenset({'erlotinib', 'pemetrexed'}),\n",
       "   frozenset({'osimertinib'}),\n",
       "   frozenset({'canertinib'}),\n",
       "   frozenset({'staurosporine'}),\n",
       "   frozenset({'neratinib'}),\n",
       "   frozenset({'afatinib'}),\n",
       "   frozenset({'rociletinib'})},\n",
       "  {frozenset({'crizotinib'})},\n",
       "  {frozenset({'dasatinib', 'erlotinib'})},\n",
       "  {frozenset({'chemotherapy', 'osimertinib'}),\n",
       "   frozenset({'amivantamab', 'carboplatin', 'pemetrexed'}),\n",
       "   frozenset({'erlotinib', 'ramucirumab'}),\n",
       "   frozenset({'erlotinib', 'gefitinib'}),\n",
       "   frozenset({'lapatinib'}),\n",
       "   frozenset({'dacomitinib'}),\n",
       "   frozenset({'amivantamab', 'lazertinib'}),\n",
       "   frozenset({'gefitinib'}),\n",
       "   frozenset({'osimertinib'}),\n",
       "   frozenset({'erlotinib'}),\n",
       "   frozenset({'canertinib'}),\n",
       "   frozenset({'neratinib'}),\n",
       "   frozenset({'afatinib'})},\n",
       "  {frozenset({'rucaparib'}), frozenset({'olaparib'})},\n",
       "  {frozenset({'lapatinib'}),\n",
       "   frozenset({'capecitabine', 'lapatinib'}),\n",
       "   frozenset({'trastuzumab'}),\n",
       "   frozenset({'irinotecan', 'trastuzumab'}),\n",
       "   frozenset({'pilaralisib', 'trastuzumab'}),\n",
       "   frozenset({'pictilisib'}),\n",
       "   frozenset({'lapatinib', 'trastuzumab'}),\n",
       "   frozenset({'trastuzumab emtansine'}),\n",
       "   frozenset({'docetaxel', 'pertuzumab', 'trastuzumab'}),\n",
       "   frozenset({'trastuzumab deruxtecan'}),\n",
       "   frozenset({'afatinib', 'lapatinib', 'trastuzumab'}),\n",
       "   frozenset({'palbociclib', 'trastuzumab'}),\n",
       "   frozenset({'capecitabine', 'trastuzumab'}),\n",
       "   frozenset({'neratinib', 'trastuzumab'}),\n",
       "   frozenset({'pertuzumab', 'trastuzumab'}),\n",
       "   frozenset({'afatinib'}),\n",
       "   frozenset({'afatinib', 'trastuzumab'}),\n",
       "   frozenset({'neratinib'}),\n",
       "   frozenset({'a66'})},\n",
       "  {frozenset({'brigatinib'}),\n",
       "   frozenset({'crizotinib'}),\n",
       "   frozenset({'lorlatinib'}),\n",
       "   frozenset({'pemetrexed'}),\n",
       "   frozenset({'alectinib'}),\n",
       "   frozenset({'retaspimycin hydrochloride'}),\n",
       "   frozenset({'alectinib', 'crizotinib'}),\n",
       "   frozenset({'ceritinib'})},\n",
       "  {frozenset({'akt inhibitor mk2206'})},\n",
       "  {frozenset({'trastuzumab deruxtecan'})},\n",
       "  {frozenset({'cetuximab', 'dasatinib'}),\n",
       "   frozenset({'binimetinib', 'palbociclib'}),\n",
       "   frozenset({'b-raf/vegfr-2 inhibitor raf265', 'selumetinib'}),\n",
       "   frozenset({'selumetinib', 'teprotumumab'}),\n",
       "   frozenset({'epidermal growth factor receptor tyrosine kinase inhibitor',\n",
       "              'immunomodulatory oligonucleotide'}),\n",
       "   frozenset({'afatinib', 'trametinib'})},\n",
       "  {frozenset({'crizotinib'}),\n",
       "   frozenset({'lorlatinib'}),\n",
       "   frozenset({'alk inhibitor tae684'}),\n",
       "   frozenset({'alectinib'}),\n",
       "   frozenset({'azd3463'})},\n",
       "  {frozenset({'capivasertib', 'fulvestrant'})},\n",
       "  {frozenset({'olaparib'}),\n",
       "   frozenset({'cediranib', 'olaparib'}),\n",
       "   frozenset({'rucaparib'})},\n",
       "  {frozenset({'alectinib'}), frozenset({'ceritinib'})},\n",
       "  {frozenset({'olaparib'})},\n",
       "  {frozenset({'alpelisib'}),\n",
       "   frozenset({'pictilisib'}),\n",
       "   frozenset({'dactolisib', 'lapatinib'})},\n",
       "  {frozenset({'erlotinib'})},\n",
       "  {frozenset({'gemcitabine'}),\n",
       "   frozenset({'cisplatin', 'gemcitabine'}),\n",
       "   frozenset({'gemcitabine', 'paclitaxel', 'vinorelbine'}),\n",
       "   frozenset({'carboplatin', 'gemcitabine'})},\n",
       "  {frozenset({'palbociclib'})},\n",
       "  {frozenset({'ceritinib'})},\n",
       "  {frozenset({'erlotinib', 'gefitinib'})},\n",
       "  {frozenset({'cisplatin', 'gemcitabine', 'veliparib'}),\n",
       "   frozenset({'olaparib'}),\n",
       "   frozenset({'cisplatin', 'oxaliplatin'})},\n",
       "  {frozenset({'crenolanib', 'imatinib'})},\n",
       "  {frozenset({'axitinib'})},\n",
       "  {frozenset({'erdafitinib'})},\n",
       "  {frozenset({'epidermal growth factor receptor tyrosine kinase inhibitor'}),\n",
       "   frozenset({'gefitinib'})},\n",
       "  {frozenset({'chemotherapy'})},\n",
       "  {frozenset({'trastuzumab emtansine'})},\n",
       "  {frozenset({'dabrafenib'}),\n",
       "   frozenset({'trametinib'}),\n",
       "   frozenset({'vemurafenib'}),\n",
       "   frozenset({'dabrafenib', 'trametinib'})},\n",
       "  {frozenset({'infigratinib'})},\n",
       "  {frozenset({'pembrolizumab'})},\n",
       "  {frozenset({'palbociclib'})},\n",
       "  {frozenset({'azacitidine', 'eprenetapopt'}),\n",
       "   frozenset({'cisplatin', 'doxorubicin', 'etoposide'})},\n",
       "  {frozenset({'dasatinib'}), frozenset({'imatinib'})},\n",
       "  {frozenset({'selumetinib'}),\n",
       "   frozenset({'everolimus', 'trametinib'}),\n",
       "   frozenset({'tovorafenib'}),\n",
       "   frozenset({'trametinib'})},\n",
       "  {frozenset({'osimertinib'})},\n",
       "  {frozenset({'olaparib'})},\n",
       "  {frozenset({'lapatinib'}),\n",
       "   frozenset({'capecitabine', 'lapatinib'}),\n",
       "   frozenset({'trastuzumab'}),\n",
       "   frozenset({'irinotecan', 'trastuzumab'}),\n",
       "   frozenset({'pilaralisib', 'trastuzumab'}),\n",
       "   frozenset({'pictilisib'}),\n",
       "   frozenset({'lapatinib', 'trastuzumab'}),\n",
       "   frozenset({'trastuzumab emtansine'}),\n",
       "   frozenset({'docetaxel', 'pertuzumab', 'trastuzumab'}),\n",
       "   frozenset({'trastuzumab deruxtecan'}),\n",
       "   frozenset({'afatinib', 'lapatinib', 'trastuzumab'}),\n",
       "   frozenset({'palbociclib', 'trastuzumab'}),\n",
       "   frozenset({'capecitabine', 'trastuzumab'}),\n",
       "   frozenset({'neratinib', 'trastuzumab'}),\n",
       "   frozenset({'pertuzumab', 'trastuzumab'}),\n",
       "   frozenset({'afatinib'}),\n",
       "   frozenset({'afatinib', 'trastuzumab'}),\n",
       "   frozenset({'neratinib'}),\n",
       "   frozenset({'a66'})},\n",
       "  {frozenset({'sunitinib'})},\n",
       "  {frozenset({'olaparib'})},\n",
       "  {frozenset({'dabrafenib'}),\n",
       "   frozenset({'braf inhibitor',\n",
       "              'mitogen-activated protein kinase kinase inhibitor'}),\n",
       "   frozenset({'vemurafenib'}),\n",
       "   frozenset({'braf inhibitor'})},\n",
       "  {frozenset({'tretinoin'}), frozenset({'arsenic trioxide', 'tretinoin'})},\n",
       "  {frozenset({'docetaxel', 'selumetinib'})},\n",
       "  {frozenset({'larotrectinib'})},\n",
       "  {frozenset({'talazoparib'}), frozenset({'pidnarulex', 'quarfloxin'})},\n",
       "  {frozenset({'rucaparib'})},\n",
       "  {frozenset({'larotrectinib'})},\n",
       "  {frozenset({'erlotinib'})},\n",
       "  {frozenset({'cisplatin', 'fluorouracil'})},\n",
       "  {frozenset({'midostaurin'}), frozenset({'gilteritinib'})},\n",
       "  {frozenset({'patidegib'})},\n",
       "  {frozenset({'larotrectinib'})},\n",
       "  {frozenset({'vemurafenib'}), frozenset({'dabrafenib', 'trametinib'})},\n",
       "  {frozenset({'pasireotide'})},\n",
       "  {frozenset({'jq1', 'panobinostat'}),\n",
       "   frozenset({'fact complex-targeting curaxin cbl0137'})},\n",
       "  {frozenset({'erlotinib'})},\n",
       "  {frozenset({'dabrafenib'}),\n",
       "   frozenset({'trametinib'}),\n",
       "   frozenset({'dabrafenib', 'trametinib'}),\n",
       "   frozenset({'atezolizumab', 'cobimetinib', 'vemurafenib'}),\n",
       "   frozenset({'binimetinib', 'encorafenib'}),\n",
       "   frozenset({'cobimetinib', 'vemurafenib'})},\n",
       "  {frozenset({'ponatinib'})},\n",
       "  {frozenset({'dasatinib'}),\n",
       "   frozenset({'imatinib'}),\n",
       "   frozenset({'tyrosine kinase inhibitor'})},\n",
       "  {frozenset({'atezolizumab'}),\n",
       "   frozenset({'pembrolizumab'}),\n",
       "   frozenset({'nivolumab', 'pembrolizumab'}),\n",
       "   frozenset({'atezolizumab', 'avelumab', 'nivolumab', 'pembrolizumab'}),\n",
       "   frozenset({'atezolizumab',\n",
       "              'avelumab',\n",
       "              'durvalumab',\n",
       "              'nivolumab',\n",
       "              'pembrolizumab'})},\n",
       "  {frozenset({'entrectinib'}), frozenset({'larotrectinib'})},\n",
       "  {frozenset({'gemcitabine'})},\n",
       "  {frozenset({'gemcitabine'})},\n",
       "  {frozenset({'carboplatin', 'paclitaxel'})},\n",
       "  {frozenset({'dasatinib'}),\n",
       "   frozenset({'dasatinib', 'nilotinib'}),\n",
       "   frozenset({'bafetinib', 'dasatinib', 'nilotinib'}),\n",
       "   frozenset({'imatinib'})},\n",
       "  {frozenset({'nimotuzumab'}), frozenset({'erlotinib'})},\n",
       "  {frozenset({'vemurafenib'})},\n",
       "  {frozenset({'rucaparib'})},\n",
       "  {frozenset({'cixutumumab', 'teprotumumab'})},\n",
       "  {frozenset({'lapatinib', 'neratinib', 'trastuzumab'})},\n",
       "  {frozenset({'doxorubicin', 'salinomycin'})},\n",
       "  {frozenset({'pemigatinib'})},\n",
       "  {frozenset({'pemigatinib'})},\n",
       "  {frozenset({'tretinoin'}), frozenset({'arsenic trioxide', 'tretinoin'})},\n",
       "  {frozenset({'checkpoint kinase inhibitor azd7762', 'irinotecan'})},\n",
       "  {frozenset({'zenocutuzumab-zbco'}), frozenset({'afatinib'})},\n",
       "  {frozenset({'afatinib'}),\n",
       "   frozenset({'erlotinib'}),\n",
       "   frozenset({'gefitinib'})},\n",
       "  {frozenset({'tepotinib'}),\n",
       "   frozenset({'capmatinib'}),\n",
       "   frozenset({'crizotinib'})},\n",
       "  {frozenset({'crizotinib'})},\n",
       "  {frozenset({'capivasertib'}),\n",
       "   frozenset({'buparlisib', 'carboplatin', 'paclitaxel'})},\n",
       "  {frozenset({'immune checkpoint inhibitor'}),\n",
       "   frozenset({'abemaciclib'}),\n",
       "   frozenset({'erlotinib', 'teprotumumab'}),\n",
       "   frozenset({'trametinib'}),\n",
       "   frozenset({'b-raf/vegfr-2 inhibitor raf265', 'selumetinib'}),\n",
       "   frozenset({'docetaxel', 'pemetrexed', 'trametinib'}),\n",
       "   frozenset({'docetaxel', 'selumetinib'}),\n",
       "   frozenset({'atezolizumab', 'nivolumab'}),\n",
       "   frozenset({'afatinib', 'trametinib'})},\n",
       "  {frozenset({'afatinib'}), frozenset({'dacomitinib'})},\n",
       "  {frozenset({'sb202190'})},\n",
       "  {frozenset({'erlotinib'}),\n",
       "   frozenset({'erlotinib', 'gefitinib', 'multikinase inhibitor aee788'})},\n",
       "  {frozenset({'erlotinib'})},\n",
       "  {frozenset({'palbociclib'})},\n",
       "  {frozenset({'neratinib'})},\n",
       "  {frozenset({'olaparib'})},\n",
       "  {frozenset({'dasatinib'}), frozenset({'nilotinib'})},\n",
       "  {frozenset({'neratinib'})},\n",
       "  {frozenset({'tovorafenib'})},\n",
       "  {frozenset({'entrectinib'}), frozenset({'crizotinib'})},\n",
       "  {frozenset({'adjuvant chemotherapy'})},\n",
       "  {frozenset({'gefitinib'})},\n",
       "  {frozenset({'regorafenib'}), frozenset({'imatinib'})},\n",
       "  {frozenset({'afatinib'})},\n",
       "  {frozenset({'erlotinib', 'gefitinib'}),\n",
       "   frozenset({'epidermal growth factor receptor tyrosine kinase inhibitor'}),\n",
       "   frozenset({'dacomitinib'})},\n",
       "  {frozenset({'talazoparib'}), frozenset({'olaparib'})},\n",
       "  {frozenset({'chemotherapy', 'osimertinib'}),\n",
       "   frozenset({'amivantamab', 'carboplatin', 'pemetrexed'}),\n",
       "   frozenset({'dacomitinib', 'erlotinib'}),\n",
       "   frozenset({'erlotinib', 'ramucirumab'}),\n",
       "   frozenset({'erlotinib', 'gefitinib'}),\n",
       "   frozenset({'dacomitinib'}),\n",
       "   frozenset({'amivantamab', 'lazertinib'}),\n",
       "   frozenset({'gefitinib'}),\n",
       "   frozenset({'osimertinib'}),\n",
       "   frozenset({'erlotinib'}),\n",
       "   frozenset({'afatinib'})},\n",
       "  {frozenset({'afatinib'}),\n",
       "   frozenset({'erlotinib'}),\n",
       "   frozenset({'gefitinib'})},\n",
       "  {frozenset({'entrectinib'}), frozenset({'crizotinib'})},\n",
       "  {frozenset({'infigratinib'})},\n",
       "  {frozenset({'regorafenib'}), frozenset({'imatinib'})},\n",
       "  {frozenset({'lapatinib'}),\n",
       "   frozenset({'capecitabine', 'lapatinib'}),\n",
       "   frozenset({'trastuzumab'}),\n",
       "   frozenset({'irinotecan', 'trastuzumab'}),\n",
       "   frozenset({'pilaralisib', 'trastuzumab'}),\n",
       "   frozenset({'pictilisib'}),\n",
       "   frozenset({'lapatinib', 'trastuzumab'}),\n",
       "   frozenset({'trastuzumab emtansine'}),\n",
       "   frozenset({'docetaxel', 'pertuzumab', 'trastuzumab'}),\n",
       "   frozenset({'trastuzumab deruxtecan'}),\n",
       "   frozenset({'afatinib', 'lapatinib', 'trastuzumab'}),\n",
       "   frozenset({'palbociclib', 'trastuzumab'}),\n",
       "   frozenset({'capecitabine', 'trastuzumab'}),\n",
       "   frozenset({'neratinib', 'trastuzumab'}),\n",
       "   frozenset({'pertuzumab', 'trastuzumab'}),\n",
       "   frozenset({'afatinib'}),\n",
       "   frozenset({'afatinib', 'trastuzumab'}),\n",
       "   frozenset({'neratinib'}),\n",
       "   frozenset({'a66'})},\n",
       "  {frozenset({'erlotinib', 'gefitinib'})},\n",
       "  {frozenset({'platinum compound'}),\n",
       "   frozenset({'niraparib'}),\n",
       "   frozenset({'carboplatin', 'cisplatin'}),\n",
       "   frozenset({'olaparib'})},\n",
       "  {frozenset({'pazopanib'}), frozenset({'ponatinib'})},\n",
       "  {frozenset({'pazopanib'}), frozenset({'ponatinib'})},\n",
       "  {frozenset({'palbociclib'})},\n",
       "  {frozenset({'palbociclib'})},\n",
       "  {frozenset({'rucaparib'})},\n",
       "  {frozenset({'temsirolimus'})},\n",
       "  {frozenset({'pazopanib', 'vorinostat'})},\n",
       "  {frozenset({'sapanisertib'})},\n",
       "  {frozenset({'entrectinib'})},\n",
       "  {frozenset({'chemotherapy', 'osimertinib'}),\n",
       "   frozenset({'amivantamab', 'carboplatin', 'pemetrexed'}),\n",
       "   frozenset({'erlotinib', 'ramucirumab'}),\n",
       "   frozenset({'erlotinib', 'gefitinib'}),\n",
       "   frozenset({'lapatinib'}),\n",
       "   frozenset({'dacomitinib'}),\n",
       "   frozenset({'amivantamab', 'lazertinib'}),\n",
       "   frozenset({'gefitinib'}),\n",
       "   frozenset({'osimertinib'}),\n",
       "   frozenset({'erlotinib'}),\n",
       "   frozenset({'canertinib'}),\n",
       "   frozenset({'neratinib'}),\n",
       "   frozenset({'afatinib'})},\n",
       "  {frozenset({'osimertinib', 'rociletinib'}),\n",
       "   frozenset({'dacomitinib'}),\n",
       "   frozenset({'erlotinib', 'pemetrexed'}),\n",
       "   frozenset({'osimertinib'}),\n",
       "   frozenset({'canertinib'}),\n",
       "   frozenset({'staurosporine'}),\n",
       "   frozenset({'neratinib'}),\n",
       "   frozenset({'afatinib'}),\n",
       "   frozenset({'rociletinib'})},\n",
       "  {frozenset({'dactolisib'}),\n",
       "   frozenset({'alpelisib'}),\n",
       "   frozenset({'cetuximab', 'dactolisib'})},\n",
       "  {frozenset({'neratinib'})},\n",
       "  {frozenset({'afatinib'})},\n",
       "  {frozenset({'letetresgene autoleucel'})},\n",
       "  {frozenset({'olaparib'})},\n",
       "  {frozenset({'crizotinib'})},\n",
       "  {frozenset({'met tyrosine kinase inhibitor sgx523'})},\n",
       "  {frozenset({'bosutinib'})},\n",
       "  {frozenset({'regorafenib'})},\n",
       "  {frozenset({'regorafenib'}), frozenset({'imatinib'})},\n",
       "  {frozenset({'docetaxel'})},\n",
       "  {frozenset({'dabrafenib', 'panitumumab', 'trametinib'}),\n",
       "   frozenset({'cetuximab', 'gefitinib', 'vemurafenib'}),\n",
       "   frozenset({'cetuximab', 'encorafenib'}),\n",
       "   frozenset({'vemurafenib'}),\n",
       "   frozenset({'panitumumab', 'sorafenib'}),\n",
       "   frozenset({'pictilisib bismesylate', 'plx4720'}),\n",
       "   frozenset({'panitumumab', 'vemurafenib'}),\n",
       "   frozenset({'erlotinib', 'vemurafenib'}),\n",
       "   frozenset({'cobimetinib', 'vemurafenib'}),\n",
       "   frozenset({'dactolisib', 'gdc-0879'}),\n",
       "   frozenset({'cetuximab', 'irinotecan', 'vemurafenib'}),\n",
       "   frozenset({'binimetinib', 'cetuximab', 'encorafenib'}),\n",
       "   frozenset({'bevacizumab', 'capecitabine', 'vemurafenib'})},\n",
       "  {frozenset({'platinum compound', 'taxane compound'})},\n",
       "  {frozenset({'lapatinib'}),\n",
       "   frozenset({'capecitabine', 'lapatinib'}),\n",
       "   frozenset({'trastuzumab'}),\n",
       "   frozenset({'irinotecan', 'trastuzumab'}),\n",
       "   frozenset({'pilaralisib', 'trastuzumab'}),\n",
       "   frozenset({'pictilisib'}),\n",
       "   frozenset({'lapatinib', 'trastuzumab'}),\n",
       "   frozenset({'trastuzumab emtansine'}),\n",
       "   frozenset({'docetaxel', 'pertuzumab', 'trastuzumab'}),\n",
       "   frozenset({'trastuzumab deruxtecan'}),\n",
       "   frozenset({'afatinib', 'lapatinib', 'trastuzumab'}),\n",
       "   frozenset({'palbociclib', 'trastuzumab'}),\n",
       "   frozenset({'capecitabine', 'trastuzumab'}),\n",
       "   frozenset({'neratinib', 'trastuzumab'}),\n",
       "   frozenset({'pertuzumab', 'trastuzumab'}),\n",
       "   frozenset({'afatinib'}),\n",
       "   frozenset({'afatinib', 'trastuzumab'}),\n",
       "   frozenset({'neratinib'}),\n",
       "   frozenset({'a66'})},\n",
       "  {frozenset({'erlotinib'})},\n",
       "  {frozenset({'crizotinib'})},\n",
       "  {frozenset({'afatinib'})},\n",
       "  {frozenset({'pembrolizumab'})},\n",
       "  {frozenset({'crizotinib'})},\n",
       "  {frozenset({'imatinib'})},\n",
       "  {frozenset({'chemotherapy', 'osimertinib'}),\n",
       "   frozenset({'amivantamab', 'carboplatin', 'pemetrexed'}),\n",
       "   frozenset({'erlotinib', 'ramucirumab'}),\n",
       "   frozenset({'erlotinib', 'gefitinib'}),\n",
       "   frozenset({'lapatinib'}),\n",
       "   frozenset({'dacomitinib'}),\n",
       "   frozenset({'amivantamab', 'lazertinib'}),\n",
       "   frozenset({'gefitinib'}),\n",
       "   frozenset({'osimertinib'}),\n",
       "   frozenset({'erlotinib'}),\n",
       "   frozenset({'canertinib'}),\n",
       "   frozenset({'neratinib'}),\n",
       "   frozenset({'afatinib'})},\n",
       "  {frozenset({'lapatinib'}),\n",
       "   frozenset({'capecitabine', 'lapatinib'}),\n",
       "   frozenset({'trastuzumab'}),\n",
       "   frozenset({'irinotecan', 'trastuzumab'}),\n",
       "   frozenset({'pilaralisib', 'trastuzumab'}),\n",
       "   frozenset({'pictilisib'}),\n",
       "   frozenset({'lapatinib', 'trastuzumab'}),\n",
       "   frozenset({'trastuzumab emtansine'}),\n",
       "   frozenset({'docetaxel', 'pertuzumab', 'trastuzumab'}),\n",
       "   frozenset({'trastuzumab deruxtecan'}),\n",
       "   frozenset({'afatinib', 'lapatinib', 'trastuzumab'}),\n",
       "   frozenset({'palbociclib', 'trastuzumab'}),\n",
       "   frozenset({'capecitabine', 'trastuzumab'}),\n",
       "   frozenset({'neratinib', 'trastuzumab'}),\n",
       "   frozenset({'pertuzumab', 'trastuzumab'}),\n",
       "   frozenset({'afatinib'}),\n",
       "   frozenset({'afatinib', 'trastuzumab'}),\n",
       "   frozenset({'neratinib'}),\n",
       "   frozenset({'a66'})},\n",
       "  {frozenset({'irbesartan'})},\n",
       "  {frozenset({'erlotinib', 'gefitinib'}),\n",
       "   frozenset({'epidermal growth factor receptor tyrosine kinase inhibitor'}),\n",
       "   frozenset({'dacomitinib'})},\n",
       "  {frozenset({'selumetinib'}), frozenset({'binimetinib'})},\n",
       "  {frozenset({'imatinib'})},\n",
       "  {frozenset({'cetuximab', 'dasatinib'}),\n",
       "   frozenset({'binimetinib', 'palbociclib'}),\n",
       "   frozenset({'b-raf/vegfr-2 inhibitor raf265', 'selumetinib'}),\n",
       "   frozenset({'selumetinib', 'teprotumumab'}),\n",
       "   frozenset({'epidermal growth factor receptor tyrosine kinase inhibitor',\n",
       "              'immunomodulatory oligonucleotide'}),\n",
       "   frozenset({'afatinib', 'trametinib'})},\n",
       "  {frozenset({'platinum compound'})},\n",
       "  {frozenset({'onatasertib', 'sapanisertib'})},\n",
       "  {frozenset({'gsk126'})}]}"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from utils.evaluation import calc_eval_metrics\n",
    "\n",
    "output_eval = calc_eval_metrics(output_res['full output'][0], \n",
    "                                standardized_to_raw_mapping_subset.reset_index(drop=True)['prompt'], \n",
    "                                synthetic_query_therapy_pair_dict)\n",
    "output_eval"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "ec7174ea",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Index([  0,   1,   3,   4,   7,  10,  12,  13,  14,  15,  16,  19,  20,  22,\n",
      "        23,  25,  26,  27,  30,  31,  34,  35,  36,  37,  38,  43,  44,  45,\n",
      "        46,  47,  48,  49,  50,  51,  52,  54,  59,  60,  61,  62,  63,  64,\n",
      "        66,  67,  68,  69,  70,  71,  73,  74,  75,  79,  83,  84,  85,  86,\n",
      "        87,  89,  90,  91,  93,  98, 101, 103, 104, 106, 107, 108, 109, 110,\n",
      "       112, 113, 114, 115, 116, 117, 120, 121, 122, 125, 126, 127, 131, 136,\n",
      "       138, 140, 144, 147, 148, 150, 151, 153, 154, 155, 156],\n",
      "      dtype='int64')\n"
     ]
    }
   ],
   "source": [
    "exact_failed_ind = standardized_to_raw_mapping_subset.reset_index(drop=True)[~np.array(output_eval['exact_match_acc'])].index\n",
    "print(exact_failed_ind)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "db44b4dc",
   "metadata": {},
   "outputs": [
    {
     "ename": "FileNotFoundError",
     "evalue": "[Errno 2] No such file or directory: 'external-validation/non-moa-database/civic/civic-db/synthetic_query_answer_pair_dict.pkl'",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mFileNotFoundError\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[37], line 4\u001b[0m\n\u001b[1;32m      1\u001b[0m \u001b[38;5;28;01mfrom\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21;01mutils\u001b[39;00m\u001b[38;5;21;01m.\u001b[39;00m\u001b[38;5;21;01mio\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mimport\u001b[39;00m load_object, save_object\n\u001b[1;32m      2\u001b[0m synthetic_query_therapy_pair_dict \u001b[38;5;241m=\u001b[39m load_object(\n\u001b[1;32m      3\u001b[0m             \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mexternal-validation/non-moa-database/civic/civic-db/synthetic_query_therapy_pair_dict.pkl\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n\u001b[0;32m----> 4\u001b[0m synthetic_query_answer_pair_dict \u001b[38;5;241m=\u001b[39m \u001b[43mload_object\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m      5\u001b[0m \u001b[43m            \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mexternal-validation/non-moa-database/civic/civic-db/synthetic_query_answer_pair_dict.pkl\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m)\u001b[49m\n",
      "File \u001b[0;32m~/Documents/GitHub/rag-llm-cancer-paper/utils/io.py:11\u001b[0m, in \u001b[0;36mload_object\u001b[0;34m(filename)\u001b[0m\n\u001b[1;32m     10\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;21mload_object\u001b[39m(filename):\n\u001b[0;32m---> 11\u001b[0m     \u001b[38;5;28;01mwith\u001b[39;00m \u001b[38;5;28;43mopen\u001b[39;49m\u001b[43m(\u001b[49m\u001b[43mfilename\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[38;5;124;43mrb\u001b[39;49m\u001b[38;5;124;43m\"\u001b[39;49m\u001b[43m)\u001b[49m \u001b[38;5;28;01mas\u001b[39;00m \u001b[38;5;28minput\u001b[39m:\n\u001b[1;32m     12\u001b[0m         obj \u001b[38;5;241m=\u001b[39m pickle\u001b[38;5;241m.\u001b[39mload(\u001b[38;5;28minput\u001b[39m)\n\u001b[1;32m     13\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m(obj)\n",
      "\u001b[0;31mFileNotFoundError\u001b[0m: [Errno 2] No such file or directory: 'external-validation/non-moa-database/civic/civic-db/synthetic_query_answer_pair_dict.pkl'"
     ]
    }
   ],
   "source": [
    "from utils.io import load_object, save_object\n",
    "synthetic_query_therapy_pair_dict = load_object(\n",
    "            \"external-validation/non-moa-database/civic/civic-db/synthetic_query_therapy_pair_dict.pkl\")\n",
    "synthetic_query_answer_pair_dict = load_object(\n",
    "            \"external-validation/non-moa-database/civic/civic-db/synthetic_query_answer_pair_dict.pkl\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "bb72c751",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "if a patient with Ovarian Cancer cancer has brca2 mutation, what therapy is recommended?\n",
      "[{'cediranib', 'olaparib'}, {'olaparib'}, {'rucaparib'}, {'rucaparib'}, {'olaparib'}, {'rucaparib'}, {'rucaparib'}]\n",
      "7\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/7276', 'If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/1773', 'If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/11137', 'If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/11139', 'If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is cediranib + olaparib. entry url: https://civicdb.org/links/evidence_items/1678', 'If a patient with Ovarian Cancer cancer has brca2 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/212', 'If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/6343', 'If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2868', 'If a patient with Ovarian Cancer cancer has brca2 v211l, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2882', 'If a patient with Ovarian Cancer cancer has brca2 v211i, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2883']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Ovarian Cancer cancer has brca2 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Ovarian Cancer\",\n",
      "    \"Disease Phase or Condition\": \"Cancer with BRCA2 mutation\",\n",
      "    \"Drug Name\": \"olaparib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"BRCA2 mutation\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/7276\"\n",
      "  }\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, what therapy is recommended?\n",
      "[{'erlotinib', 'gefitinib'}, {'erlotinib', 'gefitinib'}, {'gefitinib'}, {'erlotinib'}, {'afatinib'}, {'gefitinib'}, {'gefitinib'}, {'gefitinib'}, {'lapatinib'}, {'dacomitinib'}, {'neratinib'}, {'afatinib'}, {'canertinib'}, {'erlotinib'}, {'erlotinib'}, {'afatinib'}, {'erlotinib'}, {'erlotinib'}, {'erlotinib'}, {'osimertinib'}, {'erlotinib', 'gefitinib'}, {'dacomitinib'}, {'dacomitinib'}, {'osimertinib'}, {'dacomitinib'}, {'erlotinib', 'ramucirumab'}, {'gefitinib'}, {'osimertinib', 'chemotherapy'}, {'amivantamab', 'lazertinib'}, {'amivantamab', 'pemetrexed', 'carboplatin'}]\n",
      "30\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4286', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4287', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4284', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/2994', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is canertinib. entry url: https://civicdb.org/links/evidence_items/2631', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/885', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2621', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/276', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2156', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/2628']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 v299l, what therapy is recommended?\n",
      "[{'nilotinib'}, {'axitinib'}, {'axitinib'}]\n",
      "3\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 v299l, one recommended therapy is axitinib. entry url: https://civicdb.org/links/evidence_items/7767', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 v299l, one recommended therapy is axitinib. entry url: https://civicdb.org/links/evidence_items/4537', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 v299l, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2862', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 q252h, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/2650', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 m351t, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/2682', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 m351t, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/2684', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 e255k, abl1 v299l, one recommended therapy is ponatinib + dasatinib. entry url: https://civicdb.org/links/evidence_items/7781', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 t315v, one recommended therapy is axitinib. entry url: https://civicdb.org/links/evidence_items/7766', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 d276g, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2666', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 e279k, one recommended therapy is axitinib. entry url: https://civicdb.org/links/evidence_items/7772']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 v299l, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Chronic Myelogenous Leukemia\",\n",
      "    \"Disease Phase or Condition\": \"Chronic phase\",\n",
      "    \"Drug Name\": \"Axitinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"V299L mutation in BCR::ABL1 fusion\",\n",
      "    \"Genomic Features\": \"bcr::abl1 fusion, abl1 v299l\",\n",
      "    \"FDA-approval status\": \"Not explicitly FDA-approved for CML, but recommended based on evidence\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/7767\"\n",
      "  }\n",
      "}\n",
      "if a patient with Acute Myeloid Leukemia cancer has idh1 mutation, what therapy is recommended?\n",
      "[{'ivosidenib'}, {'venetoclax'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Acute Myeloid Leukemia cancer has idh1 mutation, one recommended therapy is ivosidenib. entry url: https://civicdb.org/links/evidence_items/7278', 'If a patient with Acute Myeloid Leukemia cancer has idh1 mutation, one recommended therapy is venetoclax. entry url: https://civicdb.org/links/evidence_items/8856', 'If a patient with Acute Myeloid Leukemia cancer has idh1 r132c, one recommended therapy is ivosidenib. entry url: https://civicdb.org/links/evidence_items/2331', 'If a patient with Acute Myeloid Leukemia cancer has idh1 r132c, one recommended therapy is gsk321. entry url: https://civicdb.org/links/evidence_items/732', 'If a patient with Acute Myeloid Leukemia cancer has idh1 r132c, one recommended therapy is bptes. entry url: https://civicdb.org/links/evidence_items/2332', 'If a patient with Acute Myeloid Leukemia cancer has kit rs3733542, one recommended therapy is selumetinib. entry url: https://civicdb.org/links/evidence_items/1136', 'If a patient with Melanoma cancer has nras q61r, one recommended therapy is temozolomide. entry url: https://civicdb.org/links/evidence_items/23', 'If a patient with Melanoma cancer has nras q61l, one recommended therapy is temozolomide. entry url: https://civicdb.org/links/evidence_items/22', 'If a patient with Melanoma cancer has nras mutation, one recommended therapy is binimetinib. entry url: https://civicdb.org/links/evidence_items/2937', 'If a patient with Melanoma cancer has nras mutation, one recommended therapy is binimetinib. entry url: https://civicdb.org/links/evidence_items/1472']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Acute Myeloid Leukemia cancer has idh1 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "    \"Disease Phase or Condition\": \"cancer\",\n",
      "    \"Drug Name\": \"ivosidenib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"not specified\",\n",
      "    \"Genomic Features\": \"idh1 mutation\",\n",
      "    \"FDA-approval status\": \"recommended therapy for IDH1 mutation in AML\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/7278\"\n",
      "  }\n",
      "}\n",
      "if a patient with Cancer cancer has egfr l858r, what therapy is recommended?\n",
      "[{'erlotinib', 'gefitinib', 'multikinase inhibitor aee788'}, {'erlotinib'}, {'erlotinib'}, {'erlotinib'}]\n",
      "4\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4285', 'If a patient with Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4265', 'If a patient with Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/5922', 'If a patient with nan cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4295', 'If a patient with nan cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4293', 'If a patient with Lung Adenocarcinoma cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4291', 'If a patient with Lung Adenocarcinoma cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/3791', 'If a patient with Lung Adenocarcinoma cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4290', 'If a patient with Lung Adenocarcinoma cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2634', 'If a patient with Lung Adenocarcinoma cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2624']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Cancer cancer has egfr l858r, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, what therapy is recommended?\n",
      "[{'erlotinib', 'pemetrexed'}, {'staurosporine'}, {'rociletinib'}, {'rociletinib'}, {'osimertinib'}, {'osimertinib'}, {'osimertinib'}, {'osimertinib', 'rociletinib'}, {'osimertinib'}, {'osimertinib'}, {'dacomitinib'}, {'neratinib'}, {'afatinib'}, {'afatinib'}, {'canertinib'}]\n",
      "15\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/2164', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is canertinib. entry url: https://civicdb.org/links/evidence_items/2165', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/2162', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/965', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is dacomitinib. entry url: https://civicdb.org/links/evidence_items/2161', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/1592', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is staurosporine. entry url: https://civicdb.org/links/evidence_items/278', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/966', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/1867', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/2163']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "    \"Disease Phase or Condition\": \"EGFR T790M mutation\",\n",
      "    \"Drug Name\": \"osimertinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"Resistance to first-generation EGFR inhibitors\",\n",
      "    \"Genomic Features\": \"EGFR T790M mutation\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/965\"\n",
      "  }\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has ddr2 s768r, what therapy is recommended?\n",
      "[{'dasatinib', 'erlotinib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has ddr2 s768r, one recommended therapy is dasatinib + erlotinib. entry url: https://civicdb.org/links/evidence_items/272', 'If a patient with Melanoma cancer has nras q61, one recommended therapy is binimetinib. entry url: https://civicdb.org/links/evidence_items/1226', 'If a patient with Melanoma cancer has braf v600e, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/1398', 'If a patient with Melanoma cancer has nras mutation, one recommended therapy is binimetinib. entry url: https://civicdb.org/links/evidence_items/1472', 'If a patient with Melanoma cancer has nras g13d, one recommended therapy is tanespimycin. entry url: https://civicdb.org/links/evidence_items/21', 'If a patient with Melanoma cancer has akt1 e17k, one recommended therapy is uprosertib. entry url: https://civicdb.org/links/evidence_items/707', 'If a patient with Melanoma cancer has nras q61l, one recommended therapy is temozolomide. entry url: https://civicdb.org/links/evidence_items/22', 'If a patient with Melanoma cancer has kit l576p, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/42', 'If a patient with Melanoma cancer has nras q61r, one recommended therapy is temozolomide. entry url: https://civicdb.org/links/evidence_items/23', 'If a patient with Melanoma cancer has braf v600e, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/3755']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has ddr2 s768r, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, what therapy is recommended?\n",
      "[{'erlotinib', 'gefitinib'}, {'erlotinib', 'gefitinib'}, {'gefitinib'}, {'erlotinib'}, {'afatinib'}, {'gefitinib'}, {'gefitinib'}, {'gefitinib'}, {'lapatinib'}, {'dacomitinib'}, {'neratinib'}, {'afatinib'}, {'canertinib'}, {'erlotinib'}, {'erlotinib'}, {'afatinib'}, {'erlotinib'}, {'erlotinib'}, {'erlotinib'}, {'osimertinib'}, {'erlotinib', 'gefitinib'}, {'dacomitinib'}, {'dacomitinib'}, {'osimertinib'}, {'dacomitinib'}, {'erlotinib', 'ramucirumab'}, {'gefitinib'}, {'osimertinib', 'chemotherapy'}, {'amivantamab', 'lazertinib'}, {'amivantamab', 'pemetrexed', 'carboplatin'}]\n",
      "30\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4287', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2621', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/276', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2156', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/2628', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/968', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is lapatinib. entry url: https://civicdb.org/links/evidence_items/2626', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/11219', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is dacomitinib. entry url: https://civicdb.org/links/evidence_items/11239', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is dacomitinib. entry url: https://civicdb.org/links/evidence_items/4860']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "    \"Disease Phase or Condition\": \"EGFR L858R mutation\",\n",
      "    \"Drug Name\": \"Erlotinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"EGFR L858R\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/4287\"\n",
      "  }\n",
      "}\n",
      "if a patient with nan cancer has brca1 loss-of-function, what therapy is recommended?\n",
      "[{'olaparib'}, {'olaparib'}, {'olaparib'}, {'rucaparib'}]\n",
      "4\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has brca1 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/11216', 'If a patient with nan cancer has brca1 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/5815', 'If a patient with nan cancer has brca1 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/11201', 'If a patient with nan cancer has brca1 loss-of-function, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/11739', 'If a patient with Prostate Cancer cancer has brca1 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/845', 'If a patient with Pancreatic Adenocarcinoma cancer has brca1 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/7384', 'If a patient with Breast Cancer cancer has brca1 loss-of-function, one recommended therapy is talazoparib. entry url: https://civicdb.org/links/evidence_items/4838', 'If a patient with Ovarian Cancer cancer has brca1 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/211', 'If a patient with Ovarian Cancer cancer has brca1 loss-of-function, one recommended therapy is talazoparib. entry url: https://civicdb.org/links/evidence_items/4876', 'If a patient with nan cancer has bcr::pdgfra fusion, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/7990']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has brca1 loss-of-function, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"nan cancer\",\n",
      "    \"Disease Phase or Condition\": \"nan cancer with BRCA1 loss-of-function\",\n",
      "    \"Drug Name\": \"olaparib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"not specified\",\n",
      "    \"Genomic Features\": \"BRCA1 loss-of-function\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/11216\"\n",
      "  }\n",
      "}\n",
      "if a patient with nan cancer has erbb2 amplification, what therapy is recommended?\n",
      "[{'trastuzumab'}, {'trastuzumab'}, {'neratinib'}, {'afatinib'}, {'afatinib', 'trastuzumab', 'lapatinib'}, {'afatinib'}, {'trastuzumab', 'lapatinib'}, {'trastuzumab', 'lapatinib'}, {'afatinib'}, {'afatinib', 'trastuzumab'}, {'trastuzumab', 'irinotecan'}, {'docetaxel', 'trastuzumab', 'pertuzumab'}, {'trastuzumab'}, {'neratinib', 'trastuzumab'}, {'trastuzumab'}, {'capecitabine', 'lapatinib'}, {'trastuzumab', 'capecitabine'}, {'trastuzumab emtansine'}, {'trastuzumab emtansine'}, {'pictilisib'}, {'a66'}, {'trastuzumab emtansine'}, {'docetaxel', 'trastuzumab', 'pertuzumab'}, {'trastuzumab', 'lapatinib'}, {'trastuzumab', 'pilaralisib'}, {'trastuzumab', 'palbociclib'}, {'trastuzumab'}, {'trastuzumab emtansine'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab deruxtecan'}, {'lapatinib'}]\n",
      "32\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/761', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is a66. entry url: https://civicdb.org/links/evidence_items/1381', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/1011', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/961', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/529', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/528', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/1693', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/1764', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/1122', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/886']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has erbb2 amplification, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"nan cancer\",\n",
      "    \"Disease Phase or Condition\": \"nan cancer with ERBB2 amplification\",\n",
      "    \"Drug Name\": \"trastuzumab\",\n",
      "    \"Prior Treatment or Resistance Status\": \"not specified\",\n",
      "    \"Genomic Features\": \"ERBB2 amplification\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/529\"\n",
      "  }\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has v::alk fusion, what therapy is recommended?\n",
      "[{'pemetrexed'}, {'ceritinib'}, {'crizotinib'}, {'crizotinib'}, {'crizotinib'}, {'crizotinib'}, {'crizotinib'}, {'retaspimycin hydrochloride'}, {'alectinib'}, {'alectinib'}, {'alectinib'}, {'alectinib'}, {'crizotinib'}, {'crizotinib'}, {'brigatinib'}, {'alectinib', 'crizotinib'}, {'alectinib'}, {'ceritinib'}, {'lorlatinib'}, {'alectinib'}, {'brigatinib'}, {'alectinib'}]\n",
      "22\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has v::alk fusion, one recommended therapy is alectinib. entry url: https://civicdb.org/links/evidence_items/12012', 'If a patient with Non-Small Cell Lung Cancer cancer has v::alk fusion, one recommended therapy is alectinib. entry url: https://civicdb.org/links/evidence_items/1272', 'If a patient with Non-Small Cell Lung Cancer cancer has v::alk fusion, one recommended therapy is alectinib. entry url: https://civicdb.org/links/evidence_items/1279', 'If a patient with Non-Small Cell Lung Cancer cancer has v::alk fusion, one recommended therapy is alectinib. entry url: https://civicdb.org/links/evidence_items/1282', 'If a patient with Non-Small Cell Lung Cancer cancer has v::alk fusion, one recommended therapy is lorlatinib. entry url: https://civicdb.org/links/evidence_items/7286', 'If a patient with Non-Small Cell Lung Cancer cancer has v::alk fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1577', 'If a patient with Non-Small Cell Lung Cancer cancer has v::alk fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1198', 'If a patient with Non-Small Cell Lung Cancer cancer has v::alk fusion, one recommended therapy is retaspimycin hydrochloride. entry url: https://civicdb.org/links/evidence_items/1202', 'If a patient with Non-Small Cell Lung Cancer cancer has v::alk fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1419', 'If a patient with Non-Small Cell Lung Cancer cancer has v::alk fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1187']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has v::alk fusion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "    \"Disease Phase or Condition\": \"v::alk fusion positive\",\n",
      "    \"Drug Name\": \"Alectinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "    \"Genomic Features\": \"v::alk fusion\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/12012\"\n",
      "  }\n",
      "}\n",
      "if a patient with Colorectal Cancer cancer has kras mutation, what therapy is recommended?\n",
      "[{'immunomodulatory oligonucleotide', 'epidermal growth factor receptor tyrosine kinase inhibitor'}, {'dasatinib', 'cetuximab'}, {'selumetinib', 'b-raf/vegfr-2 inhibitor raf265'}, {'afatinib', 'trametinib'}, {'selumetinib', 'teprotumumab'}, {'palbociclib', 'binimetinib'}]\n",
      "6\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Colorectal Cancer cancer has kras mutation, one recommended therapy is trametinib + afatinib. entry url: https://civicdb.org/links/evidence_items/991', 'If a patient with Colorectal Cancer cancer has kras mutation, one recommended therapy is dasatinib + cetuximab. entry url: https://civicdb.org/links/evidence_items/947', 'If a patient with Colorectal Cancer cancer has kras mutation, one recommended therapy is teprotumumab + selumetinib. entry url: https://civicdb.org/links/evidence_items/1004', 'If a patient with Colorectal Cancer cancer has kras mutation, one recommended therapy is b-raf/vegfr-2 inhibitor raf265 + selumetinib. entry url: https://civicdb.org/links/evidence_items/988', 'If a patient with Colorectal Cancer cancer has kras mutation, one recommended therapy is palbociclib + binimetinib. entry url: https://civicdb.org/links/evidence_items/4869', 'If a patient with Colorectal Cancer cancer has kras exon 2 mutation, one recommended therapy is selumetinib + irinotecan. entry url: https://civicdb.org/links/evidence_items/1326', 'If a patient with Colorectal Cancer cancer has kras g13d, one recommended therapy is cetuximab. entry url: https://civicdb.org/links/evidence_items/145', 'If a patient with Colorectal Cancer cancer has kras g13d, one recommended therapy is cetuximab. entry url: https://civicdb.org/links/evidence_items/306', 'If a patient with Colorectal Cancer cancer has kras g12v, one recommended therapy is dactolisib + selumetinib. entry url: https://civicdb.org/links/evidence_items/2001', 'If a patient with Colorectal Cancer cancer has kras g12c, one recommended therapy is adagrasib + cetuximab. entry url: https://civicdb.org/links/evidence_items/12063']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Colorectal Cancer cancer has kras mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Colorectal Cancer\",\n",
      "    \"Disease Phase or Condition\": \"Kras mutation\",\n",
      "    \"Drug Name\": \"trametinib + afatinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"kras mutation\",\n",
      "    \"FDA-approval status\": \"No\",\n",
      "    \"Link to FDA-approved Label\": \"\"\n",
      "  }\n",
      "}\n",
      "if a patient with Neuroblastoma cancer has alk f1174l, what therapy is recommended?\n",
      "[{'alectinib'}, {'crizotinib'}, {'alk inhibitor tae684'}, {'azd3463'}, {'lorlatinib'}]\n",
      "5\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Neuroblastoma cancer has alk f1174l, one recommended therapy is alk inhibitor tae684. entry url: https://civicdb.org/links/evidence_items/142', 'If a patient with Neuroblastoma cancer has alk f1174l, one recommended therapy is alectinib. entry url: https://civicdb.org/links/evidence_items/37', 'If a patient with Neuroblastoma cancer has alk f1174l, one recommended therapy is lorlatinib. entry url: https://civicdb.org/links/evidence_items/1329', 'If a patient with Neuroblastoma cancer has alk f1174l, one recommended therapy is azd3463. entry url: https://civicdb.org/links/evidence_items/1327', 'If a patient with Neuroblastoma cancer has alk f1174l, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/38', 'If a patient with Neuroblastoma cancer has alk f1245c, one recommended therapy is lorlatinib. entry url: https://civicdb.org/links/evidence_items/1330', 'If a patient with Neuroblastoma cancer has alk f1245v, one recommended therapy is entrectinib. entry url: https://civicdb.org/links/evidence_items/2987', 'If a patient with Neuroblastoma cancer has alk i1171t, one recommended therapy is ceritinib. entry url: https://civicdb.org/links/evidence_items/9404', 'If a patient with Neuroblastoma cancer has alk r1275q, one recommended therapy is lorlatinib. entry url: https://civicdb.org/links/evidence_items/1331', 'If a patient with Neuroblastoma cancer has alk r1275q, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1270']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Neuroblastoma cancer has alk f1174l, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Neuroblastoma\",\n",
      "    \"Disease Phase or Condition\": \"cancer\",\n",
      "    \"Drug Name\": \"alectinib\",\n",
      "    \"Prior Treatment or Resistance Status\": null,\n",
      "    \"Genomic Features\": \"alk f1174l\",\n",
      "    \"FDA-approval status\": \"not specified in the provided data\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/37\"\n",
      "  }\n",
      "}\n",
      "if a patient with Ovarian Cancer cancer has brca2 mutation, what therapy is recommended?\n",
      "[{'cediranib', 'olaparib'}, {'olaparib'}, {'rucaparib'}, {'rucaparib'}, {'olaparib'}, {'rucaparib'}, {'rucaparib'}]\n",
      "7\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/7276', 'If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/1773', 'If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/11137', 'If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/11139', 'If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is cediranib + olaparib. entry url: https://civicdb.org/links/evidence_items/1678', 'If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/6343', 'If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2868', 'If a patient with Ovarian Cancer cancer has brca2 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/212', 'If a patient with Ovarian Cancer cancer has brca2 v211l, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2882', 'If a patient with Ovarian Cancer cancer has brca2 v211i, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2883']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Ovarian Cancer cancer has brca2 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Ovarian Cancer\",\n",
      "    \"Disease Phase or Condition\": \"Cancer with BRCA2 mutation\",\n",
      "    \"Drug Name\": \"olaparib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"BRCA2 mutation\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/7276\"\n",
      "  }\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has eml4::alk fusion, alk l1196m, what therapy is recommended?\n",
      "[{'alectinib'}, {'ceritinib'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has eml4::alk fusion, alk l1196m, one recommended therapy is alectinib. entry url: https://civicdb.org/links/evidence_items/141', 'If a patient with Non-Small Cell Lung Cancer cancer has eml4::alk fusion, alk l1196m, one recommended therapy is ceritinib. entry url: https://civicdb.org/links/evidence_items/1341', 'If a patient with nan cancer has eml4::alk fusion, alk i1171n, alk l1196m, one recommended therapy is lorlatinib. entry url: https://civicdb.org/links/evidence_items/11113', 'If a patient with Melanoma cancer has agk::braf fusion, one recommended therapy is sorafenib. entry url: https://civicdb.org/links/evidence_items/723', 'If a patient with Melanoma cancer has ppfibp2::braf fusion, one recommended therapy is trametinib. entry url: https://civicdb.org/links/evidence_items/1570', 'If a patient with Melanoma cancer has alk alternative transcript (ati), one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1936', 'If a patient with Melanoma cancer has braf v600e, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/1398', 'If a patient with Melanoma cancer has nras g13d, one recommended therapy is tanespimycin. entry url: https://civicdb.org/links/evidence_items/21', 'If a patient with Melanoma cancer has nras q61, one recommended therapy is binimetinib. entry url: https://civicdb.org/links/evidence_items/1226', 'If a patient with Melanoma cancer has nras mutation, one recommended therapy is binimetinib. entry url: https://civicdb.org/links/evidence_items/1472']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has eml4::alk fusion, alk l1196m, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "    \"Disease Phase or Condition\": \"cancer\",\n",
      "    \"Drug Name\": \"alectinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"alk l1196m\",\n",
      "    \"Genomic Features\": [\"eml4::alk fusion\", \"alk l1196m\"],\n",
      "    \"FDA-approval status\": \"recommended\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/141\"\n",
      "  }\n",
      "}\n",
      "if a patient with nan cancer has pik3ca amplification, what therapy is recommended?\n",
      "[{'pictilisib'}, {'alpelisib'}, {'dactolisib', 'lapatinib'}]\n",
      "3\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has pik3ca amplification, one recommended therapy is pictilisib. entry url: https://civicdb.org/links/evidence_items/756', 'If a patient with nan cancer has pik3ca amplification, one recommended therapy is dactolisib + lapatinib. entry url: https://civicdb.org/links/evidence_items/8271', 'If a patient with nan cancer has pik3ca amplification, one recommended therapy is alpelisib. entry url: https://civicdb.org/links/evidence_items/1403', 'If a patient with nan cancer has pik3ca k111n, one recommended therapy is pi3ka/di. entry url: https://civicdb.org/links/evidence_items/8020', 'If a patient with nan cancer has pik3ca e545k, one recommended therapy is pi3ka/di. entry url: https://civicdb.org/links/evidence_items/8017', 'If a patient with nan cancer has pik3ca e542k, one recommended therapy is pi3ka/di. entry url: https://civicdb.org/links/evidence_items/8013', 'If a patient with nan cancer has pik3ca e542k, one recommended therapy is pi-103. entry url: https://civicdb.org/links/evidence_items/2058', 'If a patient with nan cancer has pik3ca k111n, one recommended therapy is pi-103. entry url: https://civicdb.org/links/evidence_items/8011', 'If a patient with nan cancer has pik3ca c420r, one recommended therapy is pictilisib. entry url: https://civicdb.org/links/evidence_items/2078', 'If a patient with nan cancer has pik3ca e545k, one recommended therapy is pictilisib. entry url: https://civicdb.org/links/evidence_items/2062']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has pik3ca amplification, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with nan cancer has egfr r108k, what therapy is recommended?\n",
      "[{'erlotinib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has egfr r108k, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4186', 'If a patient with nan cancer has kit internal duplication, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/302', 'If a patient with Melanoma cancer has braf v600e, one recommended therapy is nutlin-3 + plx4720. entry url: https://civicdb.org/links/evidence_items/97', 'If a patient with Melanoma cancer has nras g13d, one recommended therapy is tanespimycin. entry url: https://civicdb.org/links/evidence_items/21', 'If a patient with Melanoma cancer has braf v600e, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/1398', 'If a patient with Melanoma cancer has nras q61, one recommended therapy is binimetinib. entry url: https://civicdb.org/links/evidence_items/1226', 'If a patient with Melanoma cancer has nras mutation, one recommended therapy is binimetinib. entry url: https://civicdb.org/links/evidence_items/1472', 'If a patient with Melanoma cancer has braf v600d, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/4488', 'If a patient with Melanoma cancer has braf v600, one recommended therapy is trametinib. entry url: https://civicdb.org/links/evidence_items/1750', 'If a patient with Melanoma cancer has nras q61l, one recommended therapy is temozolomide. entry url: https://civicdb.org/links/evidence_items/22']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has egfr r108k, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has rrm1 underexpression, what therapy is recommended?\n",
      "[{'gemcitabine', 'cisplatin'}, {'gemcitabine'}, {'gemcitabine', 'vinorelbine', 'paclitaxel'}, {'gemcitabine', 'carboplatin'}]\n",
      "4\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has rrm1 underexpression, one recommended therapy is gemcitabine. entry url: https://civicdb.org/links/evidence_items/5530', 'If a patient with Non-Small Cell Lung Cancer cancer has rrm1 underexpression, one recommended therapy is carboplatin + gemcitabine. entry url: https://civicdb.org/links/evidence_items/10143', 'If a patient with Non-Small Cell Lung Cancer cancer has rrm1 underexpression, one recommended therapy is cisplatin + gemcitabine. entry url: https://civicdb.org/links/evidence_items/2905', 'If a patient with Non-Small Cell Lung Cancer cancer has rrm1 underexpression, one recommended therapy is gemcitabine + vinorelbine + paclitaxel. entry url: https://civicdb.org/links/evidence_items/5599', 'If a patient with Pancreatic Cancer cancer has rrm1 underexpression, one recommended therapy is gemcitabine. entry url: https://civicdb.org/links/evidence_items/5508', 'If a patient with Pancreatic Cancer cancer has rrm1 underexpression, one recommended therapy is gemcitabine. entry url: https://civicdb.org/links/evidence_items/5506', 'If a patient with Colorectal Cancer cancer has lmna::ntrk1 fusion, one recommended therapy is larotrectinib. entry url: https://civicdb.org/links/evidence_items/978', 'If a patient with Colorectal Cancer cancer has top1 amplification, one recommended therapy is irinotecan. entry url: https://civicdb.org/links/evidence_items/888', 'If a patient with Colorectal Cancer cancer has bard1 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/5953', 'If a patient with Colorectal Cancer cancer has braf v600e, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/5960']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has rrm1 underexpression, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has egfr rare exon 18-21 mutation, what therapy is recommended?\n",
      "[{'erlotinib', 'gefitinib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has alk mutation, one recommended therapy is ceritinib. entry url: https://civicdb.org/links/evidence_items/1237', 'If a patient with Neuroblastoma cancer has alk r1275q, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/143', 'If a patient with Neuroblastoma cancer has alk r1275q, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1270', 'If a patient with Neuroblastoma cancer has alk f1174l, one recommended therapy is alectinib. entry url: https://civicdb.org/links/evidence_items/37', 'If a patient with Neuroblastoma cancer has alk f1174l, one recommended therapy is alk inhibitor tae684. entry url: https://civicdb.org/links/evidence_items/142', 'If a patient with Neuroblastoma cancer has alk r1275q, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1269', 'If a patient with Neuroblastoma cancer has alk f1174l, one recommended therapy is lorlatinib. entry url: https://civicdb.org/links/evidence_items/1329', 'If a patient with Neuroblastoma cancer has alk f1174l, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/38', 'If a patient with Neuroblastoma cancer has alk f1245c, one recommended therapy is lorlatinib. entry url: https://civicdb.org/links/evidence_items/1330', 'If a patient with Neuroblastoma cancer has alk r1275q, one recommended therapy is lorlatinib. entry url: https://civicdb.org/links/evidence_items/1331']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has egfr rare exon 18-21 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Pancreatic Cancer cancer has brca1 mutation, what therapy is recommended?\n",
      "[{'olaparib'}, {'oxaliplatin', 'cisplatin'}, {'gemcitabine', 'cisplatin', 'veliparib'}]\n",
      "3\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Pancreatic Cancer cancer has brca1 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/5914', 'If a patient with Pancreatic Cancer cancer has brca1 mutation, one recommended therapy is oxaliplatin + cisplatin. entry url: https://civicdb.org/links/evidence_items/5915', 'If a patient with Pancreatic Cancer cancer has brca1 mutation, one recommended therapy is cisplatin + veliparib + gemcitabine. entry url: https://civicdb.org/links/evidence_items/5932', 'If a patient with Pancreatic Cancer cancer has brca2 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/5913', 'If a patient with Pancreatic Cancer cancer has brca2 mutation, one recommended therapy is iniparib. entry url: https://civicdb.org/links/evidence_items/5936', 'If a patient with Pancreatic Adenocarcinoma cancer has brca1 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/7384', 'If a patient with Prostate Cancer cancer has brca1 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/11666', 'If a patient with Ovarian Cancer cancer has brca1 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/7275', 'If a patient with Ovarian Cancer cancer has brca1 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/1772', 'If a patient with Ovarian Cancer cancer has brca1 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/7274']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Pancreatic Cancer cancer has brca1 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Pancreatic Cancer\",\n",
      "    \"Disease Phase or Condition\": \"Pancreatic Cancer with BRCA1 mutation\",\n",
      "    \"Drug Name\": \"Olaparib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"BRCA1 mutation\",\n",
      "    \"FDA-approval status\": \"Not specified in the provided data\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/5914\"\n",
      "  }\n",
      "}\n",
      "if a patient with adrenal cancer has fgfr3::tacc3 fusion, fgfr2::ccdc6 fusion, what therapy is recommended?\n",
      "[{'erdafitinib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with adrenal cancer has fgfr3::tacc3 fusion, fgfr2::ccdc6 fusion, one recommended therapy is erdafitinib. entry url: https://civicdb.org/links/evidence_items/4861', 'If a patient with Acute Myeloid Leukemia cancer has fgfr1op2::fgfr1 fusion, one recommended therapy is ponatinib. entry url: https://civicdb.org/links/evidence_items/7380', 'If a patient with Acute Myeloid Leukemia cancer has fip1l1::pdgfra fusion, one recommended therapy is sorafenib + sunitinib. entry url: https://civicdb.org/links/evidence_items/7378', 'If a patient with Acute Myeloid Leukemia cancer has flt3 itd, one recommended therapy is sorafenib. entry url: https://civicdb.org/links/evidence_items/298', 'If a patient with Acute Myeloid Leukemia cancer has npm1 w288fs, one recommended therapy is nsc348884. entry url: https://civicdb.org/links/evidence_items/152', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is daunorubicin. entry url: https://civicdb.org/links/evidence_items/147', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is valproic acid. entry url: https://civicdb.org/links/evidence_items/148', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is tretinoin. entry url: https://civicdb.org/links/evidence_items/146', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is tretinoin + nsc348884. entry url: https://civicdb.org/links/evidence_items/149', 'If a patient with Acute Myeloid Leukemia cancer has npm1 w288fs, one recommended therapy is daunorubicin + cytarabine + etoposide. entry url: https://civicdb.org/links/evidence_items/153']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with adrenal cancer has fgfr3::tacc3 fusion, fgfr2::ccdc6 fusion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has egfr overexpression, what therapy is recommended?\n",
      "[{'epidermal growth factor receptor tyrosine kinase inhibitor'}, {'epidermal growth factor receptor tyrosine kinase inhibitor'}, {'gefitinib'}]\n",
      "3\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has egfr overexpression, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/954', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr exon 18 overexpression, one recommended therapy is erlotinib + bevacizumab. entry url: https://civicdb.org/links/evidence_items/898', 'If a patient with Non-Small Cell Lung Cancer cancer has jak1 overexpression, one recommended therapy is enzastaurin. entry url: https://civicdb.org/links/evidence_items/931', 'If a patient with Acute Myeloid Leukemia cancer has npm1 w288fs, one recommended therapy is nsc348884. entry url: https://civicdb.org/links/evidence_items/152', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is daunorubicin. entry url: https://civicdb.org/links/evidence_items/147', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is valproic acid. entry url: https://civicdb.org/links/evidence_items/148', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is tretinoin. entry url: https://civicdb.org/links/evidence_items/146', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is tretinoin + nsc348884. entry url: https://civicdb.org/links/evidence_items/149', 'If a patient with Acute Myeloid Leukemia cancer has npm1 w288fs, one recommended therapy is daunorubicin + cytarabine + etoposide. entry url: https://civicdb.org/links/evidence_items/153', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is anti-cd33. entry url: https://civicdb.org/links/evidence_items/151']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has egfr overexpression, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "    \"Disease Phase or Condition\": \"cancer\",\n",
      "    \"Drug Name\": \"Gefitinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"\",\n",
      "    \"Genomic Features\": \"egfr overexpression\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/954\"\n",
      "  }\n",
      "}\n",
      "if a patient with nan cancer has rb1 mutation, what therapy is recommended?\n",
      "[{'chemotherapy'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has rb1 mutation, one recommended therapy is chemotherapy. entry url: https://civicdb.org/links/evidence_items/1866', 'If a patient with nan cancer has pml::rara fusion, one recommended therapy is tretinoin. entry url: https://civicdb.org/links/evidence_items/1519', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is daunorubicin. entry url: https://civicdb.org/links/evidence_items/147', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is valproic acid. entry url: https://civicdb.org/links/evidence_items/148', 'If a patient with Acute Myeloid Leukemia cancer has npm1 w288fs, one recommended therapy is nsc348884. entry url: https://civicdb.org/links/evidence_items/152', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is tretinoin. entry url: https://civicdb.org/links/evidence_items/146', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is tretinoin + nsc348884. entry url: https://civicdb.org/links/evidence_items/149', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is anti-cd33. entry url: https://civicdb.org/links/evidence_items/151', 'If a patient with Acute Myeloid Leukemia cancer has npm1 w288fs, one recommended therapy is daunorubicin + cytarabine + etoposide. entry url: https://civicdb.org/links/evidence_items/153', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is anti-cd123 + anti-cd33. entry url: https://civicdb.org/links/evidence_items/150']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has rb1 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has erbb2 amplification, what therapy is recommended?\n",
      "[{'trastuzumab emtansine'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has erbb2 amplification, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/1050', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/761', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/529', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/528', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/961', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/1693', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/1011', 'If a patient with Acute Myeloid Leukemia cancer has npm1 w288fs, one recommended therapy is nsc348884. entry url: https://civicdb.org/links/evidence_items/152', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is daunorubicin. entry url: https://civicdb.org/links/evidence_items/147', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is valproic acid. entry url: https://civicdb.org/links/evidence_items/148']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has erbb2 amplification, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Melanoma cancer has braf v600k, what therapy is recommended?\n",
      "[{'vemurafenib'}, {'vemurafenib'}, {'dabrafenib'}, {'trametinib'}, {'vemurafenib'}, {'dabrafenib', 'trametinib'}, {'dabrafenib', 'trametinib'}, {'dabrafenib', 'trametinib'}, {'dabrafenib', 'trametinib'}]\n",
      "9\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Melanoma cancer has braf v600k, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/1399', 'If a patient with Melanoma cancer has braf v600k, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/1400', 'If a patient with Melanoma cancer has braf v600k, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/4180', 'If a patient with Melanoma cancer has braf v600k, one recommended therapy is dabrafenib. entry url: https://civicdb.org/links/evidence_items/2505', 'If a patient with Melanoma cancer has braf v600k, one recommended therapy is trametinib. entry url: https://civicdb.org/links/evidence_items/2506', 'If a patient with Melanoma cancer has braf v600k, one recommended therapy is dabrafenib + trametinib. entry url: https://civicdb.org/links/evidence_items/6965', 'If a patient with Melanoma cancer has braf v600k, one recommended therapy is dabrafenib + trametinib. entry url: https://civicdb.org/links/evidence_items/6939', 'If a patient with Melanoma cancer has braf v600k, one recommended therapy is trametinib + dabrafenib. entry url: https://civicdb.org/links/evidence_items/6179', 'If a patient with Melanoma cancer has braf v600k, one recommended therapy is trametinib + dabrafenib. entry url: https://civicdb.org/links/evidence_items/4181', 'If a patient with Acute Myeloid Leukemia cancer has npm1 exon 11 mutation, one recommended therapy is anti-cd123 + anti-cd33. entry url: https://civicdb.org/links/evidence_items/150']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Melanoma cancer has braf v600k, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Melanoma\",\n",
      "    \"Disease Phase or Condition\": \"cancer with BRAF V600K mutation\",\n",
      "    \"Drug Name\": \"Vemurafenib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"BRAF V600K mutation\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/1399\"\n",
      "  }\n",
      "}\n",
      "if a patient with B-lymphoblastic Leukemia/lymphoma cancer has etv6::abl1 fusion, what therapy is recommended?\n",
      "[{'dasatinib'}, {'imatinib'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with B-lymphoblastic Leukemia/lymphoma cancer has etv6::abl1 fusion, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/9171', 'If a patient with B-lymphoblastic Leukemia/lymphoma cancer has etv6::abl1 fusion, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/6969', 'If a patient with B-lymphoblastic Leukemia/lymphoma cancer has etv6::ntrk3 fusion, one recommended therapy is larotrectinib. entry url: https://civicdb.org/links/evidence_items/6930', 'If a patient with B-lymphoblastic Leukemia/lymphoma cancer has etv6::ntrk3 fusion, one recommended therapy is larotrectinib. entry url: https://civicdb.org/links/evidence_items/7993', 'If a patient with B-lymphoblastic Leukemia/lymphoma cancer has etv6::ntrk3 fusion, one recommended therapy is larotrectinib. entry url: https://civicdb.org/links/evidence_items/8930', 'If a patient with B-lymphoblastic Leukemia/lymphoma cancer has rcsd1::abl1 fusion, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/7783', 'If a patient with B-lymphoblastic Leukemia/lymphoma cancer has nup214::abl1 fusion, one recommended therapy is imatinib mesylate. entry url: https://civicdb.org/links/evidence_items/12218', 'If a patient with B-lymphoblastic Leukemia/lymphoma cancer has foxp1::abl1 fusion, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/7292', 'If a patient with B-lymphoblastic Leukemia/lymphoma cancer has rcsd1::abl1 fusion, one recommended therapy is ponatinib. entry url: https://civicdb.org/links/evidence_items/9213', 'If a patient with B-lymphoblastic Leukemia/lymphoma cancer has rcsd1::abl1 fusion, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/9168']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with B-lymphoblastic Leukemia/lymphoma cancer has etv6::abl1 fusion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"B-lymphoblastic Leukemia/lymphoma\",\n",
      "    \"Disease Phase or Condition\": \"cancer with etv6::abl1 fusion\",\n",
      "    \"Drug Name\": \"imatinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"not specified\",\n",
      "    \"Genomic Features\": \"etv6::abl1 fusion\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/9171\"\n",
      "  }\n",
      "}\n",
      "if a patient with nan cancer has kiaa1549::braf fusion, what therapy is recommended?\n",
      "[{'trametinib', 'everolimus'}, {'selumetinib'}, {'trametinib'}, {'tovorafenib'}]\n",
      "4\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has brca2 mutation, one recommended therapy is niraparib. entry url: https://civicdb.org/links/evidence_items/11243', 'If a patient with nan cancer has brca1 mutation, one recommended therapy is niraparib. entry url: https://civicdb.org/links/evidence_items/11243', 'If a patient with nan cancer has brca1 mutation, one recommended therapy is platinum compound. entry url: https://civicdb.org/links/evidence_items/1529', 'If a patient with nan cancer has brca1 mutation, one recommended therapy is platinum compound. entry url: https://civicdb.org/links/evidence_items/1531', 'If a patient with nan cancer has brca2 mutation, one recommended therapy is platinum compound. entry url: https://civicdb.org/links/evidence_items/1530', 'If a patient with nan cancer has brca1 expression, one recommended therapy is vinorelbine. entry url: https://civicdb.org/links/evidence_items/933', 'If a patient with Ovarian Cancer cancer has brca2 m1i, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2880', 'If a patient with Ovarian Cancer cancer has brca2 v211l, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2882', 'If a patient with Ovarian Cancer cancer has brca2 v159m, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2881', 'If a patient with Ovarian Cancer cancer has brca2 m1r, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2879']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has kiaa1549::braf fusion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Lung Adenocarcinoma cancer has egfr t790m, what therapy is recommended?\n",
      "[{'osimertinib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Ovarian Cancer cancer has brca2 r2336p, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2884', 'If a patient with Ovarian Cancer cancer has brca2 v211i, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2883', 'If a patient with Ovarian Cancer cancer has brca2 v211l, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2882', 'If a patient with Ovarian Cancer cancer has brca2 v159m, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2881', 'If a patient with Ovarian Cancer cancer has brca2 m1i, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2880', 'If a patient with Ovarian Cancer cancer has brca2 m1r, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2879', 'If a patient with Ovarian Cancer cancer has brca1 q1467*, one recommended therapy is rucaparib. entry url: https://civicdb.org/links/evidence_items/2878', 'If a patient with Ovarian Cancer cancer has brca2 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/7276', 'If a patient with Ovarian Cancer cancer has brca1 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/7275', 'If a patient with Ovarian Cancer cancer has brca1 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/7274']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Lung Adenocarcinoma cancer has egfr t790m, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Prostate Cancer cancer has brca1 loss-of-function, what therapy is recommended?\n",
      "[{'olaparib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Lung Cancer cancer has egfr mutation, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/3864', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr expression, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/4877', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/3016', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2621', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/965', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/229', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr overexpression, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/954', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4287', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr a864t, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4495', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr r776c, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4468']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Prostate Cancer cancer has brca1 loss-of-function, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with nan cancer has erbb2 amplification, what therapy is recommended?\n",
      "[{'trastuzumab'}, {'trastuzumab'}, {'neratinib'}, {'afatinib'}, {'afatinib', 'trastuzumab', 'lapatinib'}, {'afatinib'}, {'trastuzumab', 'lapatinib'}, {'trastuzumab', 'lapatinib'}, {'afatinib'}, {'afatinib', 'trastuzumab'}, {'trastuzumab', 'irinotecan'}, {'docetaxel', 'trastuzumab', 'pertuzumab'}, {'trastuzumab'}, {'neratinib', 'trastuzumab'}, {'trastuzumab'}, {'capecitabine', 'lapatinib'}, {'trastuzumab', 'capecitabine'}, {'trastuzumab emtansine'}, {'trastuzumab emtansine'}, {'pictilisib'}, {'a66'}, {'trastuzumab emtansine'}, {'docetaxel', 'trastuzumab', 'pertuzumab'}, {'trastuzumab', 'lapatinib'}, {'trastuzumab', 'pilaralisib'}, {'trastuzumab', 'palbociclib'}, {'trastuzumab'}, {'trastuzumab emtansine'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab deruxtecan'}, {'lapatinib'}]\n",
      "32\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has bcr::abl1 fusion, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4436', 'If a patient with nan cancer has bcr::pdgfra fusion, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/7990', 'If a patient with Acute Myeloid Leukemia cancer has bcr::abl1 fusion, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/259', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4706', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 v299l, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2862', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 e279k, one recommended therapy is axitinib. entry url: https://civicdb.org/links/evidence_items/7772', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 d276g, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2666', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4561', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 m351t, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2685', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2864']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has erbb2 amplification, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Rhabdomyosarcoma cancer has pdgfra overexpression, what therapy is recommended?\n",
      "[{'sunitinib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4706', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 v299l, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2862', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 m351t, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2685', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4561', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 d276g, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2666', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2864', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 e279k, one recommended therapy is axitinib. entry url: https://civicdb.org/links/evidence_items/7772', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, one recommended therapy is nilotinib + dasatinib + bafetinib. entry url: https://civicdb.org/links/evidence_items/7838', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 e255k, abl1 v299l, one recommended therapy is ponatinib + dasatinib. entry url: https://civicdb.org/links/evidence_items/7781', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 t315i, one recommended therapy is ponatinib. entry url: https://civicdb.org/links/evidence_items/1390']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Rhabdomyosarcoma cancer has pdgfra overexpression, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with nan cancer has chek2 mutation, what therapy is recommended?\n",
      "[{'olaparib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has bcr::abl1 fusion, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4436', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4706', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 d276g, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2666', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4561', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 v299l, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2862', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 m351t, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2685', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2864', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 e279k, one recommended therapy is axitinib. entry url: https://civicdb.org/links/evidence_items/7772', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, one recommended therapy is nilotinib + dasatinib + bafetinib. entry url: https://civicdb.org/links/evidence_items/7838', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 t315i, one recommended therapy is ponatinib. entry url: https://civicdb.org/links/evidence_items/1390']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has chek2 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Melanoma cancer has braf v600d, what therapy is recommended?\n",
      "[{'dabrafenib'}, {'vemurafenib'}, {'vemurafenib'}, {'braf inhibitor'}, {'mitogen-activated protein kinase kinase inhibitor', 'braf inhibitor'}]\n",
      "5\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Melanoma cancer has braf v600d, one recommended therapy is braf inhibitor. entry url: https://civicdb.org/links/evidence_items/7616', 'If a patient with Melanoma cancer has braf v600d, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/4488', 'If a patient with Melanoma cancer has braf v600d, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/4489', 'If a patient with Melanoma cancer has braf v600d, one recommended therapy is dabrafenib. entry url: https://civicdb.org/links/evidence_items/94', 'If a patient with Lung Adenocarcinoma cancer has kif5b::ret fusion, one recommended therapy is vandetanib + everolimus. entry url: https://civicdb.org/links/evidence_items/1622', 'If a patient with Lung Adenocarcinoma cancer has kif5b::ret fusion, one recommended therapy is vandetanib. entry url: https://civicdb.org/links/evidence_items/698', 'If a patient with Lung Adenocarcinoma cancer has v::alk fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1691', 'If a patient with Lung Adenocarcinoma cancer has eml4::alk fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/262', 'If a patient with Colorectal Adenocarcinoma cancer has v::alk fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1334', 'If a patient with Non-Small Cell Lung Cancer cancer has eml4::alk e2::e20, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1190']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Melanoma cancer has braf v600d, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Melanoma cancer\",\n",
      "    \"Disease Phase or Condition\": \"braf v600d mutation\",\n",
      "    \"Drug Name\": \"vemurafenib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"braf v600d\",\n",
      "    \"FDA-approval status\": \"FDA-approved\"\n",
      "  }\n",
      "}\n",
      "if a patient with nan cancer has pml::rara fusion, what therapy is recommended?\n",
      "[{'tretinoin'}, {'tretinoin', 'arsenic trioxide'}, {'tretinoin'}]\n",
      "3\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has pml::rara fusion, one recommended therapy is tretinoin. entry url: https://civicdb.org/links/evidence_items/316', 'If a patient with nan cancer has pml::rara fusion, one recommended therapy is tretinoin. entry url: https://civicdb.org/links/evidence_items/1519', 'If a patient with nan cancer has pml::rara fusion, one recommended therapy is arsenic trioxide + tretinoin. entry url: https://civicdb.org/links/evidence_items/1091', 'If a patient with nan cancer has pik3ca k111n, one recommended therapy is pi-103. entry url: https://civicdb.org/links/evidence_items/8011', 'If a patient with nan cancer has pik3ca c420r, one recommended therapy is pictilisib. entry url: https://civicdb.org/links/evidence_items/2078', 'If a patient with nan cancer has pik3ca k111n, one recommended therapy is pi3ka/di. entry url: https://civicdb.org/links/evidence_items/8020', 'If a patient with nan cancer has pik3ca e542k, one recommended therapy is pi-103. entry url: https://civicdb.org/links/evidence_items/2058', 'If a patient with nan cancer has pik3ca e542k, one recommended therapy is pi3ka/di. entry url: https://civicdb.org/links/evidence_items/8013', 'If a patient with nan cancer has pik3ca e545k, one recommended therapy is pi3ka/di. entry url: https://civicdb.org/links/evidence_items/8017', 'If a patient with nan cancer has pik3ca e545k, one recommended therapy is pictilisib. entry url: https://civicdb.org/links/evidence_items/2062']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has pml::rara fusion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"nan cancer\",\n",
      "    \"Disease Phase or Condition\": \"nan\",\n",
      "    \"Drug Name\": \"tretinoin\",\n",
      "    \"Prior Treatment or Resistance Status\": \"none specified\",\n",
      "    \"Genomic Features\": \"pml::rara fusion\",\n",
      "    \"FDA-approval status\": \"recommended therapy based on evidence\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/316\"\n",
      "  }\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has tp53 mutation, what therapy is recommended?\n",
      "[{'docetaxel', 'selumetinib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has tp53 wildtype, one recommended therapy is adjuvant chemotherapy. entry url: https://civicdb.org/links/evidence_items/1149', 'If a patient with Non-Small Cell Lung Cancer cancer has tp53 mutation, one recommended therapy is docetaxel + selumetinib. entry url: https://civicdb.org/links/evidence_items/1145', 'If a patient with Breast Cancer cancer has tp53 mutation, one recommended therapy is doxorubicin. entry url: https://civicdb.org/links/evidence_items/851', 'If a patient with Cancer cancer has tp53 mutation, one recommended therapy is vegf/vegfr inhibitors. entry url: https://civicdb.org/links/evidence_items/11709', 'If a patient with Cancer cancer has tp53 wildtype, one recommended therapy is mdm2 inhibitor amgmds3. entry url: https://civicdb.org/links/evidence_items/2964', 'If a patient with Cancer cancer has tp53 wildtype, one recommended therapy is rebemadlin. entry url: https://civicdb.org/links/evidence_items/2963', 'If a patient with gastric adeno cancer has tp53 mutation, one recommended therapy is chemotherapy. entry url: https://civicdb.org/links/evidence_items/850', 'If a patient with Breast Cancer cancer has tp53 r175h, one recommended therapy is doxorubicin. entry url: https://civicdb.org/links/evidence_items/319', 'If a patient with Breast Cancer cancer has tp53 r249, one recommended therapy is doxorubicin. entry url: https://civicdb.org/links/evidence_items/399', 'If a patient with Colorectal Cancer cancer has tp53 wildtype, one recommended therapy is cetuximab + capecitabine + oxaliplatin. entry url: https://civicdb.org/links/evidence_items/875']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has tp53 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Breast Cancer cancer has brca2 loss-of-function, what therapy is recommended?\n",
      "[{'pidnarulex', 'quarfloxin'}, {'talazoparib'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Breast Cancer cancer has brca2 loss-of-function, one recommended therapy is talazoparib. entry url: https://civicdb.org/links/evidence_items/4839', 'If a patient with Breast Cancer cancer has brca2 loss-of-function, one recommended therapy is quarfloxin + pidnarulex. entry url: https://civicdb.org/links/evidence_items/1925', 'If a patient with Prostate Cancer cancer has brca2 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/650', 'If a patient with Breast Cancer cancer has brca2 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/5831', 'If a patient with Ovarian Cancer cancer has brca2 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/212', 'If a patient with nan cancer has brca2 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/11217', 'If a patient with nan cancer has brca2 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/5816', 'If a patient with nan cancer has brca2 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/11202', 'If a patient with Ovarian Cancer cancer has brca2 loss-of-function, one recommended therapy is talazoparib. entry url: https://civicdb.org/links/evidence_items/4875', 'If a patient with Breast Cancer cancer has brca1 loss-of-function, one recommended therapy is talazoparib. entry url: https://civicdb.org/links/evidence_items/4838']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Breast Cancer cancer has brca2 loss-of-function, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Breast Cancer\",\n",
      "    \"Disease Phase or Condition\": \"cancer with brca2 loss-of-function\",\n",
      "    \"Drug Name\": \"talazoparib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"not specified\",\n",
      "    \"Genomic Features\": \"brca2 loss-of-function\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/4839\"\n",
      "  }\n",
      "}\n",
      "if a patient with Acute Myeloid Leukemia cancer has flt3 mutation, what therapy is recommended?\n",
      "[{'midostaurin'}, {'gilteritinib'}, {'gilteritinib'}]\n",
      "3\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Acute Myeloid Leukemia cancer has flt3 mutation, one recommended therapy is midostaurin. entry url: https://civicdb.org/links/evidence_items/5261', 'If a patient with Acute Myeloid Leukemia cancer has flt3 mutation, one recommended therapy is gilteritinib. entry url: https://civicdb.org/links/evidence_items/7283', 'If a patient with Acute Myeloid Leukemia cancer has flt3 mutation, one recommended therapy is gilteritinib. entry url: https://civicdb.org/links/evidence_items/7728', 'If a patient with Acute Myeloid Leukemia cancer has flt3 tkd mutation, one recommended therapy is midostaurin. entry url: https://civicdb.org/links/evidence_items/1295', 'If a patient with Acute Myeloid Leukemia cancer has flt3 itd, one recommended therapy is lestaurtinib. entry url: https://civicdb.org/links/evidence_items/297', 'If a patient with Acute Myeloid Leukemia cancer has flt3 y842c, one recommended therapy is lestaurtinib. entry url: https://civicdb.org/links/evidence_items/8339', 'If a patient with Acute Myeloid Leukemia cancer has flt3 itd, one recommended therapy is gilteritinib. entry url: https://civicdb.org/links/evidence_items/8923', 'If a patient with Acute Myeloid Leukemia cancer has flt3 itd, one recommended therapy is gilteritinib. entry url: https://civicdb.org/links/evidence_items/8924', 'If a patient with Acute Myeloid Leukemia cancer has flt3 y842c, one recommended therapy is midostaurin. entry url: https://civicdb.org/links/evidence_items/8340', 'If a patient with Acute Myeloid Leukemia cancer has flt3 d835h, one recommended therapy is gilteritinib. entry url: https://civicdb.org/links/evidence_items/8517']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Acute Myeloid Leukemia cancer has flt3 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Acute Myeloid Leukemia\",\n",
      "    \"Disease Phase or Condition\": \"cancer with FLT3 mutation\",\n",
      "    \"Drug Name\": \"midostaurin\",\n",
      "    \"Prior Treatment or Resistance Status\": \"not specified\",\n",
      "    \"Genomic Features\": \"FLT3 mutation\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/5261\"\n",
      "  }\n",
      "}\n",
      "if a patient with Medulloblastoma cancer has smo d473h, what therapy is recommended?\n",
      "[{'patidegib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Lung Cancer cancer has egfr mutation, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/3864', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr expression, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/4877', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2621', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/3016', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/965', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/229', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/2053', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4287', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is canertinib. entry url: https://civicdb.org/links/evidence_items/2631', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/2629']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Medulloblastoma cancer has smo d473h, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Sarcoma cancer has lmna::ntrk1 fusion, what therapy is recommended?\n",
      "[{'larotrectinib'}, {'larotrectinib'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Lung Cancer cancer has egfr mutation, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/3864', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr expression, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/4877', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/3016', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2621', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/965', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/229', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2559', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr overexpression, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/954', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr g719s, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4190', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr v742a, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4197']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Sarcoma cancer has lmna::ntrk1 fusion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Low-Grade Glioma, NOS cancer has braf v600e, what therapy is recommended?\n",
      "[{'vemurafenib'}, {'dabrafenib', 'trametinib'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/2629', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr v742a, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4197', 'If a patient with Lung Cancer cancer has egfr mutation, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/3864', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr expression, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/4877', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/965', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/3016', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2621', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/229', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/2053', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr g719s, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4190']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Low-Grade Glioma, NOS cancer has braf v600e, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with nan cancer has sstr5 expression, what therapy is recommended?\n",
      "[{'pasireotide'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has egfr expression, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/4877', 'If a patient with Lung Cancer cancer has egfr mutation, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/3864', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/3016', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2621', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/965', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/229', 'If a patient with Colorectal Cancer cancer has egfr expression, one recommended therapy is cetuximab. entry url: https://civicdb.org/links/evidence_items/1572', 'If a patient with Colorectal Cancer cancer has egfr expression, one recommended therapy is cetuximab. entry url: https://civicdb.org/links/evidence_items/1709', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr r776c, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4468', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2559']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has sstr5 expression, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Neuroblastoma cancer has mycn amplification, what therapy is recommended?\n",
      "[{'fact complex-targeting curaxin cbl0137'}, {'panobinostat', 'jq1'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Lung Cancer cancer has egfr mutation, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/3864', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr amplification, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/5925', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr expression, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/4877', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2621', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/3016', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/965', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr amplification, one recommended therapy is gefitinib + erlotinib. entry url: https://civicdb.org/links/evidence_items/5924', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/229', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr r776c, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4468', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr v742a, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4197']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Neuroblastoma cancer has mycn amplification, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Melanoma cancer has braf v600, what therapy is recommended?\n",
      "[{'dabrafenib', 'trametinib'}, {'dabrafenib'}, {'dabrafenib', 'trametinib'}, {'cobimetinib', 'vemurafenib'}, {'trametinib'}, {'cobimetinib', 'vemurafenib'}, {'dabrafenib', 'trametinib'}, {'dabrafenib', 'trametinib'}, {'cobimetinib', 'vemurafenib'}, {'encorafenib', 'binimetinib'}, {'cobimetinib', 'atezolizumab', 'vemurafenib'}]\n",
      "11\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Breast Cancer cancer has erbb2 v777l, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/11690', 'If a patient with Breast Cancer cancer has erbb2 s310f, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/11691', 'If a patient with Breast Cancer cancer has erbb2 v842i, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/289', 'If a patient with Breast Cancer cancer has erbb2 v777l, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/288', 'If a patient with Breast Cancer cancer has erbb2 amplification, one recommended therapy is trastuzumab + lapatinib. entry url: https://civicdb.org/links/evidence_items/1006', 'If a patient with Breast Cancer cancer has erbb2 d769h, one recommended therapy is neratinib + lapatinib. entry url: https://civicdb.org/links/evidence_items/279', 'If a patient with Breast Cancer cancer has erbb2 r678q, one recommended therapy is neratinib + lapatinib. entry url: https://civicdb.org/links/evidence_items/286', 'If a patient with Breast Cancer cancer has erbb2 mutation, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/5338', 'If a patient with Breast Cancer cancer has erbb2 l755_t759del, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/281', 'If a patient with Breast Cancer cancer has erbb2 d769y, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/280']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Melanoma cancer has braf v600, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Acute Myeloid Leukemia cancer has kit n822k, what therapy is recommended?\n",
      "[{'ponatinib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Breast Cancer cancer has erbb2 v842i, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/289', 'If a patient with Breast Cancer cancer has erbb2 v777l, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/288', 'If a patient with Breast Cancer cancer has erbb2 amplification, one recommended therapy is trastuzumab + lapatinib. entry url: https://civicdb.org/links/evidence_items/1006', 'If a patient with Breast Cancer cancer has erbb2 r678q, one recommended therapy is neratinib + lapatinib. entry url: https://civicdb.org/links/evidence_items/286', 'If a patient with Breast Cancer cancer has erbb2 d769h, one recommended therapy is neratinib + lapatinib. entry url: https://civicdb.org/links/evidence_items/279', 'If a patient with Breast Cancer cancer has erbb2 s310f, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/11691', 'If a patient with Breast Cancer cancer has erbb2 v777l, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/11690', 'If a patient with Breast Cancer cancer has erbb2 g778_p780dup, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/285', 'If a patient with Breast Cancer cancer has erbb2 mutation, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/5338', 'If a patient with Breast Cancer cancer has erbb2 l755w, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/284']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Acute Myeloid Leukemia cancer has kit n822k, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with nan cancer has rcsd1::abl1 fusion, what therapy is recommended?\n",
      "[{'imatinib'}, {'dasatinib'}, {'tyrosine kinase inhibitor'}]\n",
      "3\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/961', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/761', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/1011', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/529', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/528', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab + capecitabine. entry url: https://civicdb.org/links/evidence_items/1133', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib + trastuzumab. entry url: https://civicdb.org/links/evidence_items/1113', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is lapatinib + capecitabine. entry url: https://civicdb.org/links/evidence_items/1132', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/1160', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/1432']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has rcsd1::abl1 fusion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has cd274 expression, what therapy is recommended?\n",
      "[{'pembrolizumab', 'nivolumab'}, {'pembrolizumab', 'atezolizumab', 'avelumab', 'nivolumab'}, {'atezolizumab'}, {'pembrolizumab'}, {'atezolizumab', 'pembrolizumab', 'nivolumab', 'avelumab', 'durvalumab'}, {'pembrolizumab'}]\n",
      "6\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Breast Cancer cancer has erbb2 v842i, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/289', 'If a patient with Breast Cancer cancer has erbb2 v777l, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/288', 'If a patient with Breast Cancer cancer has erbb2 amplification, one recommended therapy is trastuzumab + lapatinib. entry url: https://civicdb.org/links/evidence_items/1006', 'If a patient with Breast Cancer cancer has erbb2 r678q, one recommended therapy is neratinib + lapatinib. entry url: https://civicdb.org/links/evidence_items/286', 'If a patient with Breast Cancer cancer has erbb2 d769h, one recommended therapy is neratinib + lapatinib. entry url: https://civicdb.org/links/evidence_items/279', 'If a patient with Breast Cancer cancer has erbb2 s310f, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/11691', 'If a patient with Breast Cancer cancer has erbb2 v777l, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/11690', 'If a patient with Breast Cancer cancer has erbb2 g778_p780dup, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/285', 'If a patient with Breast Cancer cancer has erbb2 l755s, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/283', 'If a patient with Breast Cancer cancer has erbb2 d769y, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/280']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has cd274 expression, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Solid Tumor cancer has v::ntrk3 fusion, what therapy is recommended?\n",
      "[{'larotrectinib'}, {'entrectinib'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Breast Cancer cancer has erbb2 v777l, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/288', 'If a patient with Breast Cancer cancer has erbb2 v842i, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/289', 'If a patient with Breast Cancer cancer has erbb2 amplification, one recommended therapy is trastuzumab + lapatinib. entry url: https://civicdb.org/links/evidence_items/1006', 'If a patient with Breast Cancer cancer has erbb2 d769h, one recommended therapy is neratinib + lapatinib. entry url: https://civicdb.org/links/evidence_items/279', 'If a patient with Breast Cancer cancer has erbb2 r678q, one recommended therapy is neratinib + lapatinib. entry url: https://civicdb.org/links/evidence_items/286', 'If a patient with Breast Cancer cancer has erbb2 v777l, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/11690', 'If a patient with Breast Cancer cancer has erbb2 s310f, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/11691', 'If a patient with Breast Cancer cancer has erbb2 l755_t759del, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/281', 'If a patient with Breast Cancer cancer has erbb2 d769y, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/280', 'If a patient with Breast Cancer cancer has erbb2 r896c, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/287']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Solid Tumor cancer has v::ntrk3 fusion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with nan cancer has cip2a underexpression, what therapy is recommended?\n",
      "[{'gemcitabine'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/761', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is lapatinib + capecitabine. entry url: https://civicdb.org/links/evidence_items/1132', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/961', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/1011', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab + capecitabine. entry url: https://civicdb.org/links/evidence_items/1133', 'If a patient with nan cancer has erbb2 overexpression, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/4840', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/529', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/528', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/1160', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/1432']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has cip2a underexpression, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has ercc2 k751q, what therapy is recommended?\n",
      "[{'paclitaxel', 'carboplatin'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Breast Cancer cancer has erbb2 r678q, one recommended therapy is neratinib + lapatinib. entry url: https://civicdb.org/links/evidence_items/286', 'If a patient with Breast Cancer cancer has erbb2 v777l, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/288', 'If a patient with Breast Cancer cancer has erbb2 v842i, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/289', 'If a patient with Breast Cancer cancer has erbb2 l755_t759del, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/281', 'If a patient with Breast Cancer cancer has erbb2 l755w, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/284', 'If a patient with Breast Cancer cancer has erbb2 l755s, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/283', 'If a patient with Breast Cancer cancer has erbb2 r896c, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/287', 'If a patient with Breast Cancer cancer has erbb2 g778_p780dup, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/285', 'If a patient with Breast Cancer cancer has erbb2 d769y, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/280', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is lapatinib + capecitabine. entry url: https://civicdb.org/links/evidence_items/1132']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has ercc2 k751q, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, what therapy is recommended?\n",
      "[{'imatinib'}, {'dasatinib', 'nilotinib'}, {'imatinib'}, {'dasatinib'}, {'dasatinib', 'nilotinib', 'bafetinib'}]\n",
      "5\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Breast Cancer cancer has erbb2 v842i, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/289', 'If a patient with Breast Cancer cancer has erbb2 v777l, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/288', 'If a patient with Breast Cancer cancer has erbb2 amplification, one recommended therapy is trastuzumab + lapatinib. entry url: https://civicdb.org/links/evidence_items/1006', 'If a patient with Breast Cancer cancer has erbb2 r678q, one recommended therapy is neratinib + lapatinib. entry url: https://civicdb.org/links/evidence_items/286', 'If a patient with Breast Cancer cancer has erbb2 d769h, one recommended therapy is neratinib + lapatinib. entry url: https://civicdb.org/links/evidence_items/279', 'If a patient with Breast Cancer cancer has erbb2 s310f, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/11691', 'If a patient with Breast Cancer cancer has erbb2 v777l, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/11690', 'If a patient with Breast Cancer cancer has erbb2 l755s, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/283', 'If a patient with Breast Cancer cancer has erbb2 d769y, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/280', 'If a patient with Breast Cancer cancer has erbb2 l755_t759del, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/281']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with nan cancer has egfr viii, what therapy is recommended?\n",
      "[{'nimotuzumab'}, {'erlotinib'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/961', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/761', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/1011', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab + capecitabine. entry url: https://civicdb.org/links/evidence_items/1133', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/529', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/528', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is lapatinib + capecitabine. entry url: https://civicdb.org/links/evidence_items/1132', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib + trastuzumab. entry url: https://civicdb.org/links/evidence_items/1113', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/1432', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/1160']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has egfr viii, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with nan cancer has erbb2 v777l, what therapy is recommended?\n",
      "[{'neratinib', 'trastuzumab', 'lapatinib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Breast Cancer cancer has erbb2 v777l, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/288', 'If a patient with nan cancer has erbb2 v777l, one recommended therapy is lapatinib + neratinib + trastuzumab. entry url: https://civicdb.org/links/evidence_items/1177', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/761', 'If a patient with Cancer cancer has erbb2 v777l, one recommended therapy is lapatinib. entry url: https://civicdb.org/links/evidence_items/9697', 'If a patient with Breast Cancer cancer has erbb2 v777l, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/11690', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is a66. entry url: https://civicdb.org/links/evidence_items/1381', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/529', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/961', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/528', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/1011']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has erbb2 v777l, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with nan cancer has pml::rara fusion, what therapy is recommended?\n",
      "[{'tretinoin'}, {'tretinoin', 'arsenic trioxide'}, {'tretinoin'}]\n",
      "3\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has pml::rara fusion, one recommended therapy is tretinoin. entry url: https://civicdb.org/links/evidence_items/316', 'If a patient with nan cancer has pml::rara fusion, one recommended therapy is tretinoin. entry url: https://civicdb.org/links/evidence_items/1519', 'If a patient with nan cancer has pml::rara fusion, one recommended therapy is arsenic trioxide + tretinoin. entry url: https://civicdb.org/links/evidence_items/1091', 'If a patient with nan cancer has fgfr2::v fusion, one recommended therapy is pemigatinib. entry url: https://civicdb.org/links/evidence_items/8173', 'If a patient with nan cancer has fgfr2::? fusion, one recommended therapy is pemigatinib. entry url: https://civicdb.org/links/evidence_items/8173', 'If a patient with nan cancer has fgfr3::tacc3 fusion, one recommended therapy is infigratinib. entry url: https://civicdb.org/links/evidence_items/6409', 'If a patient with Cholangiocarcinoma cancer has fgfr2::tacc3 fusion, one recommended therapy is pazopanib + ponatinib. entry url: https://civicdb.org/links/evidence_items/296', 'If a patient with Cholangiocarcinoma cancer has fgfr2::? fusion, one recommended therapy is infigratinib. entry url: https://civicdb.org/links/evidence_items/11230', 'If a patient with Cholangiocarcinoma cancer has fgfr2::v fusion, one recommended therapy is infigratinib. entry url: https://civicdb.org/links/evidence_items/11230', 'If a patient with Cholangiocarcinoma cancer has fgfr2::oga fusion, one recommended therapy is ponatinib. entry url: https://civicdb.org/links/evidence_items/295']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has pml::rara fusion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"nan cancer\",\n",
      "    \"Disease Phase or Condition\": \"nan cancer with pml::rara fusion\",\n",
      "    \"Drug Name\": \"tretinoin\",\n",
      "    \"Prior Treatment or Resistance Status\": \"none specified\",\n",
      "    \"Genomic Features\": \"pml::rara fusion\",\n",
      "    \"FDA-approval status\": \"not specified\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/316\"\n",
      "  }\n",
      "}\n",
      "if a patient with nan cancer has rad50 l1237f, what therapy is recommended?\n",
      "[{'checkpoint kinase inhibitor azd7762', 'irinotecan'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has flt3 overexpression, one recommended therapy is sunitinib. entry url: https://civicdb.org/links/evidence_items/1528', 'If a patient with Acute Myeloid Leukemia cancer has flt3 itd, one recommended therapy is sorafenib. entry url: https://civicdb.org/links/evidence_items/298', 'If a patient with Acute Myeloid Leukemia cancer has flt3 d835v, one recommended therapy is sunitinib. entry url: https://civicdb.org/links/evidence_items/4022', 'If a patient with Acute Myeloid Leukemia cancer has flt3 y842c, one recommended therapy is lestaurtinib. entry url: https://civicdb.org/links/evidence_items/8339', 'If a patient with Acute Myeloid Leukemia cancer has flt3 d835v, one recommended therapy is sunitinib + cytarabine. entry url: https://civicdb.org/links/evidence_items/3009', 'If a patient with Acute Myeloid Leukemia cancer has flt3 d835v, one recommended therapy is sunitinib + daunorubicin. entry url: https://civicdb.org/links/evidence_items/3010', 'If a patient with Acute Myeloid Leukemia cancer has flt3 itd, one recommended therapy is tyrphostin ag 1296. entry url: https://civicdb.org/links/evidence_items/299', 'If a patient with Acute Myeloid Leukemia cancer has flt3 d835v, one recommended therapy is as602868 + tyrphostin ag 1296. entry url: https://civicdb.org/links/evidence_items/3034', 'If a patient with Acute Myeloid Leukemia cancer has flt3 itd, one recommended therapy is sorafenib. entry url: https://civicdb.org/links/evidence_items/1555', 'If a patient with Acute Myeloid Leukemia cancer has flt3 itd, one recommended therapy is sorafenib. entry url: https://civicdb.org/links/evidence_items/1040']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has rad50 l1237f, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Pancreatic Adenocarcinoma cancer has v::nrg1 fusion, what therapy is recommended?\n",
      "[{'afatinib'}, {'zenocutuzumab-zbco'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Acute Myeloid Leukemia cancer has flt3 d835v, one recommended therapy is sunitinib. entry url: https://civicdb.org/links/evidence_items/4022', 'If a patient with Acute Myeloid Leukemia cancer has flt3 y842c, one recommended therapy is lestaurtinib. entry url: https://civicdb.org/links/evidence_items/8339', 'If a patient with Acute Myeloid Leukemia cancer has flt3 itd, one recommended therapy is sorafenib. entry url: https://civicdb.org/links/evidence_items/298', 'If a patient with Acute Myeloid Leukemia cancer has flt3 d835v, one recommended therapy is sunitinib + cytarabine. entry url: https://civicdb.org/links/evidence_items/3009', 'If a patient with Acute Myeloid Leukemia cancer has flt3 d835v, one recommended therapy is sunitinib + daunorubicin. entry url: https://civicdb.org/links/evidence_items/3010', 'If a patient with Acute Myeloid Leukemia cancer has flt3 itd, one recommended therapy is tyrphostin ag 1296. entry url: https://civicdb.org/links/evidence_items/299', 'If a patient with Acute Myeloid Leukemia cancer has flt3 d835v, one recommended therapy is as602868 + tyrphostin ag 1296. entry url: https://civicdb.org/links/evidence_items/3034', 'If a patient with Acute Myeloid Leukemia cancer has flt3 d835y, one recommended therapy is gilteritinib. entry url: https://civicdb.org/links/evidence_items/8108', 'If a patient with Acute Myeloid Leukemia cancer has flt3 mutation, one recommended therapy is gilteritinib. entry url: https://civicdb.org/links/evidence_items/7283', 'If a patient with Acute Myeloid Leukemia cancer has flt3 d835i, one recommended therapy is gilteritinib. entry url: https://civicdb.org/links/evidence_items/8351']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Pancreatic Adenocarcinoma cancer has v::nrg1 fusion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Lung Adenocarcinoma cancer has egfr l858r, what therapy is recommended?\n",
      "[{'afatinib'}, {'afatinib'}, {'afatinib'}, {'gefitinib'}, {'gefitinib'}, {'erlotinib'}, {'erlotinib'}, {'erlotinib'}, {'gefitinib'}]\n",
      "9\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Acute Myeloid Leukemia cancer has flt3 d835v, one recommended therapy is sunitinib. entry url: https://civicdb.org/links/evidence_items/4022', 'If a patient with Acute Myeloid Leukemia cancer has flt3 itd, one recommended therapy is sorafenib. entry url: https://civicdb.org/links/evidence_items/298', 'If a patient with Acute Myeloid Leukemia cancer has flt3 y842c, one recommended therapy is lestaurtinib. entry url: https://civicdb.org/links/evidence_items/8339', 'If a patient with Acute Myeloid Leukemia cancer has flt3 d835v, one recommended therapy is sunitinib + daunorubicin. entry url: https://civicdb.org/links/evidence_items/3010', 'If a patient with Acute Myeloid Leukemia cancer has flt3 d835v, one recommended therapy is sunitinib + cytarabine. entry url: https://civicdb.org/links/evidence_items/3009', 'If a patient with Acute Myeloid Leukemia cancer has flt3 itd, one recommended therapy is tyrphostin ag 1296. entry url: https://civicdb.org/links/evidence_items/299', 'If a patient with Acute Myeloid Leukemia cancer has flt3 d835y, one recommended therapy is gilteritinib. entry url: https://civicdb.org/links/evidence_items/8108', 'If a patient with Acute Myeloid Leukemia cancer has flt3 itd, one recommended therapy is sorafenib. entry url: https://civicdb.org/links/evidence_items/1555', 'If a patient with Acute Myeloid Leukemia cancer has flt3 mutation, one recommended therapy is gilteritinib. entry url: https://civicdb.org/links/evidence_items/7283', 'If a patient with Acute Myeloid Leukemia cancer has flt3 d835i, one recommended therapy is gilteritinib. entry url: https://civicdb.org/links/evidence_items/8351']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Lung Adenocarcinoma cancer has egfr l858r, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has met exon 14 skipping mutation, what therapy is recommended?\n",
      "[{'tepotinib'}, {'crizotinib'}, {'crizotinib'}, {'capmatinib'}]\n",
      "4\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has met exon 14 skipping mutation, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/7643', 'If a patient with Lung Adenocarcinoma cancer has met exon 14 skipping mutation, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1651', 'If a patient with Lung Adenocarcinoma cancer has met exon 14 skipping mutation, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1185', 'If a patient with Lung Adenocarcinoma cancer has met exon 14 skipping mutation, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/4786', 'If a patient with Lung Adenocarcinoma cancer has met exon 14 skipping mutation, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/797', 'If a patient with Non-Small Cell Lung Cancer cancer has met exon 14 skipping mutation, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/7642', 'If a patient with Non-Small Cell Lung Cancer cancer has met exon 14 skipping mutation, one recommended therapy is tepotinib. entry url: https://civicdb.org/links/evidence_items/7272', 'If a patient with Lung Adenocarcinoma cancer has met exon 14 skipping mutation, one recommended therapy is capmatinib. entry url: https://civicdb.org/links/evidence_items/1186', 'If a patient with Non-Small Cell Lung Cancer cancer has met exon 14 skipping mutation, one recommended therapy is capmatinib. entry url: https://civicdb.org/links/evidence_items/8847', 'If a patient with Cancer cancer has met exon 14 skipping mutation, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/736']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has met exon 14 skipping mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "    \"Disease Phase or Condition\": \"met exon 14 skipping mutation\",\n",
      "    \"Drug Name\": \"crizotinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"exon 14 skipping mutation\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/7643\"\n",
      "  }\n",
      "}\n",
      "if a patient with Cancer cancer has pten loss, what therapy is recommended?\n",
      "[{'buparlisib', 'carboplatin', 'paclitaxel'}, {'capivasertib'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Cancer cancer has pten loss, one recommended therapy is capivasertib. entry url: https://civicdb.org/links/evidence_items/1502', 'If a patient with nan cancer has pten loss, one recommended therapy is pi-103. entry url: https://civicdb.org/links/evidence_items/8012', 'If a patient with Breast Cancer cancer has pten loss, one recommended therapy is pi3kbeta inhibitor azd8186. entry url: https://civicdb.org/links/evidence_items/711', 'If a patient with nan cancer has pten loss, one recommended therapy is pictilisib. entry url: https://civicdb.org/links/evidence_items/2045', 'If a patient with Prostate Cancer cancer has pten loss, one recommended therapy is temsirolimus. entry url: https://civicdb.org/links/evidence_items/507', 'If a patient with Cancer cancer has pten mutation, one recommended therapy is ipatasertib. entry url: https://civicdb.org/links/evidence_items/1491', 'If a patient with Endometrial Cancer cancer has pten loss, one recommended therapy is temsirolimus. entry url: https://civicdb.org/links/evidence_items/1614', 'If a patient with Cancer cancer has pten loss, one recommended therapy is paclitaxel + buparlisib + carboplatin. entry url: https://civicdb.org/links/evidence_items/714', 'If a patient with Melanoma cancer has pten loss, one recommended therapy is uprosertib. entry url: https://civicdb.org/links/evidence_items/708', 'If a patient with nan cancer has pten loss, one recommended therapy is capivasertib + docetaxel. entry url: https://civicdb.org/links/evidence_items/1500']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Cancer cancer has pten loss, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Cancer\",\n",
      "    \"Disease Phase or Condition\": \"cancer with PTEN loss\",\n",
      "    \"Drug Name\": \"capivasertib\",\n",
      "    \"Prior Treatment or Resistance Status\": null,\n",
      "    \"Genomic Features\": \"PTEN loss\",\n",
      "    \"FDA-approval status\": \"Not specified in the provided data\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/1502\"\n",
      "  }\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has kras mutation, what therapy is recommended?\n",
      "[{'selumetinib', 'b-raf/vegfr-2 inhibitor raf265'}, {'afatinib', 'trametinib'}, {'docetaxel', 'selumetinib'}, {'trametinib'}, {'erlotinib', 'teprotumumab'}, {'abemaciclib'}, {'docetaxel', 'pemetrexed', 'trametinib'}, {'atezolizumab', 'nivolumab'}, {'immune checkpoint inhibitor'}]\n",
      "9\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has kras mutation, one recommended therapy is trametinib. entry url: https://civicdb.org/links/evidence_items/1220', 'If a patient with Non-Small Cell Lung Cancer cancer has kras mutation, one recommended therapy is immune checkpoint inhibitor. entry url: https://civicdb.org/links/evidence_items/4864', 'If a patient with Non-Small Cell Lung Cancer cancer has kras mutation, one recommended therapy is abemaciclib. entry url: https://civicdb.org/links/evidence_items/4842', 'If a patient with Non-Small Cell Lung Cancer cancer has kras mutation, one recommended therapy is selumetinib + docetaxel. entry url: https://civicdb.org/links/evidence_items/999', 'If a patient with Non-Small Cell Lung Cancer cancer has kras mutation, one recommended therapy is trametinib + afatinib. entry url: https://civicdb.org/links/evidence_items/992', 'If a patient with Non-Small Cell Lung Cancer cancer has kras mutation, one recommended therapy is teprotumumab + erlotinib. entry url: https://civicdb.org/links/evidence_items/3713', 'If a patient with Non-Small Cell Lung Cancer cancer has kras mutation, one recommended therapy is b-raf/vegfr-2 inhibitor raf265 + selumetinib. entry url: https://civicdb.org/links/evidence_items/989', 'If a patient with Non-Small Cell Lung Cancer cancer has kras mutation, one recommended therapy is atezolizumab + nivolumab. entry url: https://civicdb.org/links/evidence_items/4863', 'If a patient with Non-Small Cell Lung Cancer cancer has kras g12c, one recommended therapy is sotorasib. entry url: https://civicdb.org/links/evidence_items/9431', 'If a patient with Cancer cancer has kras mutation, one recommended therapy is azd5438. entry url: https://civicdb.org/links/evidence_items/1183']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has kras mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "    \"Disease Phase or Condition\": \"KRAS mutation\",\n",
      "    \"Drug Name\": \"trametinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"KRAS mutation\",\n",
      "    \"FDA-approval status\": \"Not specified in the provided data\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/1220\"\n",
      "  }\n",
      "}\n",
      "if a patient with Lung Adenocarcinoma cancer has erbb2 g778_p780dup, what therapy is recommended?\n",
      "[{'dacomitinib'}, {'afatinib'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Lung Adenocarcinoma cancer has erbb2 g778_p780dup, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/1890', 'If a patient with Lung Adenocarcinoma cancer has erbb2 g778_p780dup, one recommended therapy is dacomitinib. entry url: https://civicdb.org/links/evidence_items/1048', 'If a patient with Non-Small Cell Lung Cancer cancer has erbb2 g778_p780dup, one recommended therapy is trastuzumab deruxtecan. entry url: https://civicdb.org/links/evidence_items/11762', 'If a patient with Non-Small Cell Lung Cancer cancer has erbb2 g778_p780dup, one recommended therapy is dacomitinib. entry url: https://civicdb.org/links/evidence_items/1892', 'If a patient with Pancreatic Adenocarcinoma cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/962', 'If a patient with Lung Cancer cancer has fgfr1 expression, one recommended therapy is ponatinib. entry url: https://civicdb.org/links/evidence_items/681', 'If a patient with Non-Small Cell Lung Cancer cancer has kras g12c, one recommended therapy is sotorasib. entry url: https://civicdb.org/links/evidence_items/9431', 'If a patient with Non-Small Cell Lung Cancer cancer has kras mutation, one recommended therapy is teprotumumab + erlotinib. entry url: https://civicdb.org/links/evidence_items/3713', 'If a patient with Non-Small Cell Lung Cancer cancer has kras g12d, one recommended therapy is selumetinib + dactolisib. entry url: https://civicdb.org/links/evidence_items/305', 'If a patient with Non-Small Cell Lung Cancer cancer has kras mutation, one recommended therapy is selumetinib + docetaxel. entry url: https://civicdb.org/links/evidence_items/999']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Lung Adenocarcinoma cancer has erbb2 g778_p780dup, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Lung Adenocarcinoma\",\n",
      "    \"Disease Phase or Condition\": \"cancer\",\n",
      "    \"Drug Name\": \"afatinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"\",\n",
      "    \"Genomic Features\": \"erbb2 g778_p780dup\",\n",
      "    \"FDA-approval status\": \"recommended therapy\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/1890\"\n",
      "  }\n",
      "}\n",
      "if a patient with Cancer cancer has egfr l858r, what therapy is recommended?\n",
      "[{'erlotinib', 'gefitinib', 'multikinase inhibitor aee788'}, {'erlotinib'}, {'erlotinib'}, {'erlotinib'}]\n",
      "4\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4285', 'If a patient with Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4265', 'If a patient with Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/5922', 'If a patient with nan cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4295', 'If a patient with nan cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4293', 'If a patient with Lung Adenocarcinoma cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4291', 'If a patient with Lung Adenocarcinoma cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4290', 'If a patient with Lung Adenocarcinoma cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2634', 'If a patient with Lung Adenocarcinoma cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/6183', 'If a patient with Lung Adenocarcinoma cancer has egfr l858r, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/879']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Cancer cancer has egfr l858r, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Cancer\",\n",
      "    \"Disease Phase or Condition\": \"cancer with EGFR L858R mutation\",\n",
      "    \"Drug Name\": \"Erlotinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"not specified\",\n",
      "    \"Genomic Features\": \"EGFR L858R\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/4285\"\n",
      "  }\n",
      "}\n",
      "if a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, what therapy is recommended?\n",
      "[{'nilotinib'}, {'dasatinib'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2864', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4561', 'If a patient with Breast Cancer cancer has pik3ca e542k, one recommended therapy is izorlisib. entry url: https://civicdb.org/links/evidence_items/310', 'If a patient with Breast Cancer cancer has pik3ca h1047l, one recommended therapy is pi-103. entry url: https://civicdb.org/links/evidence_items/8009', 'If a patient with Breast Cancer cancer has pik3ca e542k, one recommended therapy is sirolimus. entry url: https://civicdb.org/links/evidence_items/311', 'If a patient with Breast Cancer cancer has pik3ca h1047r, one recommended therapy is izorlisib. entry url: https://civicdb.org/links/evidence_items/314', 'If a patient with nan cancer has pik3ca k111n, one recommended therapy is pi-103. entry url: https://civicdb.org/links/evidence_items/8011', 'If a patient with Breast Cancer cancer has pik3ca h1047l, one recommended therapy is pictilisib. entry url: https://civicdb.org/links/evidence_items/2089', 'If a patient with Breast Cancer cancer has pik3ca h1047l, one recommended therapy is pi3ka/di. entry url: https://civicdb.org/links/evidence_items/8019', 'If a patient with nan cancer has pik3ca k111n, one recommended therapy is pictilisib. entry url: https://civicdb.org/links/evidence_items/2085']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Chronic Myelogenous Leukemia\",\n",
      "    \"Disease Phase or Condition\": \"cancer\",\n",
      "    \"Drug Name\": \"nilotinib\",\n",
      "    \"Prior Treatment or Resistance Status\": null,\n",
      "    \"Genomic Features\": \"bcr::abl1 fusion, abl1 g398r\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/2864\"\n",
      "  }\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, what therapy is recommended?\n",
      "[{'crizotinib'}, {'crizotinib'}, {'entrectinib'}, {'crizotinib'}, {'crizotinib'}, {'entrectinib'}]\n",
      "6\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/688', 'If a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, one recommended therapy is entrectinib. entry url: https://civicdb.org/links/evidence_items/11123', 'If a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/7282', 'If a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, one recommended therapy is entrectinib. entry url: https://civicdb.org/links/evidence_items/2951', 'If a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/7933', 'If a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1030', 'If a patient with Cancer cancer has v::ros1 fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/11671', 'If a patient with Breast Cancer cancer has tp53 r175h, one recommended therapy is doxorubicin. entry url: https://civicdb.org/links/evidence_items/319', 'If a patient with Breast Cancer cancer has tp53 r249, one recommended therapy is doxorubicin. entry url: https://civicdb.org/links/evidence_items/399', 'If a patient with Breast Cancer cancer has tp53 mutation, one recommended therapy is doxorubicin. entry url: https://civicdb.org/links/evidence_items/851']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "    \"Disease Phase or Condition\": \"cancer with v::ros1 fusion\",\n",
      "    \"Drug Name\": \"crizotinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"v::ros1 fusion\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/688\"\n",
      "  }\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has egfr e746_a750del, what therapy is recommended?\n",
      "[{'gefitinib'}, {'gefitinib'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4706', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 d276g, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2666', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 e279k, one recommended therapy is axitinib. entry url: https://civicdb.org/links/evidence_items/7772', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 m351t, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2685', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2864', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4561', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 v299l, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2862', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, one recommended therapy is nilotinib + dasatinib + bafetinib. entry url: https://civicdb.org/links/evidence_items/7838', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 t315i, one recommended therapy is ponatinib. entry url: https://civicdb.org/links/evidence_items/1390', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 e255k, abl1 v299l, one recommended therapy is ponatinib + dasatinib. entry url: https://civicdb.org/links/evidence_items/7781']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has egfr e746_a750del, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, what therapy is recommended?\n",
      "[{'imatinib'}, {'imatinib'}, {'regorafenib'}, {'regorafenib'}, {'regorafenib'}]\n",
      "5\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/2471', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/654', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is regorafenib. entry url: https://civicdb.org/links/evidence_items/4599', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is regorafenib. entry url: https://civicdb.org/links/evidence_items/6377', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is regorafenib. entry url: https://civicdb.org/links/evidence_items/4629', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 9 mutation, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/1221', 'If a patient with Cancer cancer has tp53 mutation, one recommended therapy is vegf/vegfr inhibitors. entry url: https://civicdb.org/links/evidence_items/11709', 'If a patient with Breast Cancer cancer has tp53 r249, one recommended therapy is doxorubicin. entry url: https://civicdb.org/links/evidence_items/399', 'If a patient with Breast Cancer cancer has tp53 r175h, one recommended therapy is doxorubicin. entry url: https://civicdb.org/links/evidence_items/319', 'If a patient with Breast Cancer cancer has tp53 mutation, one recommended therapy is doxorubicin. entry url: https://civicdb.org/links/evidence_items/851']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Gastrointestinal Stromal Tumor cancer\",\n",
      "    \"Disease Phase or Condition\": \"Gastrointestinal Stromal Tumor with KIT exon 11 mutation\",\n",
      "    \"Drug Name\": \"imatinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"KIT exon 11 mutation\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/2471\"\n",
      "  }\n",
      "}\n",
      "if a patient with Glioblastoma cancer has pten expression, what therapy is recommended?\n",
      "[{'epidermal growth factor receptor tyrosine kinase inhibitor'}, {'dacomitinib'}, {'erlotinib', 'gefitinib'}]\n",
      "3\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Glioblastoma cancer has pten expression, one recommended therapy is dacomitinib. entry url: https://civicdb.org/links/evidence_items/775', 'If a patient with Glioblastoma cancer has pten expression, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/1129', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr expression, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/4877', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr overexpression, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/954', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr e746_a750del, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2625', 'If a patient with Lung Cancer cancer has egfr mutation, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/3864', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/3016', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/965', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2621', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/229']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Glioblastoma cancer has pten expression, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Glioblastoma\",\n",
      "    \"Disease Phase or Condition\": \"cancer\",\n",
      "    \"Drug Name\": \"dacomitinib\",\n",
      "    \"Prior Treatment or Resistance Status\": null,\n",
      "    \"Genomic Features\": \"pten expression\",\n",
      "    \"FDA-approval status\": \"recommended therapy based on evidence\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/775\"\n",
      "  }\n",
      "}\n",
      "if a patient with Ovarian Cancer cancer has brca1 loss-of-function, what therapy is recommended?\n",
      "[{'olaparib'}, {'talazoparib'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Ovarian Cancer cancer has brca1 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/211', 'If a patient with Prostate Cancer cancer has brca1 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/845', 'If a patient with Ovarian Cancer cancer has brca1 loss-of-function, one recommended therapy is talazoparib. entry url: https://civicdb.org/links/evidence_items/4876', 'If a patient with Ovarian Cancer cancer has brca2 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/212', 'If a patient with Ovarian Cancer cancer has brca1 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/1772', 'If a patient with Ovarian Cancer cancer has brca1 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/7275', 'If a patient with Ovarian Cancer cancer has brca1 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/7274', 'If a patient with Prostate Cancer cancer has brca2 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/650', 'If a patient with Prostate Cancer cancer has brca1 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/11666', 'If a patient with Ovarian Cancer cancer has brca1 mutation, one recommended therapy is olaparib + cediranib. entry url: https://civicdb.org/links/evidence_items/1677']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Ovarian Cancer cancer has brca1 loss-of-function, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Ovarian Cancer\",\n",
      "    \"Disease Phase or Condition\": \"loss-of-function\",\n",
      "    \"Drug Name\": \"olaparib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"brca1 loss-of-function\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/211\"\n",
      "  }\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has egfr exon 19 deletion, what therapy is recommended?\n",
      "[{'gefitinib'}, {'erlotinib', 'gefitinib'}, {'afatinib'}, {'erlotinib'}, {'afatinib'}, {'gefitinib'}, {'gefitinib'}, {'erlotinib'}, {'afatinib'}, {'erlotinib', 'gefitinib'}, {'erlotinib', 'dacomitinib'}, {'dacomitinib'}, {'osimertinib'}, {'dacomitinib'}, {'erlotinib', 'ramucirumab'}, {'gefitinib'}, {'osimertinib', 'chemotherapy'}, {'amivantamab', 'lazertinib'}, {'amivantamab', 'pemetrexed', 'carboplatin'}]\n",
      "19\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has egfr exon 19 deletion, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/2995', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr exon 19 deletion, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/969', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr exon 19 deletion, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2156', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr exon 19 deletion, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/273', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr exon 19 deletion, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/11241', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr exon 19 deletion, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/884', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr exon 19 deletion, one recommended therapy is gefitinib + erlotinib. entry url: https://civicdb.org/links/evidence_items/4759', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr exon 19 deletion, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/1666', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr exon 19 deletion, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/881', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr exon 19 deletion, one recommended therapy is dacomitinib + erlotinib. entry url: https://civicdb.org/links/evidence_items/4859']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has egfr exon 19 deletion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "    \"Disease Phase or Condition\": \"EGFR exon 19 deletion\",\n",
      "    \"Drug Name\": \"erlotinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"EGFR exon 19 deletion\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/2995\"\n",
      "  }\n",
      "}\n",
      "if a patient with Lung Adenocarcinoma cancer has egfr exon 19 deletion, what therapy is recommended?\n",
      "[{'afatinib'}, {'afatinib'}, {'afatinib'}, {'afatinib'}, {'gefitinib'}, {'erlotinib'}, {'erlotinib'}, {'gefitinib'}]\n",
      "8\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Lung Adenocarcinoma cancer has egfr exon 19 deletion, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4766', 'If a patient with Lung Adenocarcinoma cancer has egfr exon 19 deletion, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/880', 'If a patient with Lung Adenocarcinoma cancer has egfr exon 19 deletion, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/882', 'If a patient with Lung Adenocarcinoma cancer has egfr exon 19 deletion, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2519', 'If a patient with Lung Adenocarcinoma cancer has egfr exon 19 deletion, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/3791', 'If a patient with Lung Adenocarcinoma cancer has egfr exon 19 deletion, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/981', 'If a patient with Lung Adenocarcinoma cancer has egfr exon 19 deletion, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/983', 'If a patient with Lung Adenocarcinoma cancer has egfr exon 19 deletion, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/6184', 'If a patient with Lung Adenocarcinoma cancer has egfr t790m, egfr exon 19 deletion, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/1397', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr exon 19 deletion, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/969']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Lung Adenocarcinoma cancer has egfr exon 19 deletion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Lung Adenocarcinoma\",\n",
      "    \"Disease Phase or Condition\": \"Cancer with EGFR exon 19 deletion\",\n",
      "    \"Drug Name\": \"Erlotinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"EGFR exon 19 deletion\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/4766\"\n",
      "  }\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, what therapy is recommended?\n",
      "[{'crizotinib'}, {'crizotinib'}, {'entrectinib'}, {'crizotinib'}, {'crizotinib'}, {'entrectinib'}]\n",
      "6\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, one recommended therapy is entrectinib. entry url: https://civicdb.org/links/evidence_items/11123', 'If a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/7282', 'If a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/688', 'If a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, one recommended therapy is entrectinib. entry url: https://civicdb.org/links/evidence_items/2951', 'If a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/7933', 'If a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/1030', 'If a patient with Non-Small Cell Lung Cancer cancer has ros1 g2032r, v::ros1 fusion, one recommended therapy is lorlatinib. entry url: https://civicdb.org/links/evidence_items/1251', 'If a patient with Cancer cancer has v::ros1 fusion, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/11671', 'If a patient with Glioblastoma cancer has atm mutation, one recommended therapy is temozolomide. entry url: https://civicdb.org/links/evidence_items/452', 'If a patient with Prostate Cancer cancer has atm mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/1960']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has v::ros1 fusion, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Non-Small Cell Lung Cancer\",\n",
      "    \"Disease Phase or Condition\": \"cancer with v::ros1 fusion\",\n",
      "    \"Drug Name\": \"entrectinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"not specified\",\n",
      "    \"Genomic Features\": \"v::ros1 fusion\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/11123\"\n",
      "  }\n",
      "}\n",
      "if a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, what therapy is recommended?\n",
      "[{'imatinib'}, {'imatinib'}, {'regorafenib'}, {'regorafenib'}, {'regorafenib'}]\n",
      "5\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/2471', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is regorafenib. entry url: https://civicdb.org/links/evidence_items/4599', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/654', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is regorafenib. entry url: https://civicdb.org/links/evidence_items/6377', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is regorafenib. entry url: https://civicdb.org/links/evidence_items/4629', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 9 mutation, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/1221', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 13 mutation, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/2475', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 9 mutation, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/2466', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 9 mutation, one recommended therapy is sunitinib. entry url: https://civicdb.org/links/evidence_items/1223', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 9 mutation, one recommended therapy is sunitinib. entry url: https://civicdb.org/links/evidence_items/1424']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Gastrointestinal Stromal Tumor\",\n",
      "    \"Disease Phase or Condition\": \"cancer with KIT exon 11 mutation\",\n",
      "    \"Drug Name\": \"imatinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"not specified\",\n",
      "    \"Genomic Features\": \"KIT exon 11 mutation\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/2471\"\n",
      "  }\n",
      "}\n",
      "if a patient with nan cancer has erbb2 amplification, what therapy is recommended?\n",
      "[{'trastuzumab'}, {'trastuzumab'}, {'neratinib'}, {'afatinib'}, {'afatinib', 'trastuzumab', 'lapatinib'}, {'afatinib'}, {'trastuzumab', 'lapatinib'}, {'trastuzumab', 'lapatinib'}, {'afatinib'}, {'afatinib', 'trastuzumab'}, {'trastuzumab', 'irinotecan'}, {'docetaxel', 'trastuzumab', 'pertuzumab'}, {'trastuzumab'}, {'neratinib', 'trastuzumab'}, {'trastuzumab'}, {'capecitabine', 'lapatinib'}, {'trastuzumab', 'capecitabine'}, {'trastuzumab emtansine'}, {'trastuzumab emtansine'}, {'pictilisib'}, {'a66'}, {'trastuzumab emtansine'}, {'docetaxel', 'trastuzumab', 'pertuzumab'}, {'trastuzumab', 'lapatinib'}, {'trastuzumab', 'pilaralisib'}, {'trastuzumab', 'palbociclib'}, {'trastuzumab'}, {'trastuzumab emtansine'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab deruxtecan'}, {'lapatinib'}]\n",
      "32\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/761', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is a66. entry url: https://civicdb.org/links/evidence_items/1381', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/961', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/529', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/528', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/1011', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/1693', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/1122', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/1160', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/1432']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has erbb2 amplification, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"nan cancer\",\n",
      "    \"Disease Phase or Condition\": \"nan cancer with ERBB2 amplification\",\n",
      "    \"Drug Name\": \"trastuzumab\",\n",
      "    \"Prior Treatment or Resistance Status\": \"not specified\",\n",
      "    \"Genomic Features\": \"ERBB2 amplification\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/529\"\n",
      "  }\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has egfr l861, what therapy is recommended?\n",
      "[{'erlotinib', 'gefitinib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has egfr l861, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/4298', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/229', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2621', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr g719a, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2508', 'If a patient with Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4265', 'If a patient with Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4285', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr expression, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/4877', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is dacomitinib. entry url: https://civicdb.org/links/evidence_items/11239', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/3016', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is lazertinib + amivantamab. entry url: https://civicdb.org/links/evidence_items/12131']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has egfr l861, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with nan cancer has brca1 mutation, what therapy is recommended?\n",
      "[{'platinum compound'}, {'platinum compound'}, {'cisplatin', 'carboplatin'}, {'olaparib'}, {'olaparib'}, {'niraparib'}]\n",
      "6\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has brca1 mutation, one recommended therapy is platinum compound. entry url: https://civicdb.org/links/evidence_items/1529', 'If a patient with nan cancer has brca1 mutation, one recommended therapy is platinum compound. entry url: https://civicdb.org/links/evidence_items/1531', 'If a patient with nan cancer has brca1 mutation, one recommended therapy is niraparib. entry url: https://civicdb.org/links/evidence_items/11243', 'If a patient with nan cancer has brca1 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/5830', 'If a patient with nan cancer has brca1 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/11203', 'If a patient with nan cancer has brca1 mutation, one recommended therapy is carboplatin + cisplatin. entry url: https://civicdb.org/links/evidence_items/1684', 'If a patient with nan cancer has brca1 w1815x, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/4623', 'If a patient with nan cancer has brca1 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/11216', 'If a patient with nan cancer has brca1 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/5815', 'If a patient with nan cancer has brca1 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/11201']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has brca1 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with nan cancer has fgfr1 amplification, what therapy is recommended?\n",
      "[{'ponatinib'}, {'ponatinib'}, {'pazopanib'}]\n",
      "3\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has fgfr1 amplification, one recommended therapy is ponatinib. entry url: https://civicdb.org/links/evidence_items/1767', 'If a patient with nan cancer has fgfr1 amplification, one recommended therapy is pazopanib. entry url: https://civicdb.org/links/evidence_items/7811', 'If a patient with nan cancer has fgfr1 amplification, one recommended therapy is ponatinib. entry url: https://civicdb.org/links/evidence_items/1247', 'If a patient with Breast Cancer cancer has fgfr1 amplification, one recommended therapy is fexagratinib. entry url: https://civicdb.org/links/evidence_items/1991', 'If a patient with Breast Cancer cancer has fgfr1 amplification, one recommended therapy is erdafitinib. entry url: https://civicdb.org/links/evidence_items/12469', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/961', 'If a patient with Breast Cancer cancer has fgfr1 amplification, one recommended therapy is lucitanib. entry url: https://civicdb.org/links/evidence_items/7488', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/761', 'If a patient with Breast Cancer cancer has fgfr1 amplification, one recommended therapy is pazopanib. entry url: https://civicdb.org/links/evidence_items/7246', 'If a patient with Breast Cancer cancer has fgfr1 amplification, one recommended therapy is dovitinib. entry url: https://civicdb.org/links/evidence_items/12478']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has fgfr1 amplification, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with nan cancer has fgfr1 amplification, what therapy is recommended?\n",
      "[{'ponatinib'}, {'ponatinib'}, {'pazopanib'}]\n",
      "3\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has fgfr1 amplification, one recommended therapy is ponatinib. entry url: https://civicdb.org/links/evidence_items/1767', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/961', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/1011', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/886', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/761', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib + trastuzumab + lapatinib. entry url: https://civicdb.org/links/evidence_items/887', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/529', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/528', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib + trastuzumab. entry url: https://civicdb.org/links/evidence_items/1113', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab deruxtecan. entry url: https://civicdb.org/links/evidence_items/7647']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has fgfr1 amplification, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"nan cancer\",\n",
      "    \"Disease Phase or Condition\": \"nan cancer\",\n",
      "    \"Drug Name\": \"ponatinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"fgfr1 amplification\",\n",
      "    \"FDA-approval status\": \"not specified in the provided data\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/1767\"\n",
      "  }\n",
      "}\n",
      "if a patient with Ovarian Cancer cancer has brca2 m1r, what therapy is recommended?\n",
      "[{'rucaparib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4706', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 v299l, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2862', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 e279k, one recommended therapy is axitinib. entry url: https://civicdb.org/links/evidence_items/7772', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 m351t, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2685', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2864', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4561', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 d276g, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2666', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, one recommended therapy is nilotinib + dasatinib + bafetinib. entry url: https://civicdb.org/links/evidence_items/7838', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 e255k, abl1 v299l, one recommended therapy is ponatinib + dasatinib. entry url: https://civicdb.org/links/evidence_items/7781', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 t315i, one recommended therapy is ponatinib. entry url: https://civicdb.org/links/evidence_items/1390']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Ovarian Cancer cancer has brca2 m1r, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Endometrial Cancer cancer has pten loss, what therapy is recommended?\n",
      "[{'temsirolimus'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4706', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, one recommended therapy is dasatinib. entry url: https://civicdb.org/links/evidence_items/4561', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 m351t, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2685', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 v299l, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2862', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 g398r, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2864', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 e279k, one recommended therapy is axitinib. entry url: https://civicdb.org/links/evidence_items/7772', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 d276g, one recommended therapy is nilotinib. entry url: https://civicdb.org/links/evidence_items/2666', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, one recommended therapy is nilotinib + dasatinib + bafetinib. entry url: https://civicdb.org/links/evidence_items/7838', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 e255k, abl1 v299l, one recommended therapy is ponatinib + dasatinib. entry url: https://civicdb.org/links/evidence_items/7781', 'If a patient with Chronic Myelogenous Leukemia cancer has bcr::abl1 fusion, abl1 t315i, one recommended therapy is ponatinib. entry url: https://civicdb.org/links/evidence_items/1390']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Endometrial Cancer cancer has pten loss, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Solid Tumor cancer has tp53 mutation, what therapy is recommended?\n",
      "[{'vorinostat', 'pazopanib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Lung Cancer cancer has egfr mutation, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/3864', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/3016', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2559', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/2053', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/1937', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr expression, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/4877', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2621', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/965', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib + gefitinib. entry url: https://civicdb.org/links/evidence_items/229', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr mutation, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4201']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Solid Tumor cancer has tp53 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, what therapy is recommended?\n",
      "[{'erlotinib', 'gefitinib'}, {'erlotinib', 'gefitinib'}, {'gefitinib'}, {'erlotinib'}, {'afatinib'}, {'gefitinib'}, {'gefitinib'}, {'gefitinib'}, {'lapatinib'}, {'dacomitinib'}, {'neratinib'}, {'afatinib'}, {'canertinib'}, {'erlotinib'}, {'erlotinib'}, {'afatinib'}, {'erlotinib'}, {'erlotinib'}, {'erlotinib'}, {'osimertinib'}, {'erlotinib', 'gefitinib'}, {'dacomitinib'}, {'dacomitinib'}, {'osimertinib'}, {'dacomitinib'}, {'erlotinib', 'ramucirumab'}, {'gefitinib'}, {'osimertinib', 'chemotherapy'}, {'amivantamab', 'lazertinib'}, {'amivantamab', 'pemetrexed', 'carboplatin'}]\n",
      "30\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4286', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4287', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4284', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2621', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/2994', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is canertinib. entry url: https://civicdb.org/links/evidence_items/2631', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/276', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2156', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/2628', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/2629']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, what therapy is recommended?\n",
      "[{'erlotinib', 'pemetrexed'}, {'staurosporine'}, {'rociletinib'}, {'rociletinib'}, {'osimertinib'}, {'osimertinib'}, {'osimertinib'}, {'osimertinib', 'rociletinib'}, {'osimertinib'}, {'osimertinib'}, {'dacomitinib'}, {'neratinib'}, {'afatinib'}, {'afatinib'}, {'canertinib'}]\n",
      "15\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is canertinib. entry url: https://civicdb.org/links/evidence_items/2165', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/2163', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/2164', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/2162', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/963', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/965', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is dacomitinib. entry url: https://civicdb.org/links/evidence_items/2161', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is osimertinib. entry url: https://civicdb.org/links/evidence_items/1592', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is rociletinib. entry url: https://civicdb.org/links/evidence_items/762', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, one recommended therapy is rociletinib. entry url: https://civicdb.org/links/evidence_items/646']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has egfr t790m, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with head and neck cancer has pik3ca h1047r, what therapy is recommended?\n",
      "[{'dactolisib'}, {'dactolisib'}, {'cetuximab', 'dactolisib'}, {'alpelisib'}]\n",
      "4\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with head and neck cancer has pik3ca h1047r, one recommended therapy is alpelisib. entry url: https://civicdb.org/links/evidence_items/1401', 'If a patient with head and neck cancer has pik3ca h1047r, one recommended therapy is dactolisib. entry url: https://civicdb.org/links/evidence_items/1362', 'If a patient with head and neck cancer has pik3ca h1047r, one recommended therapy is dactolisib. entry url: https://civicdb.org/links/evidence_items/1361', 'If a patient with head and neck cancer has pik3ca h1047r, one recommended therapy is dactolisib + cetuximab. entry url: https://civicdb.org/links/evidence_items/1363', 'If a patient with head and neck cancer has pik3ca mutation, one recommended therapy is dactolisib. entry url: https://civicdb.org/links/evidence_items/1360', 'If a patient with head and neck cancer has met r1004g, one recommended therapy is crizotinib. entry url: https://civicdb.org/links/evidence_items/7498', 'If a patient with head and neck cancer has ptprd mutation, one recommended therapy is jsi-124. entry url: https://civicdb.org/links/evidence_items/807', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 9 mutation, one recommended therapy is sunitinib. entry url: https://civicdb.org/links/evidence_items/1424', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit v560_l576del, one recommended therapy is regorafenib. entry url: https://civicdb.org/links/evidence_items/4061', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit p551_e554delpmye, one recommended therapy is ponatinib. entry url: https://civicdb.org/links/evidence_items/4125']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with head and neck cancer has pik3ca h1047r, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"head and neck cancer\",\n",
      "    \"Disease Phase or Condition\": \"head and neck cancer with pik3ca h1047r mutation\",\n",
      "    \"Drug Name\": \"alpelisib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"not specified\",\n",
      "    \"Genomic Features\": \"pik3ca h1047r\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/1401\"\n",
      "  }\n",
      "}\n",
      "if a patient with nan cancer has bard1 mutation, what therapy is recommended?\n",
      "[{'olaparib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has bard1 mutation, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/11209', 'If a patient with Colorectal Cancer cancer has bard1 loss-of-function, one recommended therapy is olaparib. entry url: https://civicdb.org/links/evidence_items/5953', 'If a patient with nan cancer has gstp1 deletion, one recommended therapy is carboplatin + paclitaxel + cisplatin. entry url: https://civicdb.org/links/evidence_items/660', 'If a patient with Colorectal Cancer cancer has gstp1 i105v, one recommended therapy is folfox regimen. entry url: https://civicdb.org/links/evidence_items/670', 'If a patient with Colorectal Cancer cancer has kras mutation, one recommended therapy is trametinib + afatinib. entry url: https://civicdb.org/links/evidence_items/991', 'If a patient with Colorectal Cancer cancer has pik3ca mutation, one recommended therapy is aspirin. entry url: https://civicdb.org/links/evidence_items/6375', 'If a patient with Colorectal Cancer cancer has pik3ca mutation, one recommended therapy is cabozantinib. entry url: https://civicdb.org/links/evidence_items/771', 'If a patient with Colorectal Cancer cancer has apc mutation, one recommended therapy is g007-lk. entry url: https://civicdb.org/links/evidence_items/446', 'If a patient with Colorectal Cancer cancer has kras mutation, one recommended therapy is b-raf/vegfr-2 inhibitor raf265 + selumetinib. entry url: https://civicdb.org/links/evidence_items/988', 'If a patient with Colorectal Cancer cancer has kras exon 2 mutation, one recommended therapy is selumetinib + irinotecan. entry url: https://civicdb.org/links/evidence_items/1326']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has bard1 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, what therapy is recommended?\n",
      "[{'imatinib'}, {'imatinib'}, {'regorafenib'}, {'regorafenib'}, {'regorafenib'}]\n",
      "5\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/2471', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/654', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is regorafenib. entry url: https://civicdb.org/links/evidence_items/4599', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is regorafenib. entry url: https://civicdb.org/links/evidence_items/6377', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, one recommended therapy is regorafenib. entry url: https://civicdb.org/links/evidence_items/4629', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 13 mutation, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/2475', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 9 mutation, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/1221', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 9 mutation, one recommended therapy is imatinib. entry url: https://civicdb.org/links/evidence_items/2466', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 9 mutation, one recommended therapy is sunitinib. entry url: https://civicdb.org/links/evidence_items/1223', 'If a patient with Gastrointestinal Stromal Tumor cancer has kit exon 9 mutation, one recommended therapy is sunitinib. entry url: https://civicdb.org/links/evidence_items/1424']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Gastrointestinal Stromal Tumor cancer has kit exon 11 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Gastrointestinal Stromal Tumor\",\n",
      "    \"Disease Phase or Condition\": \"Cancer with KIT exon 11 mutation\",\n",
      "    \"Drug Name\": \"Imatinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"KIT exon 11 mutation\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/2471\"\n",
      "  }\n",
      "}\n",
      "if a patient with Colorectal Cancer cancer has braf v600e, what therapy is recommended?\n",
      "[{'sorafenib', 'panitumumab'}, {'pictilisib bismesylate', 'plx4720'}, {'capecitabine', 'vemurafenib', 'bevacizumab'}, {'vemurafenib'}, {'gefitinib', 'cetuximab', 'vemurafenib'}, {'dactolisib', 'gdc-0879'}, {'vemurafenib', 'panitumumab'}, {'cetuximab', 'irinotecan', 'vemurafenib'}, {'vemurafenib'}, {'dabrafenib', 'panitumumab', 'trametinib'}, {'binimetinib', 'encorafenib', 'cetuximab'}, {'binimetinib', 'encorafenib', 'cetuximab'}, {'cetuximab', 'vemurafenib', 'irinotecan'}, {'erlotinib', 'vemurafenib'}, {'encorafenib', 'cetuximab'}, {'cobimetinib', 'vemurafenib'}]\n",
      "16\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Colorectal Cancer cancer has braf v600e, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/5960', 'If a patient with Colorectal Cancer cancer has braf v600e, one recommended therapy is vemurafenib + panitumumab. entry url: https://civicdb.org/links/evidence_items/1589', 'If a patient with Colorectal Cancer cancer has braf v600e, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/99', 'If a patient with Colorectal Cancer cancer has braf v600e, one recommended therapy is vemurafenib + erlotinib. entry url: https://civicdb.org/links/evidence_items/8507', 'If a patient with Colorectal Cancer cancer has braf v600e, one recommended therapy is vemurafenib + cobimetinib. entry url: https://civicdb.org/links/evidence_items/11670', 'If a patient with Colorectal Cancer cancer has braf v600e, one recommended therapy is panitumumab + sorafenib. entry url: https://civicdb.org/links/evidence_items/89', 'If a patient with Colorectal Cancer cancer has braf v600e, one recommended therapy is cetuximab + irinotecan + vemurafenib. entry url: https://civicdb.org/links/evidence_items/1902', 'If a patient with Colorectal Cancer cancer has braf v600e, one recommended therapy is encorafenib + cetuximab. entry url: https://civicdb.org/links/evidence_items/9851', 'If a patient with Colorectal Cancer cancer has braf v600e, one recommended therapy is vemurafenib + gefitinib + cetuximab. entry url: https://civicdb.org/links/evidence_items/1408', 'If a patient with Colorectal Cancer cancer has braf v600e, one recommended therapy is vemurafenib + irinotecan + cetuximab. entry url: https://civicdb.org/links/evidence_items/8506']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Colorectal Cancer cancer has braf v600e, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with nan cancer has erbb2 amplification, what therapy is recommended?\n",
      "[{'trastuzumab'}, {'trastuzumab'}, {'neratinib'}, {'afatinib'}, {'afatinib', 'trastuzumab', 'lapatinib'}, {'afatinib'}, {'trastuzumab', 'lapatinib'}, {'trastuzumab', 'lapatinib'}, {'afatinib'}, {'afatinib', 'trastuzumab'}, {'trastuzumab', 'irinotecan'}, {'docetaxel', 'trastuzumab', 'pertuzumab'}, {'trastuzumab'}, {'neratinib', 'trastuzumab'}, {'trastuzumab'}, {'capecitabine', 'lapatinib'}, {'trastuzumab', 'capecitabine'}, {'trastuzumab emtansine'}, {'trastuzumab emtansine'}, {'pictilisib'}, {'a66'}, {'trastuzumab emtansine'}, {'docetaxel', 'trastuzumab', 'pertuzumab'}, {'trastuzumab', 'lapatinib'}, {'trastuzumab', 'pilaralisib'}, {'trastuzumab', 'palbociclib'}, {'trastuzumab'}, {'trastuzumab emtansine'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab deruxtecan'}, {'lapatinib'}]\n",
      "32\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab deruxtecan. entry url: https://civicdb.org/links/evidence_items/7647', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/761', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is a66. entry url: https://civicdb.org/links/evidence_items/1381', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/961', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/529', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/528', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/1011', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/1693', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/1122', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/886']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has erbb2 amplification, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has pold1 e374k, what therapy is recommended?\n",
      "[{'pembrolizumab'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has pold1 e374k, one recommended therapy is pembrolizumab. entry url: https://civicdb.org/links/evidence_items/4777', 'If a patient with Non-Small Cell Lung Cancer cancer has cd274 expression, one recommended therapy is pembrolizumab. entry url: https://civicdb.org/links/evidence_items/5811', 'If a patient with Non-Small Cell Lung Cancer cancer has cd274 expression, one recommended therapy is pembrolizumab. entry url: https://civicdb.org/links/evidence_items/1733', 'If a patient with Non-Small Cell Lung Cancer cancer has cd274 expression, one recommended therapy is pembrolizumab + nivolumab. entry url: https://civicdb.org/links/evidence_items/743', 'If a patient with Non-Small Cell Lung Cancer cancer has cd274 expression, one recommended therapy is avelumab + atezolizumab + pembrolizumab + nivolumab + durvalumab. entry url: https://civicdb.org/links/evidence_items/4857', 'If a patient with Non-Small Cell Lung Cancer cancer has cd274 expression, one recommended therapy is avelumab + pembrolizumab + nivolumab + atezolizumab. entry url: https://civicdb.org/links/evidence_items/1167', 'If a patient with Melanoma cancer has cd274 expression, one recommended therapy is pembrolizumab + nivolumab. entry url: https://civicdb.org/links/evidence_items/704', 'If a patient with Cancer cancer has cd274 expression, one recommended therapy is nivolumab. entry url: https://civicdb.org/links/evidence_items/1517', 'If a patient with Non-Small Cell Lung Cancer cancer has cd274 expression, one recommended therapy is atezolizumab. entry url: https://civicdb.org/links/evidence_items/1172', 'If a patient with Melanoma cancer has nras q61, one recommended therapy is binimetinib. entry url: https://civicdb.org/links/evidence_items/1226']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has pold1 e374k, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, what therapy is recommended?\n",
      "[{'erlotinib', 'gefitinib'}, {'erlotinib', 'gefitinib'}, {'gefitinib'}, {'erlotinib'}, {'afatinib'}, {'gefitinib'}, {'gefitinib'}, {'gefitinib'}, {'lapatinib'}, {'dacomitinib'}, {'neratinib'}, {'afatinib'}, {'canertinib'}, {'erlotinib'}, {'erlotinib'}, {'afatinib'}, {'erlotinib'}, {'erlotinib'}, {'erlotinib'}, {'osimertinib'}, {'erlotinib', 'gefitinib'}, {'dacomitinib'}, {'dacomitinib'}, {'osimertinib'}, {'dacomitinib'}, {'erlotinib', 'ramucirumab'}, {'gefitinib'}, {'osimertinib', 'chemotherapy'}, {'amivantamab', 'lazertinib'}, {'amivantamab', 'pemetrexed', 'carboplatin'}]\n",
      "30\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4286', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4287', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/4284', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2621', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/2994', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is canertinib. entry url: https://civicdb.org/links/evidence_items/2631', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is erlotinib. entry url: https://civicdb.org/links/evidence_items/885', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/276', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is gefitinib. entry url: https://civicdb.org/links/evidence_items/2156', 'If a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/2628']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Non-Small Cell Lung Cancer cancer has egfr l858r, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with nan cancer has erbb2 amplification, what therapy is recommended?\n",
      "[{'trastuzumab'}, {'trastuzumab'}, {'neratinib'}, {'afatinib'}, {'afatinib', 'trastuzumab', 'lapatinib'}, {'afatinib'}, {'trastuzumab', 'lapatinib'}, {'trastuzumab', 'lapatinib'}, {'afatinib'}, {'afatinib', 'trastuzumab'}, {'trastuzumab', 'irinotecan'}, {'docetaxel', 'trastuzumab', 'pertuzumab'}, {'trastuzumab'}, {'neratinib', 'trastuzumab'}, {'trastuzumab'}, {'capecitabine', 'lapatinib'}, {'trastuzumab', 'capecitabine'}, {'trastuzumab emtansine'}, {'trastuzumab emtansine'}, {'pictilisib'}, {'a66'}, {'trastuzumab emtansine'}, {'docetaxel', 'trastuzumab', 'pertuzumab'}, {'trastuzumab', 'lapatinib'}, {'trastuzumab', 'pilaralisib'}, {'trastuzumab', 'palbociclib'}, {'trastuzumab'}, {'trastuzumab emtansine'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab deruxtecan'}, {'lapatinib'}]\n",
      "32\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/761', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is a66. entry url: https://civicdb.org/links/evidence_items/1381', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/961', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/529', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/528', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/1011', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/1693', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/1122', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/1160', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/1432']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has erbb2 amplification, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"nan cancer\",\n",
      "    \"Disease Phase or Condition\": \"nan cancer with ERBB2 amplification\",\n",
      "    \"Drug Name\": \"trastuzumab\",\n",
      "    \"Prior Treatment or Resistance Status\": \"not specified\",\n",
      "    \"Genomic Features\": \"ERBB2 amplification\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/529\"\n",
      "  }\n",
      "}\n",
      "if a patient with Glioblastoma cancer has pten expression, what therapy is recommended?\n",
      "[{'epidermal growth factor receptor tyrosine kinase inhibitor'}, {'dacomitinib'}, {'erlotinib', 'gefitinib'}]\n",
      "3\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Glioblastoma cancer has pten expression, one recommended therapy is dacomitinib. entry url: https://civicdb.org/links/evidence_items/775', 'If a patient with Breast Cancer cancer has pten expression, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/955', 'If a patient with Cancer cancer has pten mutation, one recommended therapy is ipatasertib. entry url: https://civicdb.org/links/evidence_items/1491', 'If a patient with Breast Cancer cancer has pten mutation, one recommended therapy is capivasertib + fulvestrant. entry url: https://civicdb.org/links/evidence_items/12020', 'If a patient with nan cancer has pten loss, one recommended therapy is everolimus. entry url: https://civicdb.org/links/evidence_items/1297', 'If a patient with Melanoma cancer has pten loss, one recommended therapy is uprosertib. entry url: https://civicdb.org/links/evidence_items/708', 'If a patient with nan cancer has pten loss, one recommended therapy is capivasertib + docetaxel. entry url: https://civicdb.org/links/evidence_items/1500', 'If a patient with Breast Cancer cancer has pik3ca e545k, one recommended therapy is akt inhibitor mk2206 + pictilisib. entry url: https://civicdb.org/links/evidence_items/710', 'If a patient with Breast Cancer cancer has pik3ca e542k, one recommended therapy is sirolimus. entry url: https://civicdb.org/links/evidence_items/311', 'If a patient with Breast Cancer cancer has pik3ca h1047l, one recommended therapy is pi-103. entry url: https://civicdb.org/links/evidence_items/8009']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Glioblastoma cancer has pten expression, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Glioblastoma\",\n",
      "    \"Disease Phase or Condition\": \"cancer\",\n",
      "    \"Drug Name\": \"dacomitinib\",\n",
      "    \"Prior Treatment or Resistance Status\": null,\n",
      "    \"Genomic Features\": \"pten expression\",\n",
      "    \"FDA-approval status\": \"not specified in the provided data\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/775\"\n",
      "  }\n",
      "}\n",
      "if a patient with Melanoma cancer has nras q61, what therapy is recommended?\n",
      "[{'binimetinib'}, {'selumetinib'}]\n",
      "2\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Melanoma cancer has nras q61, one recommended therapy is binimetinib. entry url: https://civicdb.org/links/evidence_items/1226', 'If a patient with Melanoma cancer has nras q61, one recommended therapy is selumetinib. entry url: https://civicdb.org/links/evidence_items/1473', 'If a patient with Melanoma cancer has nras q61k, one recommended therapy is selumetinib. entry url: https://civicdb.org/links/evidence_items/1475', 'If a patient with Melanoma cancer has nras q61r, one recommended therapy is temozolomide. entry url: https://civicdb.org/links/evidence_items/23', 'If a patient with Melanoma cancer has nras q61l, one recommended therapy is temozolomide. entry url: https://civicdb.org/links/evidence_items/22', 'If a patient with Melanoma cancer has nras mutation, one recommended therapy is binimetinib. entry url: https://civicdb.org/links/evidence_items/1509', 'If a patient with Melanoma cancer has nras mutation, one recommended therapy is amuvatinib. entry url: https://civicdb.org/links/evidence_items/1476', 'If a patient with Melanoma cancer has pten loss, one recommended therapy is uprosertib. entry url: https://civicdb.org/links/evidence_items/708', 'If a patient with nan cancer has pik3ca r88q, one recommended therapy is capivasertib + fulvestrant. entry url: https://civicdb.org/links/evidence_items/12034', 'If a patient with Breast Cancer cancer has pten loss, one recommended therapy is pi3kbeta inhibitor azd8186. entry url: https://civicdb.org/links/evidence_items/711']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Melanoma cancer has nras q61, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Melanoma cancer\",\n",
      "    \"Disease Phase or Condition\": \"nras q61\",\n",
      "    \"Drug Name\": \"binimetinib\",\n",
      "    \"Prior Treatment or Resistance Status\": null,\n",
      "    \"Genomic Features\": \"nras q61\",\n",
      "    \"FDA-approval status\": \"FDA-approved\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/1226\"\n",
      "  }\n",
      "}\n",
      "if a patient with Colorectal Cancer cancer has kras mutation, what therapy is recommended?\n",
      "[{'immunomodulatory oligonucleotide', 'epidermal growth factor receptor tyrosine kinase inhibitor'}, {'dasatinib', 'cetuximab'}, {'selumetinib', 'b-raf/vegfr-2 inhibitor raf265'}, {'afatinib', 'trametinib'}, {'selumetinib', 'teprotumumab'}, {'palbociclib', 'binimetinib'}]\n",
      "6\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Colorectal Cancer cancer has kras mutation, one recommended therapy is trametinib + afatinib. entry url: https://civicdb.org/links/evidence_items/991', 'If a patient with Colorectal Cancer cancer has kras mutation, one recommended therapy is b-raf/vegfr-2 inhibitor raf265 + selumetinib. entry url: https://civicdb.org/links/evidence_items/988', 'If a patient with Colorectal Cancer cancer has kras mutation, one recommended therapy is dasatinib + cetuximab. entry url: https://civicdb.org/links/evidence_items/947', 'If a patient with Colorectal Cancer cancer has kras mutation, one recommended therapy is teprotumumab + selumetinib. entry url: https://civicdb.org/links/evidence_items/1004', 'If a patient with Colorectal Cancer cancer has kras mutation, one recommended therapy is epidermal growth factor receptor tyrosine kinase inhibitor + immunomodulatory oligonucleotide. entry url: https://civicdb.org/links/evidence_items/943', 'If a patient with Colorectal Cancer cancer has kras mutation, one recommended therapy is palbociclib + binimetinib. entry url: https://civicdb.org/links/evidence_items/4869', 'If a patient with Colorectal Cancer cancer has kras exon 2 mutation, one recommended therapy is selumetinib + irinotecan. entry url: https://civicdb.org/links/evidence_items/1326', 'If a patient with Cancer cancer has kras mutation, one recommended therapy is trametinib. entry url: https://civicdb.org/links/evidence_items/935', 'If a patient with Colorectal Cancer cancer has kras g13d, one recommended therapy is cetuximab. entry url: https://civicdb.org/links/evidence_items/145', 'If a patient with Colorectal Cancer cancer has kras g13d, one recommended therapy is cetuximab. entry url: https://civicdb.org/links/evidence_items/306']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Colorectal Cancer cancer has kras mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"success\",\n",
      "  \"Treatment 1\": {\n",
      "    \"Disease Name\": \"Colorectal Cancer\",\n",
      "    \"Disease Phase or Condition\": \"Kras mutation\",\n",
      "    \"Drug Name\": \"trametinib + afatinib\",\n",
      "    \"Prior Treatment or Resistance Status\": \"N/A\",\n",
      "    \"Genomic Features\": \"kras mutation\",\n",
      "    \"FDA-approval status\": \"Not specified in the provided data\",\n",
      "    \"Link to FDA-approved Label\": \"https://civicdb.org/links/evidence_items/991\"\n",
      "  }\n",
      "}\n",
      "if a patient with nan cancer has erbb2 mutation, what therapy is recommended?\n",
      "[{'platinum compound'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib. entry url: https://civicdb.org/links/evidence_items/761', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/529', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab. entry url: https://civicdb.org/links/evidence_items/528', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/961', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is afatinib. entry url: https://civicdb.org/links/evidence_items/1011', 'If a patient with nan cancer has erbb2 overexpression, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/4840', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is neratinib + trastuzumab. entry url: https://civicdb.org/links/evidence_items/1113', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is a66. entry url: https://civicdb.org/links/evidence_items/1381', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/1160', 'If a patient with nan cancer has erbb2 amplification, one recommended therapy is trastuzumab emtansine. entry url: https://civicdb.org/links/evidence_items/1432']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with nan cancer has erbb2 mutation, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Lung Adenocarcinoma cancer has rictor amplification, what therapy is recommended?\n",
      "[{'onatasertib', 'sapanisertib'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Lung Adenocarcinoma cancer has rictor amplification, one recommended therapy is sapanisertib + onatasertib. entry url: https://civicdb.org/links/evidence_items/1440', 'If a patient with Melanoma cancer has mtor h1968y, one recommended therapy is capivasertib + pi3k/bet inhibitor ly294002. entry url: https://civicdb.org/links/evidence_items/713', 'If a patient with Melanoma cancer has mtor p2213s, one recommended therapy is capivasertib + pi3k/bet inhibitor ly294002. entry url: https://civicdb.org/links/evidence_items/722', 'If a patient with Melanoma cancer has braf v600e, one recommended therapy is pictilisib. entry url: https://civicdb.org/links/evidence_items/757', 'If a patient with Melanoma cancer has braf v600e, one recommended therapy is dactolisib + selumetinib. entry url: https://civicdb.org/links/evidence_items/1005', 'If a patient with Cancer cancer has nras mutation, one recommended therapy is trametinib + metformin. entry url: https://civicdb.org/links/evidence_items/1230', 'If a patient with nan cancer has pten loss, one recommended therapy is trastuzumab + pi3k/bet inhibitor ly294002. entry url: https://civicdb.org/links/evidence_items/1455', 'If a patient with Melanoma cancer has nras mutation, one recommended therapy is binimetinib. entry url: https://civicdb.org/links/evidence_items/1472', 'If a patient with Melanoma cancer has braf v600e, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/1398', 'If a patient with Melanoma cancer has nras g13d, one recommended therapy is tanespimycin. entry url: https://civicdb.org/links/evidence_items/21']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Lung Adenocarcinoma cancer has rictor amplification, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "if a patient with Melanoma cancer has ezh2 y646, what therapy is recommended?\n",
      "[{'gsk126'}]\n",
      "1\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a patient with Melanoma cancer has ezh2 y646, one recommended therapy is gsk126. entry url: https://civicdb.org/links/evidence_items/1494', 'If a patient with Melanoma cancer has braf v600e, ezh2 y646f, one recommended therapy is jqez5. entry url: https://civicdb.org/links/evidence_items/6952', 'If a patient with Melanoma cancer has agk::braf fusion, one recommended therapy is sorafenib. entry url: https://civicdb.org/links/evidence_items/723', 'If a patient with Melanoma cancer has braf v600e, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/3755', 'If a patient with Melanoma cancer has braf v600e, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/1398', 'If a patient with Melanoma cancer has braf v600e, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/3750', 'If a patient with Melanoma cancer has braf v600d, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/4488', 'If a patient with Melanoma cancer has braf v600e, one recommended therapy is trametinib. entry url: https://civicdb.org/links/evidence_items/2135', 'If a patient with Melanoma cancer has braf l597r, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/728', 'If a patient with Melanoma cancer has braf v600e, one recommended therapy is vemurafenib. entry url: https://civicdb.org/links/evidence_items/1409']\n",
      "    ---------------------\n",
      "    \n",
      "    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"no_match\",\n",
      "        \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "    }\n",
      "    \n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n",
      "    {\n",
      "        \"Status\": \"success\",\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: if a patient with Melanoma cancer has ezh2 y646, what therapy is recommended?\n",
      "     \n",
      "    \n",
      "{\n",
      "  \"Status\": \"no_match\",\n",
      "  \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "num_true_drugs_list = []\n",
    "cancer_types = []\n",
    "biomarkers = []\n",
    "for i, row in standardized_to_raw_mapping_subset.reset_index(drop=True)[~np.array(output_eval['exact_match_acc'])].iterrows():\n",
    "    print(row['prompt'])\n",
    "    print(synthetic_query_therapy_pair_dict[row['prompt']])\n",
    "    num_true_drugs_list.append(len(synthetic_query_therapy_pair_dict[row['prompt']]))\n",
    "    print(len(synthetic_query_therapy_pair_dict[row['prompt']]))\n",
    "    print(output_res['input prompt'][0][i])\n",
    "    print(output_res['full output'][0][i])\n",
    "    cancer_types.append(row['standardized_cancer'])\n",
    "    biomarkers.append(row['biomarker'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "a5c9138c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[7, 30, 3, 2, 4, 15, 1, 30, 4, 32, 22, 6, 5, 7, 2, 3, 1, 4, 1, 3, 1, 3, 1, 1, 9, 2, 4, 1, 1, 32, 1, 1, 5, 3, 1, 2, 3, 1, 2, 2, 1, 2, 11, 1, 3, 6, 2, 1, 1, 5, 2, 1, 3, 1, 2, 9, 4, 2, 9, 2, 4, 2, 6, 2, 5, 3, 2, 19, 8, 6, 5, 32, 1, 6, 3, 3, 1, 1, 1, 30, 15, 4, 1, 5, 16, 32, 1, 30, 32, 3, 2, 6, 1, 1, 1]\n",
      "1\n",
      "6.484210526315789\n",
      "3.0\n",
      "32\n"
     ]
    }
   ],
   "source": [
    "print(num_true_drugs_list)\n",
    "print(np.min(num_true_drugs_list))\n",
    "print(np.mean(num_true_drugs_list))\n",
    "print(np.median(num_true_drugs_list))\n",
    "print(np.max(num_true_drugs_list))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "33032cfe",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('Non-Small Cell Lung Cancer', 24),\n",
       " (nan, 24),\n",
       " ('Melanoma', 5),\n",
       " ('Lung Adenocarcinoma', 5),\n",
       " ('Ovarian Cancer', 4),\n",
       " ('Chronic Myelogenous Leukemia', 3),\n",
       " ('Acute Myeloid Leukemia', 3),\n",
       " ('Cancer', 3),\n",
       " ('Colorectal Cancer', 3),\n",
       " ('Gastrointestinal Stromal Tumor', 3),\n",
       " ('Neuroblastoma', 2),\n",
       " ('Solid Tumor', 2),\n",
       " ('Glioblastoma', 2),\n",
       " ('Pancreatic Cancer', 1),\n",
       " ('adrenal', 1),\n",
       " ('B-lymphoblastic Leukemia/lymphoma', 1),\n",
       " ('Prostate Cancer', 1),\n",
       " ('Rhabdomyosarcoma', 1),\n",
       " ('Breast Cancer', 1),\n",
       " ('Medulloblastoma', 1),\n",
       " ('Sarcoma', 1),\n",
       " ('Low-Grade Glioma, NOS', 1),\n",
       " ('Pancreatic Adenocarcinoma', 1),\n",
       " ('Endometrial Cancer', 1),\n",
       " ('head and neck', 1)]"
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from collections import Counter\n",
    "Counter(cancer_types).most_common()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "1715c003",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(\"['EGFR L858R']\", 7),\n",
       " (\"['ERBB2 Amplification']\", 6),\n",
       " (\"['EGFR T790M']\", 3),\n",
       " (\"['BRCA1 Loss-of-function']\", 3),\n",
       " (\"['KRAS Mutation']\", 3),\n",
       " (\"['KIT Exon 11 Mutation']\", 3),\n",
       " (\"['BRCA2 Mutation']\", 2),\n",
       " (\"['BRCA1 Mutation']\", 2),\n",
       " (\"['PML::RARA Fusion']\", 2),\n",
       " (\"['TP53 Mutation']\", 2),\n",
       " (\"['BRAF V600E']\", 2),\n",
       " (\"['PTEN Loss']\", 2),\n",
       " (\"['v::ROS1 Fusion']\", 2),\n",
       " (\"['PTEN Expression']\", 2),\n",
       " (\"['EGFR Exon 19 Deletion']\", 2),\n",
       " (\"['FGFR1 Amplification']\", 2),\n",
       " (\"['BCR::ABL1 Fusion', 'ABL1 V299L']\", 1),\n",
       " (\"['IDH1 Mutation']\", 1),\n",
       " (\"['DDR2 S768R']\", 1),\n",
       " (\"['v::ALK Fusion']\", 1),\n",
       " (\"['ALK F1174L']\", 1),\n",
       " (\"['EML4::ALK Fusion', 'ALK L1196M']\", 1),\n",
       " (\"['PIK3CA Amplification']\", 1),\n",
       " (\"['EGFR R108K']\", 1),\n",
       " (\"['RRM1 Underexpression']\", 1),\n",
       " (\"['EGFR Rare Exon 18-21 Mutation']\", 1),\n",
       " (\"['FGFR3::TACC3 Fusion', 'FGFR2::CCDC6 Fusion']\", 1),\n",
       " (\"['EGFR Overexpression']\", 1),\n",
       " (\"['RB1 Mutation']\", 1),\n",
       " (\"['BRAF V600K']\", 1),\n",
       " (\"['ETV6::ABL1 Fusion']\", 1),\n",
       " (\"['KIAA1549::BRAF Fusion']\", 1),\n",
       " (\"['PDGFRA Overexpression']\", 1),\n",
       " (\"['CHEK2 mutation']\", 1),\n",
       " (\"['BRAF V600D']\", 1),\n",
       " (\"['BRCA2 Loss-of-function']\", 1),\n",
       " (\"['FLT3 Mutation']\", 1),\n",
       " (\"['SMO D473H']\", 1),\n",
       " (\"['LMNA::NTRK1 Fusion']\", 1),\n",
       " (\"['SSTR5 expression']\", 1),\n",
       " (\"['MYCN Amplification']\", 1),\n",
       " (\"['BRAF V600']\", 1),\n",
       " (\"['KIT N822K']\", 1),\n",
       " (\"['RCSD1::ABL1 Fusion']\", 1),\n",
       " (\"['CD274 Expression']\", 1),\n",
       " (\"['v::NTRK3 Fusion']\", 1),\n",
       " (\"['CIP2A Underexpression']\", 1),\n",
       " (\"['ERCC2 K751Q']\", 1),\n",
       " (\"['BCR::ABL1 Fusion']\", 1),\n",
       " (\"['EGFR VIII']\", 1),\n",
       " (\"['ERBB2 V777L']\", 1),\n",
       " (\"['RAD50 L1237F']\", 1),\n",
       " (\"['v::NRG1 Fusion']\", 1),\n",
       " (\"['MET Exon 14 Skipping Mutation']\", 1),\n",
       " (\"['ERBB2 G778_P780dup']\", 1),\n",
       " (\"['BCR::ABL1 Fusion', 'ABL1 G398R']\", 1),\n",
       " (\"['EGFR E746_A750del']\", 1),\n",
       " (\"['EGFR L861']\", 1),\n",
       " (\"['BRCA2 M1R']\", 1),\n",
       " (\"['PIK3CA H1047R']\", 1),\n",
       " (\"['BARD1 Mutation']\", 1),\n",
       " (\"['POLD1 E374K']\", 1),\n",
       " (\"['NRAS Q61']\", 1),\n",
       " (\"['ERBB2 Mutation']\", 1),\n",
       " (\"['RICTOR Amplification']\", 1),\n",
       " (\"['EZH2 Y646']\", 1)]"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "Counter(biomarkers).most_common()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "dfd8723c",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
